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Abstract
Around 30,000 men in the UK are diagnosed with prostate cancer (PCa) each year. The
enzyme a-methylacyl-CoA racemase (AMACR)hasbeen found to be overexpressed in
prostate, colon, and other cancers. More recently, siRNA knockdown of the AMACR
gene expression has been shownto inhibit proliferation of the cancerous prostate cells
and therefore partially validate AMACR as a potential therapeutic target for the
disease.'| AMACRhasa wide substrate specificity; its natural role is to catalyse the
interconversion of (R) and (S)-stereoisomers at the a-position of branched chain acyl-
CoA esters such as pristanoyl and trihydroxycholestanoyl-CoA. This provides the
required (S)-configured substrate for the stereospecific oxidase enzyme for f-oxidation.
It is also involved in the metabolism of Ibuprofen.
Recent X-ray crystallography studies on Mycobacterium tuberculosis a-methylacyl-
CoA racemase (MCR) have led to a proposed mechanism for its catalytic activity.
Kinetic and structural data suggest that a 1,1-proton transfer takes place, catalysed by
the two active site bases His-126 and Asp-156, resulting in formation of an enzyme
stabilised enolate.
Our group has recently synthesised a range of competitive inhibitors which are
fluorinated analogues of the natural substrates. The most potent of these is 2-
trifluoromethyltetradecanoyl-CoA (Ki = 1uM) that may work by lowering the pKa of
the a-hydrogen and promoting enolisation. We have improved the synthesis of this
compoundand have prepared a new range of potential inhibitors. It is understood that
the coenzyme A thioester of Ibuprofen has a better binding affinity towards AMACR
than its natural substrates and also acts as a mild competitive inhibitor. This inspired us
to synthesise Ibuprofen derivatives which when thioesterfied may exhibit better
inhibition characteristics. B—Trifluoroibuprofen has shown some promising inhibition
characteristics as a prodrug.
Wehavealso designed three different assays (HPLC, LC-MS and chromogenic) in
order to test the efficacy of our new series of inhibitors. Quantification of extent of
racemisation by monitoring deuterium exchange (LC-MS)is our most efficient assay to
date.
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CHAPTER1
INTRODUCTION
1. Introduction
1.1 Introduction to Prostate Cancer
Cancer is defined as a disease in which there is an uncontrolled proliferation of cells,
typically with invasion and destruction of adjacent normaltissue. This often results in the
metastasis of the cancer to distant parts of the body via lymphatic or circulatory systems. In
2007 cancer caused about 13% (7.4 million) of all human deaths.”
The prostate is a male reproductive organ which helps make and store seminalfluid. In adult
mena typical prostate is about three centimetres long and weighs about twenty grams.”
Prostate cancer (PCa) is the most commoncancer in men in the UK.It is responsible for a
quarter of all new cases of cancer diagnosed in men. Worldwide, more than 670,000 men are
diagnosed with prostate cancer each year. The highest rates are in the USA, Australia, New
Zealand, Western and Northern Europe whilst the lowest rates are in East and South Central
Asia (Fig. 1.01).*
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Fig 1.01. Age-standardised death rates from prostate cancer by country (per 100,000
inhabitants).*
Almost 60% of prostate cancer cases are diagnosed in men aged over 70 years and
approximately one-third of men over the age of 50 have some cancer cells within their
prostate.
1.1.2 History of prostate cancer
Prostate cancer wasfirst described in 1536 by an Italian anatomist Niccolo Massa butit was
not identified until some 300 years later in 1853.° From 1904 until the mid 20" century
radical prostatectomy (removal of the prostate gland) was the main treatment.° In 1966
Charles B. Higgins, an American physician and physiologist won the Nobel Prize in
Physiology and Medicine for the discovery of ‘chemical castration’. Oestrogen was used to
opposetestosterone production in men with metastatic prostate cancer.’ In fact ‘chemical
castration’ techniquesarestill used today, as will be discussed in Section 1.3.
1.1.3 Risk Factors
The strongest risk factor for prostate cancer is age, with very low risk in men underthe age of
50 (Fig 1.02). Men with one or morefirst-degree relatives (father, brother, or son) diagnosed
with prostate cancer have an increased risk of the disease. West African and Caribbean men
have a higherrisk of prostate cancer than Caucasian men, whilst men born in Asia have the
lowestrisk of the disease.
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Fig 1.02. Graphical representation ofprostate cancer mortality rate in relation to age.
1.1.4 Symptoms
PCa often has similar symptoms to that of benign prostatic hypertrophy (BPH), an
enlargement of the prostate gland. These comprise of a range of urinal problems, including
frequent urination (particularly at night), difficulty starting and maintaining a steady stream
of urine, painful urination and haematuria (bloodin the urine). Prostate cancer may also cause
problems with sexual function, such as difficulty achieving erection or painful ejaculation.*
Advanced prostate cancer may cause additional symptomsas the disease spreads to other
parts of the body. The most common symptom is bone pain,often in the spine, pelvis or ribs’
(due to metastasis to bone).
1.2 Progress in diagnostic markers.
The most routinely used PCa diagnostic markeris prostate-specific antigen (PSA). PSA is a
serine protease, the physiological role of which is to liquefy seminalfluid.’ Prostate cancer
causes PSAto bereleased into the blood stream, increasing the plasma levels of PSA up to
10° fold.'! Although there is no experimental data on the mechanismsofincreasedrelease,it
is believed to result from the disruption of prostate integrity seen in prostate tumours, such as
the loss of basal cell layer, ductal lumen architecture and epithelial cell polarity. High PSA
levels (more than 4.0ng/ml) mayindicate the presence of prostate cancer cells. However, in
approximately 10% of prostate cancer cases, there is no rise in PSA abovethis threshold
level, which creates a diagnostic problem for this group of individuals. PSA levels can be
additionally increased by prostate infection,irritation, benign prostatic hyperplasia and recent
ejaculation.'”'? Furthermore PSA levels can also appear reducedif the individual is on statin
medication or suffers from obesity'* — providing false negative results. A digital rectal
examination (DRE) has been shownin several studies to also produce an increase in PSA’. If
the levels of PSA are over 4.0ng/ml, a biopsy is usually taken for histological analysis to
confirm the presence of malignant disease. Although PSA screening is practised in some
parts of the world for early detection of prostate cancer,it is rejected in others because of the
potential ambiguity ofthe results. '°
There has been muchinterest in utilising other diagnostic markers, many of which rely on the
absence of basal cells. These are cells which act as connective tissue between the luminal
epithelium and the stroma. Basal cells form a continuous layer that encircles the entire
luminal epithelium which is absent in cancerous glands.'’ Some of the markers of interest
include 34BE12, keratin 5/6, Bcl-2 and p63.
p63 is a homologue ofthe p53 tumoursuppressor gene'® and is thoughtto be involved in the
development and maintenanceof the prostatic secretory epithelial cell layer.'” Keratin 5/6,
normally expressed by complex epithelium is generally considered a marker of malignant
mesothelioma (usually caused by exposure to asbestos). However, it has shown to be a
demonstrable negative biomarker of prostatic, bile tract, and breast carcinomas.*””! Overall
sensitivity, specificity, and diagnostic utility of keratin 5/6 in prostate biopsies is similar to
that of 34BE12, which is a high molecular weight keratin.”” Finally, Bcl-2 governs
mitochondrial membrane permeability by regulating Ca”*, pH, andvoltage.
Diagnosing prostate cancer with basal cell biomarkers alone has its disadvantages. Notall
benign glands are stained uniformly with basal cell markers and some show false negative
staining if the individualhas partial atrophy, atypical adenomatous hyperplasia or high grade
prostatic intraepithelial neoplasia.”!”” However, the latter two are often classed as
‘precancerous’. Fig 1.03 demonstrates the difference in sensitivity and specificity between
these negative biomarkers. 34 8 E12 has the best sensitivity and specificity values (95% and
98%, respectively). The reliability of negative biomarkers in descending order is as follows:
34 6 E12, p63, bcl-2, and keratin 5/6. From this data it is suggested that keratin 5/6 and bcl-2
should not be used to identify cancerous prostate cells, however 34BE12 could be used in
conjuction with AMACRforincreasedreliability.
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More recently fatty acid synthase and Annexins have been investigated as diagnostic
markers. Fatty acid synthase plays a key role in fatty acid biosynthesis and has been found
comparable to a—methylacyl-CoA racemase (AMACR) in diagnosing malignant cells.
However, there have been nostudies performed to ascertain whetherit is a negative stain for
benign mimics of malignancy.” Annexinsare a family of calcium binding proteins with the
*> 4 Their function is to help organizeability to bind phospholipids in the plasma membrane.
exocytosis of intracellular proteins to the extracellular domain. In particular, Annexin II has
shownto participate in ion channel regulation”® and can inhibit cellular mobility. Annexin II
is usually up-regulated in response to physiologic stress but has found to be underexpressed
in prostate cancer.”° However,it is suggested that AnnexinII should be considered only as an
adjunctive diagnostic marker because it can also stain some stromalcells and blood vessels.
This can complicate interpretation of biopsy specimens by mimicking basalcells.””
Overthe last decade AMACRhasbeen thoroughly investigated and proved to be a viable and
cost effective diagnostic marker for PCa. It is consistently over expressed in cancerous
prostate cells and analysis of mRNAlevels reveals an average up-regulation of ~9 fold in
localized prostate cancer compared with normal and benign prostate.”* This has been
confirmed by real-time PCR analysis in addition to Western blotting and
immunohistochemical analysis.*’ Several studies have also shown that AMACRis over-
-32 ‘30-32 "4 precursor lesion for prostateexpressed in high-grade prostatic intraepithelial neoplasia
cancer. AMACRis thus thought to be essential for early stage prostate cancer growth. The
relative over expression of AMACRisstrongest with localized prostate cells, followed by
metastatic prostate tissue and benign prostate tissue having a negative expression of
AMACR.*®
AMACRdetection is arguably a superior diagnostic marker than PSA.***°Its sensitivity has
been reported as ranging from 82% to 100% and specificity has been reported as ranging
from 79% to 100%.°°*8 PSA’s respective sensitivity and specificity are 33% and 86%.”
AMACRover-expression has also been shown in a numberofother cancers, including breast,
ovarian, lung, colorectal adenocarcinoma, papillary renal cell (kidney) carcinoma, melanoma
and lymphoma(Fig 1.04). However, recent studies by Willemoeef al., have shownthat there
is no discernible difference in AMACRexpression between the malignant and non malignant
. . 40cells in hepatocarcinoma.
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Fig 1.04. AMACRoverexpression in multiple tumours. AMACRprotein expression was
evaluated by immunohistochemistry on a multi-tumor microarray. The percentage of cases
with positive staining (moderate andstrongstaining intensity) is summarized on the Y-axis.”'
Positive staining for PCa with AMACRis not 100% accurate. There are reports of benign
prostatic glands staining positive for AMACR*“* (0-21%). This has prompted
experimentation with immunohistochemical cocktails of basal cell markers and AMACR. A
triple immunohistochemical cocktail of 34BE12, p63 and AMACRgave a specificity of
100% with a sensitivity of 93.8%.*° Earlier in 2010 Cetin e¢ al., reviewed five different
diagnostic markers (34BE12, keratin 5/6, p63, bcl-2 and AMACR).Initial testing of the basal
cell markers for staining benign glands demonstrated that p63 and 34BE12 were far superior
to keratin 5/6 and bcl-2. Testing the same biomarkers with malignant glands gavetherelative
negative staining order as follows: p63>34BE12> bcl-2>keratin 5/6. They too noted that
AMACR’s expression could sometimes be deceiving, leading to misdiagnosis of
adenocarcinoma.** It appears that there is no one omnipotent diagnostic marker that is
universally accepted in the detection of prostate cancer. However, a combination of basalcell
markers (such as 34BE12 or p63) with AMACRisa potentially compelling combination as a
useful diagnostic strategy.
1.3 Current treatments
There are various treatment options for PCa. Thefirst strategy for slow growing tumoursis
knownas watchful waiting. The condition is monitored closely with routine check-ups and no
physical treatment is performed. In somecases, particularly with older men, the patient will
die of other causes rather than from prostate cancer.
The most commontreatment for otherwise young, healthy men whosecanceris localised is to
undergo surgery. The most commontechniqueis a radical prostatectomy, whereby the whole
prostate and some surrounding healthy tissue is removed. Recent developments in keyhole
surgery (a laparoscopic prostatectomy), where the prostate is removed through smaller
incisions and robot-assisted surgery has shownto be effective in minimising bleeding. This
meansless fatigue, and cardiovascular complications.
Conformal radiotherapy (CRT)allowsfor site specific radiotherapy that treats tumours which
in the past might have been considered too close to vital organs and structures for radiation
therapy. The tumouris scanned with X-rays to give a 3D image whichis then sent directly
into the radiotherapy planning computer. The computer program then designs radiation
beamsthat ‘conform’ more closely to the shape of the tumour and avoid healthy tissue as far
as possible. Side effects of this type of treatment mayresult in erectile dysfunction and
difficulty in urinating.
High Intensity Focused Ultrasound (HIFU)is still an experimental form of treatment for
prostate cancer. Beamsare focused on the cancertissue, causing the temperature within the
tissue to rise to 65°- 85°C, destroying the diseased tissue by necrosis. Each beam treats a
precisely defined portion of the targeted tissue which allows for non invasive ablation of the
prostate. The most commonproblemsreported after HIFU are infections in the prostate area
and incontinence.
Cryotherapy is currently available for relapsing patients who have already undergone
treatment with radiotherapy. Liquid nitrogen or argon gasis circulated through a cryoprobe,
whichis placed in contact with the tumour. Ultrasound or MRIis used to guide the cryoprobe
and monitor the freezing of the cells, thus limiting damage to nearby healthy tissue. This type
of therapy, as with HIFU and surgical methods,is limited to early localised cancer that hasn’t
spread from the prostate. The main disadvantage of this type of therapy howeveris its long
term effectiveness as it can miss microscopic cancer, which maylead to an additionalrelapse.
Hormonal therapy is the most widely used chemical treatment for prostate cancer.
Testosterone (a hormone whichincreases the growth rate of the cancer cells) is prevented
from reaching the cancer cells which limits the progression of the cancer and can even cause
shrinkage. Testosterone and dihydrotestosterone (DHT) are the two major androgens in men,
with testosterone present mainly in circulation, and DHTasthe primary androgenin prostatic
tissues. The pharmacologicalactivity of both testosterone and DHTarereliant on the binding
to androgen receptors (AR). DHTis regarded as the more potent of the two as it binds to ARs
5 times more strongly. The types of preventative testosterone production may include;
removal of the testicles (orchidectomy), which directly removes the testosterone producing
glands; injections of luteinizing hormone releasing hormone (LHRH) agonists such as
Zoladex which control the production of testosterone; or administration of prostate specific
5a- reductase inhibitors such as finasteride (Proscar) which help prevent testosterone being
converted to dihydrotestosterone. Dispite a rapid initial response in the majority of cases, PCa
will ultimately progress to a hormone refractory stage, for which no curative therapies
currently exist.*° This is due to the remaining cancerstill being driven by AR signalling
(which stimulates mitogenesis). Abiraterone (which is currently in Phase III trials*’) has
received much attention as a selective irreversible CYP17A1 inhibitor. It has proven to
significantly suppress cellular levels of dehydroepiandrostenedione (DHEA),
androstenedione, and testosterone.*® Phase II trials indicate that abiraterone shrinks the
tumour and may reduce PSA levels®’ with low levels oftoxicity.
The selection of treatment options may be a complex decision involving many factors,
including age, health, the severity of cancer and possible side effects.
1.4 a-Methylacyl-CoA Racemase and its Function.
1.4.1 AMACR’physiological role
AMACRisintrinsically involved in the B-oxidation pathway of branched chain fatty acids.It
is a peroxisomal and mitochondrial enzyme which is found in both prokaryotic and
eukaryotic organisms.It has a wide substrate specificity and its natural role is to catalyse the
interconversion of (R) and (S) stereoisomers at the a-position of branched chain acyl-CoA
esters such as pristanoyl-CoA (8) (which is acquired from meats and dairy products) and
trihydroxycholestanoyl-CoA (a bile acid intermediate). This provides the required (S)-
configured substrate for the stereospecific acyl-CoA oxidase.*°
Fatty acid B-oxidation is a universal property of peroxisomesin most, if not all, organisms. In
yeast and plants, peroxisomesare the sole site of fatty acid B-oxidation, whereas in higher
eukaryotes B-oxidation may occur in both mitochondria and peroxisomes. Its function is to
break down fatty acids by the sequential removal of two carbon units, leading to the
formation of acetyl-CoA or various derivatives which enter directly into the Krebs cycle. The
B-oxidation pathway involves dehydrogenation, hydration, dehydrogenation again, and
thiolytic cleavage (Fig 1.05). For every one cycle of B-oxidation, 14 ATP molecules are
SIproduced”. Acyl-CoA
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Fig 1.05. The B-oxidation cycle of straight chain aliphatic acids.
The major differences between peroxisomal and mitochondrial B-oxidation are the different
substrate specificities and transport of substrates/products of f-oxidation across the
membrane.” Short and medium-chain fatty acids are exclusively B-oxidised in mitochondria.
The B-oxidation pathway of VLCFA (very long chain fatty acids), 2-methyl branched-chain
fatty acids (suchaspristanic acid) and the bile acid intermediates dihydroxycholestanoic acid
(DHCA)andtrihydroxycholestanoic acid (THCA) are primarily located in the peroxisome
(Fig 1.06).
©) ©)
              
Phytanic acid Pristanic acid VLCFA DHCA THCA Acyl-CoA
+DHAP
frets frente [ress + CoASH + tiong-chain sleohol
Phytanoyl-CoA Pristanoyl-CoA VLCF-CoA DHC-CoA THC-CoA
a-oxidation B-oxidation B-oxidation B-oxidation Pteroni
(1 cycle) (3 cycles) (? cycles) (1 cycle) synthase
P—> CoASH
co, Acetyl-CoA Acetyl-CoA Chenodeoxy-choloyl-CoA P—> FA
Pristanoy!-CoA Propionyl-CoA Medium-chain- Choloy-CoA Alkyl-DHAP
Acyl-CoA
4,8-DMN-CoA | Glycine!Taurine
Glyco/Tauro Glyco/Tauro Cen) chenodeoxy cholic acidTransport to Transport to cholic acid
mitochondria mitochondria
+ further oxidation + further oxidation
T Tt T T EtherphospholipidsCo, +0 Go, + 140 Bie
Fig 1.06 Schematic representation of the pathways oflipid metabolism in peroxisomes.”
     
Pristanic acid (7) is either directly ingested through consumption of meats and dairy products,
or it is metabolised from phytol (2)/phytanic acid (4). Phytanic acid (4) can be acquired by
conversion of phytol (2) (from digestion of plant material (1)) to (£)-phytenic acid by the
successive action of a currently unknown alcohol dehydrogenase and fatty aldehyde
dehydrogenase (FALDH). Phytenic acid is then activated by a synthetase to produce (£)-
phytenoyl-CoA andfinally converted by an enoyl-CoA reductase into phytanoyl-CoA (Fig
1.07).
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Fig 1.07. Acquisition of phytanoyl-CoA from chlorophyll adapted from Mukherji e¢ a/.**
Digested phytanic acid is normally a-oxidised through shortening of the alkyl chain by one
carbon atom, yielding pristanic acid (7) and CO) (Fig 1.08). Studies have shown that
peroxisomal a-oxidation is not a stereoselective process, so that after the oxidation of
phytanic acid (4), both (2R,6R,10R,14)- and (2S,6R,10R,14)-pristanic acid (7) are formed.”
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Fig 1.08. The a-oxidation pathway of phytanic acid.
Upon CoA thioesterification, pristanoyl-CoA (8) undergoes 3 cycles of f-oxidation in
peroxisomes” to produce two propionyl-CoA (19) molecules, acetyl-CoA (20) and 4,8-
dimethylnonanoyl-CoA (21). This is then transported to the mitochondria where it is fully
oxidised.°°°’ There are two possible routes in which the peroxisomal metabolite is
transported into the mitochondria. Thefirst is the hydrolysis of the CoA thioester to form 4,8-
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dimethylnonanoic acid, transfer across the peroxisomal membrane(by a currently unknown
transporter) and finally transfer into the mitochondria in its protonated form whereit is then
further oxidised.*®
The second possible route for mitochondrial entry is conversion of the CoA ester to a
carnitine ester within the peroxisome, where it is then carried across the peroxisomal
membrane and then transported into the mitochondria’ by mitochondrial
carnitine/acylcarnitine carrier (CACT).°” *’ Once inside the mitochondria, the carnitine ester
will be re-CoAesterified and undergo further oxidation (Fig 1.09).
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Fig 1.09. A representation of a possible route of entry for short branched chain fatty acids
into the mitochondria.”
In the liver, the bile acid intermediates DHCA and THCAonly undergo one cycle of B-
oxidation in peroxisomes, with choloyl-CoA and chenodeoxycholoyl-CoA as end products
respectively. These two CoA-esters are then conjugated with either taurine or glycine within
the peroxisomes. Subsequently, the taurine and glycine esters are transported out of the
peroxisome into the cytosolic space, followed by transport across the canalicular membrane,
endingupin bile.°”
The penultimate enzymatic manipulation before B-oxidation is the racemisation of the a-
methyl group by AMACR.Thefirst step of the B-oxidation cycle is catalyzed by acyl-CoA
oxidases (ACOX) which are flavoproteins. These enzymes generate HzO, as a product to
producea trans enoyl-CoA ester. In humansthere are two main acyl-CoA oxidases (ACOX]
and ACOX2). ACOX1is specific for VLCFA-CoA, whereas ACOX2 preferentially reacts
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with the CoA-esters of 2-methyl branched-chain fatty acids, including pristanoyl-CoA (8),
DHC-CoA and THC-CoA (9)* and only accepts a- methylated substrates in the (S) form.
The next two steps in B-oxidation are catalyzed by one of two bifunctional proteins
harbouring two separate enzymatic functions: enoyl-CoA hydratase and 3-hydroxy-acyl-CoA
dehydrogenaseactivity.
Thefirst of these two bifunctional proteins, multifunctional enzyme 1 (MFE-1 - also referred
to as L-specific bifunctional protein, LBP) generates 3-ketoacyl-CoAs (12) via a (3S)-
hydroxyacyl-CoA (13) intermediate. The other bifunctional protein, multifunctional enzyme
2 (MFE-2, also referred to as DBP) has a (3R)-hydroxyacyl-CoA-ester as an intermediate
(11). (£)24-ene-THC-CoA (10) is normally hydrated to (24R,25R)-24-OH-THC-CoA(11)
by MFE-2, but can also be converted to (24$,25)-24-OH-THC-CoA (13) by the hydratase
unit of MFE-1.° (245,25S)-24-OH-THC-CoA (13) is, however, not a substrate for the
dehydrogenase unit of MFE-1 or MFE-2.°° °° but AMACRcan convert it to the (24,25R)-
isomer (14)°’ which canbe oxidised by the dehydrogenase unit of MFE-1 (Fig 1.10).
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Fig 1.10. A Schematic representation of the function of multifunctional enzyme 1 and 2 in
the B-oxidation pathway.
The final chemical manipulation of the B-oxidation pathway is the thiolytic cleavage to
release an acetyl-CoA thioester or derivative (Fig 1.11). There are two main thiolases: A
straight chain 3-oxoacyl-CoA thiolase (ACAA1) anda sterol carrier protein X (SCPx). SCPx
is reactive with the 3-ketoacyl-CoA esters of pristanic acid, DHCA and THCA whereas
ACAAIonlyaccepts the 3-ketoacyl-CoA esters of VLCFA.®
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1.4.2 Significance of AMACRdeficiency
All defects of peroxisomal f-oxidation involve the nervous system which can include
Zellweger syndrome, neonatal adrenoleukodystrophy, and infantile Refsum disease
phenotypes. In contrast, AMACRdeficiency appears to be a milder disorder. To date, only 6
patients (4 adults and 2 children) with documented a-methylacyl-CoA racemase deficiency
have been reported.Symptoms seem to be mostly delayed, developing in adulthood such as
adult-onset sensory motor neuropathy. This is a rare, congenital disorder whereby an
individual’s inability to utilize AMACR results in an accumulation of branched-chain fatty
acids.” ’° The phenotypicalexpressionofthis condition is relapsing encephalopathy, seizures
and cognitive decline.’' In one patient, AMACR deficiency lead to retinitis pigmentosa,
primary hypogonadism,epileptic seizures, and a widespread axonal neuropathy.” It has also
shown to produce demyelinating polyneuropathy. Symptoms in children can include fat
soluble vitamin deficiency (K,E,D) and cholestatic liver disease.
Studies carried out on patients with congenital deficiencies of palmitoyl-CoA oxidase’’, D-
bifunctional protein’ and B-keto-thiolase”’ respectively show symptoms which include
severe dismorphic features, neuromuscular seizures, and cardiac defects. In all cases, death
occurred before four years of age. This effectively singles out AMACRasthe only viable
branched chain metabolising enzyme that could be targeted, without the risk of severe side
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effects. Additionally in many cases, dietary modification and/or bile acid supplementation
offer an effective treatment for the symptoms of AMACRdeficiency.”
1.4.3 Splice variants and polymorphisms ofAMACR
Mubiru ef al., have cloned six different forms of AMACRtranscripts from cDNA derived
from the PC-3 humanprostate cell line. These include AMACRIA, IB, IIA, IIAs IIB and
AMACRJApe,. AMACRIAis the major isoform of AMACR,whichcontains the putative
KASL peroxisomal targeting sequence. AMACR IB contains the same sequence with
AMACRIA,but with exon 3 of the gene omitted. AMACRIIA shares the first four exons
with AMACRIA butusesan alternative fifth exon. AMACRIIAsis an alternative version of
AMACRIIA bya shortening of exon 5. AMACRIIBalso hasan alternative exon 5 and lacks
exon 3. This splice varient has a_ surprisingly high homology with fumarate
hydratase.’'AMACRp_rhas an alternative splicing event in the Sth exon of the gene which
causes a shift in the reading frame. All splice variants have the KASL peroxisomaltargeting
sequence missing andarebelieved to target the mitochondrial organelle.”°
AMACR |A
[Cn
cxon3
SoS
AMACR|8TERA
AMACRIIA
AMACRIIAs
AMACRIIB
AMACRDEL
Fig 1.12 Schematic representation of the known AMACRsplice variants. Exons are colour
coded to represent identical sequences. Exons that are represented by the colour black
represent a deviation from the major isoform AMACTIA.All variations of exon 5 differ
from each other as described above. Exonsthat are omitted in the scheme,are also absent in
the genetic sequence. Exons. Taken from Gene 2004, 327, 89-98 and Prostate 2005, 65, 117-
123.
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At present, the potential biological significance of different AMACRsplice variants remains
unclearasall splice variants are upregulated in PCa.’" © However, studies on the two major
variants of AMACR (AMACRIAand IIA,resulting from the alternative use of the last
exon) has showed that AMACR 1A is quantitatively up-regulated in prostate cancer
compared with normal prostatic tissues, whereas AMACRIIA seemedto be expressed only
in prostate cancer.’’ This indicates that AMACRIIA is only expressed whenthe cell becomes
cancerous.
Studying the difference in allele frequencies between hereditary prostate cancer (HPC) and
controls has shown a variation at four polymorphic regions in the AMACR gene (M9V,
D175G, S201L, K277E).”* The M9V polymorphism seems particularly associated with
increased risk of prostate cancer.’”” A rather compelling study that investigated a connection
between regular Ibuprofen users and AMACRexpression found that risk for prostate cancer
was significantly reduced among regular Ibuprofen users who carried the aforementioned
allele variants (M9V, D175G, S201L, and K277E*’). It may be inferred that AMACRplays a
role in converting Ibuprofen from its COX-inactive ((R)-enantiomer) to the COX-active form
((S)-enantiomer) (as will be explained in results and discussion). Both AMACR and COX-2
are overexpressed in prostate cancer.*' Ibuprofen is a substrate/competitive inhibitor of
AMACRand a competitive inhibitor of COX-2. COX-2 is involved in the production of
prostaglandins which are involved in the regulation in cell growth and inflammatory
responses. It is possible that ibuprofen has a dual anticancer effect by inhibiting both these
enzymes. Alternatively the reduced incidence of cancer in regular Ibuprofen users with these
SNPs may also be due to an increased turnover of the pharmacologically active form of
ibuprofen, which could have increasedefficacy on the COX-2 enzyme.
Although there is a link between these SNP’s with hereditary PCa, there is no evidence to
suggest that they play a significantrole in the developmentofsporadic prostate cancer.*”
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1.5 Mechanism ofAMACR
1.5.1 Substrates and substrate specificity
AMACRaccepts a wide range of CoA esterified substrates (Fig 1.13) which includebile acid
intermediates (di- and trihydroxycoprostanoic acid (9)), the non-steroidal anti-inflammatory
metabolite — ibuprofenoyl-CoA (22), and branched chain fatty acids (with a minimum chain
67, 8°84 The coenzyme A thioester activation of these substrates islength of 8 carbons).
essential for enzymatic activity, as the free acid analogues do not racemise**. [2,3-*H]
Palmitoyl-CoA and [2,3-°H] phytanoyl-CoAareinactive.*’ This suggests there is an inherent
requirement for an a- methyl group as neither 3-methyl-branched chain acyl-CoA’s nor
linear-chain acyl-CoA’s are accepted. More recently however, Lloyd ef al. have
demonstrated that straight-chain fatty acyl-CoA esters are also able to undergo deprotonation
and reprotonation events.* Nonetheless, the straight chain acyl-CoA esters undergo proton
exchangeat a significantly lower rate than their a-methylated analogues.
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Fig 1.13 Substrates of AMACRwith a representation of the SCoA moiety.
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1.5.2 Evolution ofAMACR
The current closest amino acid sequence to the human AMACRenzymewasfoundin protein
QS5RF52_PONAB from Pongo abelii (Sumatran orangutan). This protein is very similar to
human AMACR,with a remarkable 376 identical and 8 similar amino acids resulting in 97%
identity (acquired from the German cDNA consortium, 2004 via ncbi). MCR
(Mycobacterium tuberculosis racemase), also has a high sequence identity with mouse,rat
and human AMACRof41, 44 and 43% respectively, with 153 out of 353 common amino
acids®’). To date, MCRis the only fully characterised enzyme of this family. L-carnitine
dehydratase (CaiB) also shares a large degree of similarity with AMACR. This enzyme was
thought to convert L-carnitine to 4-(trimethylammonio)but-2-enoate through the abstraction
of an a—proton but according to Heider’s review,it is now thought to catalyse CoA transfer
between carnitine and amino crotonate.*’
AMACR, MCRand L-carnitine dehydratase belong to the family II] CoA transferases also
referred to as the CAIB-BAIF family.*® CoA transferases are found in organisms throughout
nature. Nominally CoA transferases catalyse reversible transfer of coenzyme A groups from
CoA thioesters to free acids. There are at least three families of CoA transferases, which
differ in sequence and reaction mechanism. The first structural studies of formyl-CoA
transferase (FRC)*” ”’, a type III CoA transferase, revealed that they are a superfamily of
interlocked dimers.
The Class I CoA transferases, such as succinyl-CoA transferase’ and butyryl-CoA
transferase” are a group of enzymesprimarily involved in fatty acid metabolism and have a
well established ‘ping pong’ mechanism. A CoA donor (24) (normally succinyl-CoA or
acetyl-CoA) formsa covalent intermediate involving a glutamate residue to form a glutamyl-
acyl anhydride intermediate (25). This undergoes nucleophilic attack from the released CoA
moiety to liberate a free acid and form a y-glutamyl-CoA thioester (26). A second free acid
(3-oxo acids or 3-keto acids) then attacks this thioester (26) which ultimately forms a
molecule of 3-oxo(keto)acyl-CoA (28) via another anhydride intermediate (27) and
reactivates the enzyme’™* (Fig 1.14).
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Fig 1.14 A Schematic representation of the mechanism of action for the type I CoA
transferases.
The smaller group of Class II CoA transferases catalyzes a partial reaction in the citrate and
citramalate lyase complexes.*” These reactions do not include covalent enzyme intermediates,
but transfers a covalently bound 3’-dephospho CoA molecule (bound to an acyl carrier
protein (ACP) in the enzyme complex) between twoacids (29, 31) via a mixed anhydride
intermediate (30).’”*° In both classes of CoAtransferases, the reactions involve formation of
thioester and anhydride intermediates, but the mechanistic details differ considerably (Fig
1.15).
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Fig 1.15. A Schematic representation of the mechanism ofaction for the type II transferases.
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Class III CoA transferases are not consistent with a ‘ping-pong’ mechanism asin the Class |
CoA transferases but form covalently enzyme bound intermediates (unlike the class II
transferases). In the case of formyl-CoA transferase the reversible mechanism proceeds
through a possible ternary complex, whereby formyl-CoAis covalently bound to an Asp side
chain to form an anhydride intermediate (33). Again, the free thio attacks this anhydride to
form an enzyme boundthioester (34). This is followed by nucleophilic attack of oxalate to
form a covalently bound oxalate anhydride intermediate (35). Finally, cleavage from the
enzyme by CoASHformsoxalyl-CoA (36) and formic acid (37) (Fig 1.16).°° ””
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Fig 1.16. A Schematic representation of the mechanism of action for Formyl-CoA
  
transferase, an extensively studied type III transferase.
MCRshares a 24% sequence identity with FRC. The quarternary structures of the interlocked
dimers are very well preserved (Fig 1.17). The tertiary structure of the large domain is also
well conserved. However, the helical part of the small domain differs’® in the loop which
connects its large domain to its small domain and provides residues which are important for
the binding of the acyl moiety. The corresponding loops of formyl-CoA transferase,
carnitinyl-CoA transferase and MCRare ofvariable lengths.°’ Due to the high sequence and
quaternary structural similarities between FRC and MCR, somehave proposed that AMACR
is possibly a bifunctional enzymethat activates (by CoA thioesterfication) and epimerisesits
7. fssubstrates®’ in a similar manner to FRC.
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Although the predicted mode of CoA binding appearsto be similar in both enzymes, that both
use an Arg residue to provide stacking interactions with adenine (Arg38 with FRC, Arg85
with MCR), a Lys residue interacting with the pantethine moiety (Lys137 and Lys62°'
respectively) and similar key catalytic residues (Asp169 as a nucleophile for FRC and
Asp156 as a base for MCR),it is unlikely that AMACRis bifunctional.
Free acids are not accepted as substrates of AMACR™and are knownto be independently
CoAthioesterfied by long chain acyl synthetase.”” Additionally, the substrate specificities are
very dissimilar. In MCR,the binding pocket is much more extended and exposedto solvent,
due to shorter loop regionsnearthe active site. This fits in with the findings that AMACRhas
a wide degree of substrate specificity with respect to its side chain (steroidal, aromatic, and
pristanoyl based moieties). FRC howeveris very specific towards small polar molecules.
Superfamily members often share key catalytic site components that have the same chemical
function across the superfamily. This commonaspect often leads to a degree of mechanistic
similarity. However, this is not the case between class III CoA transferases and AMACR.
The respective catalytic residues catalyse different reactions employing distinct chemistry.
 
Formyl-CoA Transferas Carnitinyl-CoA transferase 2-Methylacyl-CoA Racemase
Fig 1.17. X-ray crystal structures of three enzymes belonging to the type III transferase
superfamily taken from pdb.com orientated to show the high degree of structural similarity.
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1.5.3 Affinity and binding.
Structural and kinetic data of mutated variants of MCRhasprovided strong evidencethat the
residues Asp156 and His126 are crucial for the catalytic racemisation.®' The chiral a-carbon
is tightly anchored betweenthese residues with a distance of 3.7 and 3.3A respectively. These
active site catalytic residues are conserved in human AMACRIA. Glu241 and Asp152 are
also key residues, which stabilise the catalytic bases through hydrogen bonding. Dueto the
proximity of the catalytic residues in relation to the functional carbon, a two base mechanism
is hypothesised (Fig 1.18).   Aspis6 0 AsP156—— Oxa-nne=H AMACR aHN H3C, 1H abAsP152 R 2 5 Aspi52CoA IQ “CoAS. HOSH Zs HN-Asp427 Oo dp N—Asp127. Glu NS y NHis126 241 IY Hisi26
(2R)-pristanoyl-CoA Enolate (2S)-pristanoyl-CoA
Fig 1.18. Possible mechanistic pathway for racemisation by MCR.
X-ray crystallographic data of MCR has shown the 2-methyl acyl-CoA molecules hydrogen
bond with their thioester oxygen to the N-H on the Asp127residue.*’ As previously stated,
adenine on the CoA moiety of the substrates has a stacking interaction with the side chain of
Arg38. The 3’-phosphate moiety is salt bridged to Lys62 and Arg91 and the pyrophosphate
moiety is salt bridged with Arg85. The 2-methyl group contacts side chain atoms of His126,
Asp127, Asp156, Leu217 and Tyr 224. During the 1,1-proton transfer, the acyl moiety (of
Ibuprofen) moves over a methionine rich hydrophobic surface (Met50, Met198, Met199,
Met202, Met207 and Trp208), contacting Ilel6, Pro20, Met50 and Met1l98 as the (S)-
enantiomer, and contacting Met216, Leu217 and Ile240 asits (R)-counterpart. In general, the
inversion ofthe chiral center does not change the manner in which the substrate binds. The a-
carbon has a tendency to point towards Asp156 in its (R) form, whereas the analogous
enantiomerpoints towards His126. The 2-methyl group movesslightly but remains bound in
the same pocketand is an important group for the affinity of the substrate to the enzyme. The
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CoA moiety remains rigidly bound, and the acyl group glides over the large hydrophobic
pocket.*!
1.5.4 Mechanism
Incubation of [2-’H]pristanoyl-CoA and [24, 25-*H]trihydroxycopristanoyl-CoA with rat
AMACRhasshownit to catalyze a rapid exchange ofthe a-tritium against a proton from
water. This is highly indicative that the mechanism involves abstraction of a proton at the a-
position.*” It was thus assumed that the enzyme functions by proton abstraction to form a
stabilised enol(ate) in a mechanism similar to methylmalonyl-CoA racemase.'” This is
further supported by the fact that the pKa of the a-proton significantly decreases from ~34 to
21 with the thioesterification of a free acid.'”' This enables the otherwiserelatively strong C-
H bondto succumbto cleavage under mild enzymatic conditions.
Morerecently, mechanistic studies by Darley et al., on the recombinant human AMACR
' This study also showed that theusing NMR have suggested a planar intermediate.
deprotonation occurred with either enantiomer followed by a non-stereospecific reprotonation
of the planar intermediate, proving that AMACRis true racemase.
The aforementioned MCR X-raycrystallographic data has also shownthat oncea substrate is
bound to the enzyme’s active site, the thioester oxygen atom and the 2 methyl group of the
substrate are in a cis conformation with respect to each other, and both point inwards towards
the bottom of the catalytic pocket. These results are consistent with findings from Darley et
al., that the transition state consists of a planar intermediate.
A planar intermediate is not direct evidence of the existence of an enol(ate) and so two
possibilities can be postulated. The first is a ketene intermediate (Fig 1.18), whereby the
proton abstraction would temporarily dissociate the coenzyme A moiety from its parent
molecule. The second is the aforementioned enol(ate) intermediate (Fig 1.18/1.19) which is
stabilised by the enzyme andis the proposed intermediate by which related enzymescatalyse
their reactions.” There is no literature precedent for a ketene intermediate in reactions
catalysed by a racemaseandsoit is highly probable that the mechanism ofaction goes via the
enol(ate). However, one must not forget that FRC performsits catalytic activity by the release
and reattachment of the CoA moiety. A carbanion intermediate (Fig 1.19) is unlikely as it
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would provide a tetrahedral intermediate which would not facilitate inversion of
configuration and would also contradict the established evidencefor a planar intermediate.
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Fig 1.19. A Schematic representation of the possible enzymatic intermediates adapted from
p10Darley et a
Incubation of AMACRin D,O with non deuterated substrates!” has shown a higher rate of
deuterium incorporation than that of known two base racemases such as mandelate
103 04racemase, methylmalonyl-CoA epimerase'”* and diaminopimelic acid epimerase.'”
Additionally, it was noted that AMACRhad nopreference in rate of deuterium incorporation
for either enantiomer. This is more representative ofa classical one base mechanism'” andis
exemplified with the incubation of (S) 2-methyldecanoyl-CoA with AMACR in D,0O.
Quenching and analysing the reaction during the initial burst furnished incorporation of
deuterium at the a-position into both enantiomers. This is a standard method of assessing
whether the enzyme has a monoordualbase catalytic racemisation system.!°” If the enzyme
racemises the substrate by utilizing two bases, then terminating the reaction duringthe initial
burst would provide the (R) 2-methyldecanoyl-CoA in its a-deuterated form, but would have
kept the (S) 2-methyldecanoyl-CoA protonated. This is due to the inability of the monoprotic
bases to exchange a proton with the solvent during the lifetime of the enol(ate). AMACRis
different. In most racemasesutilising two bases, the catalytic active site is locked away from
the bulk solvent and deuterium incorporation can belimited.'°’ The active site of AMACR
howeverresides nearer the surface of the enzyme (Fig 4.13) as is typical of the type III
61, 90transferases and so will have a higher propensity to interact with the bulk solvent.
Further studies on mutated variants of the enzyme should be conducted to unequivocally
ascertain whether the enzymefunctions as a mono or dual base racemase. However, due to
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the proximity of Asp156 and His126 andthe relative orientation of the substrate in its
different enantiomeric state, it is difficult to imagine that it functions by using only one of
these bases.
To summarise, despite MCR/AMACR belonging to the type II transferase family,
MCR/AMACRprobably functions as a two base racemase by deprotonating/reprotonating
the a-proton from a 2-methyl CoA thioester via an enzymestabilised enol(ate) intermediate.
This is the only known racemase of this family. Moreover its substrate specificity is
surprisingly distinct from the formal type III transferases, which catalyse the transfer of the
CoA moiety between specific small, polar acyl groups.
1.6 The human AMACRmodel based on MCR homology
Dr Robert Gibson from the University of Liverpool has built a model of human AMACR
based on the crystal structure of MCR obtained from Mycobacterium tuberculosis. This was
achieved byinitially performing a blast search to check whether the key catalytic residues are
conserved. As previously stated, MCR and AMACRshare 42% sequence identity. From this
we can be confident that the fold of the protein is very similar. Since the key catalytic
residues and enzymatic function are the same (with perhaps a small change in the substrate
specificity), homology studies are then undertaken using MODELLER; which takes the
secondary structure of MCR and threads the AMACR sequence through it. This then
automatically builds the tertiary structure. Approximately 50 models are generated and the
lowest energy modelis used. As a caveat however, the model at loop regions can sometimes
be mis-represented. However, since the catalytic site is in a groove, rather than at a loop
region, this is not too important. The AMACRsequencehas an additional 30 aminoacidsat
the C-terminal, so this cannot be modelled in (Fig 1.20)
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Fig 1.20. MCR and AMACR model comparison with the catalytic residues histidine and
aspartate in shownasspheres.
Three completely conserved residues appear to be suitably positioned to act as catalytic
residues in AMACR,namely His122, Asp123, and Asp152. The CoAstacking residue Arg81
is also conserved. Lys 58 is conserved and Arg 91 of MCRis replaced by Lys87, which is
salt bridged to the 3’-phosphate moiety. The methionines in the hydrophobic pocket of MCR
are replaced by hydrophobic residues of phenylalanine, leucine and tryptophan. All in all, the
high homology between prokaryotic and eukaryotic isoforms of AMACRsuggests that their
function, substrate specificity and catalytic mode of action are likely to be very well
conserved.
1.7 Fatty Acid Metabolism as a Therapeutic Target.
One of the consistently observable features of PCa is the upregulation of fatty acid
metabolism to meet the bioenergetic requirementfor rapid cell proliferation. Several enzymes
have been identified as being overexpressed. Fatty acid synthase (FAS)is considered to be a
possible metabolic oncogene in prostate cancer’ and is found to be overexpressed at both
protein and mRNAlevels.'°* ''° Inhibiting FAS with Cerulenin and C75 (established FAS
inhibitors) has demonstrated significant antitumor activity. Both Cerulenin and C75 have
however been shownto cause profound effects on food intake and bodyweight in mice that
could limit the development of FASinhibition as a therapeutic strategy.''' To date, the most
potent inhibitor of FAS is GSK837149A, developed by GSK but biochemical studies have
shownit to have poorcell permeability.
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Studies on the upregulation of the B-oxidation pathway by Zha et al.,,''* have shown an
increased expression of mRNA, protein and accompanied enzymatic activity of MFE-2.
Furthermore, ACOX3, which is expressed at extremely low levels in other human organs
studied, including the liver, may contribute significantly to peroxisomal branchedchain fatty-
acid B-oxidation in humanprostate tissue, with possible greater significance in PCa.'!°
Using small interference RNA (siRNA) to impair AMACRexpression significantly impaired
proliferation of the androgen-responsive PCacell line LAPC-4 as an in vitro model. The
mechanism ofthis growth inhibition was found to be independent of androgen, indicating that
AMACRisessential for optimal growth of PCa cells.''* More recent studies on AMACR’s
involvement in conversion of prostate cancer from hormone independence to dependency
have shownthat by inhibiting AMACRexpression in the androgen independentcell line C4-
2, there is an increased expression of AR. Incubating the androgen dependent cell line
LNCaPwith an androgen depleted serum demonstrated significant decrease of cell viability,
whereas in the same serum, the C4-2 cells grew normally. However, when incubated in an
androgen depleted serum treated with AMACR siRNA, the C4-2 cell line showed a
significant decrease in cell viability.''” These results indicate that the expression ofAR dueto
AMACRinhibition may induce characteristic conversion of prostate cancer cells from a
hormone independent to hormone dependentstate. This is potentially hugely advantageous
whendealing with hormonerefractory PCa.
There are two thoughts in regards to AMACR’s role in the development of prostate cancer.
The first being it helps to provide metabolic support necessary for tumour growth and the
second theory is that increased peroxisomal AMACRactivity is responsible for increasing
peroxisomal f-oxidation, resulting in increased cellular peroxide production via the ACOX
enzymes. This increased production of cellular peroxide, without a compensatory increase in
catalase expression, results in a more oxidative environment in prostate cancer cells,
promoting DNA damageandincreasingthe risk of prostate cancer from high-grade prostatic
intraepithelial neoplasia.
Using AMACRas a therapeutic target for prostate cancer seems an attractive strategy.
Targeting other enzymes that are upregulated in the B-oxidation pathway (MFE-1/2 ACOX
etc.), may lead to severe side effects and additional toxicities (as described in Section 1.4.1)
whereasinhibiting the functionality of AMACRleadsto rather milder complaints that can be
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alleviated with a controlled diet. Additionally, it has been suggested that AMACRcould be
targeted as a promising avenue of treatment for hormone independent prostate cancer for
whichat present there are no effective treatments.
Upondesigning inhibitors of AMACR,one should consider enzymespecificity. Around 4%
ofall cellular enzymes are CoA utilising. The CoA moiety is frequently a prerequisite for the
binding of substrates to enzymes, with many possible hydrophilic interactions. Making
alterations to this fragment butstill maintaining enzymeaffinity is thus difficult. However,
there is scope to increase enzyme specificity with regards the acyl region of the CoA
thioester. Many CoA utilising enzymes use shorter groups extending from the thioester.
Metabolism of longer acyl coenzyme A thioesters is normally restricted to the B-oxidation
pathway. Incorporating compounds that have an a-methyl group mayincrease specificity
further towardsthe specific set of a—methylutilising enzymes.
1.8 Established and proposedinhibitors/substrates of AMACR
1.8.1 Probing the inhibition ofAMACR
Initial inhibition studies of rat AMACR werecarried out by Schimtz et al. A range of
reagents were incubated with the enzyme and the rate of which [2-*H]-pristanoyl-CoA
exchanged with the solvent was monitored. It was noted that there was strong inhibition of
the enzymatic activity by thiol directed reagents such as Hg** or NBS, which suggest the
presence and availability of a cysteine residue. The enzyme wasalso largely inactivated by
diisopropylphosphofluoridate, which is generally knownas a specific and potent inhibitor of
serine. However, these specific amino acid binders do not necessarily mean that they are
involved in the catalytic mechanism of the enzyme. Of the branched-chain fatty acyl-CoAs
tested, only 2-methyloctanoyl-CoA and 2-methylmyristoyl-CoA had an inhibitory effect.
Neither the short chain 2-methylpropionyl-CoA, 2-methylbutyryl-CoA nor the phytanic acid
(a 3-methyl branched fatty acid derivative) had any effect. The a,B,unsaturated compound, 2-
methylmyrist-2-enoyl-CoA, also did not inhibit the reaction, indicating a clear substrate
specificity of the enzyme for saturated medium and long-chain a-methyl branchedfatty acids.
Since these initial studies only Carnell et al., have performed further inhibition studies on
AMACR.!!°
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1.8.2 Designed suicide inhibitors
Prior to the publication of the bacterial crystal structure®', a series of substrate analogues
were synthesised as mechanism-based inhibitors containing one or more fluorine atoms in a
B-position to the CoAthioester''®,
Alanine racemase (a PLP-dependent (38) bacterial enzymethat catalyses the racemisation of
alanine, providing D-alanine for cell wall synthesis''’) is one of the most studied racemases
and achieves chiral inversion by deprotonation and reprotonation by a catalytic acid/base
pair. Inhibition of alanine racemase with B,B,B-trifluoroalanine (39) has been studied
previously by Walsh er a/.''® It was found that incubation of ,8,p-trifluoroalanine led to
irreversible inhibition where the enolisation process (40) leads to the formation of an a,B-
unsaturated intermediate (41) which can undergo nucleophilic attack by a basic amino acid
residue within the activesite. (Fig 1.21) foTT
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Fig 1.21. A Schematic representation of the irreversible inhibition of alanine racemise by
B.B.B-trifluoroalanine. B> represents Tyrosine 265.'"®
It was thus envisagedthat this type of inhibition could be replicated with AMACR; whereby
elimination of a fluoride from the proposed enolate (45) by an ElcB mechanism within the
active site would generate an a,B-unsaturated thioester (46) that may then undergo attack by
an active site base or nucleophile to give the inactivated enzyme (48) (Fig 1.22)
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Fig 1.22. A proposed mechanism of inhibition of AMACRby f-fluorinated analogues of
natural substrates.
However it was found that these postulated irrevsible inhibitors inhibited the enzyme
competitively (Fig. 1.23).''"° The most successful of these inhibitors is 2-
trifluoromethyltetradecanoyl-CoA (49). This has a 150 fold increase in activity compared to
its non fluorinated analogue 2-methyltetradecanoyl-CoA (53) with a K; of 0.9uM (based on
two different assays). To date, this is the most potent inhibitor of rat AMACR. Another
interesting point to make with regards to these results is the difference in K; value between
(S) and (R)-ibuprofenoyl-CoA (22a and 22b). (R)-ibuprofenoyl-CoA (22b) has a lower K;
value then its (S) counterpart (22a). This is something that should be considered when
designing potential inhibitors.
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Fig 1.23. A range of competitive inhibitors of AMACRandtheir Ki values.
From the crystal structure of MCR and mechanistic studies of AMACR, we can hypothesise
the rationale of these K;’s. Since the trifluoro group is electronegative, this would lower the
pKaof the a-proton, facilitating enolisation. The fact that all mono B-fluorinated compounds
(with the exception of compound 50) have similar K; values of 1.3-3.8uM is also an
additional verification of the proposed mechanism of inhibition. Moreover, the fluorinated
enolate intermediate, may bind morestrongly at the activesite
However, there is no direct evidence that the competitive inhibition is due to the lowering of
the pXa of the a-proton, and so one mustalso consider that the inhibition may be due to an
increased binding affinity of the substrate. This is one of the questions that we wish to answer 
 
5.4
3.8
45
by synthesising non-enolisable a-fluoro analogues and comparingtheirrelative K1’s.
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1.8.3 Proposed mechanism-based inhibitors
We have designed a series of AMACRinhibitors that have similar properties to those that
have already been synthesised and tested. These inhibitors are designed to probe three aspects
of the substrate enzymeinteraction; the first being the binding affinity between the acyl group
and the hydrophobic pocket, the second to probe the methyl binding pocket, and the third, the
catalytic mechanism (Fig 1.24).
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Fig 1.24. A range of proposed compoundsto probeinhibition and mechanism ofAMACR.
Wehavedesigned several substrates that will aid us in developing an assay in whichto test
our potential inhibitors. Two LC based assays were created along with developing a fast,
reliable chromogenic assay. It was proposed that we could monitor the rate of the
racemisation by following the rate of formation of (R)-ibuprofenoyl-CoA (22b) from the
enantiomerically pure (S)-ibuprofenoyl-CoA (22a). This was to be done using chiral RP-
HPLCto measurethe relative increase of (R)-ibuprofenoyl-CoA (22b) formed. The second
LC based assay involves the use of LCMS. We would synthesise a racemic mixture of a-
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deutero-ibuprofenoyl-CoA (67) and measure the formation of the ibuprofenoyl-CoA (22) by
injecting aliquot portions of the reaction mixture onto an LCMSsystem equipped with an RP
column (Fig 1.25).
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Fig 1.25. a—deuterio-Ibuprofenoyl-CoA and (S)-Ibuprofenyol-CoA as substrates for an LC
based assay.
The chromogenic substrates (68/69/72) were designed to form the chromophore (71/74)
through enzymatic abstraction of the a-proton of both chromogens to form the enzyme-
stabilised intermediates (70/73) followed by an ElcB elimination step to generate a
conjugated chromophore(71/74) (Fig 1.26).
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Fig 1.26. A Schematic representation of the proposed formation of a UV detectable
chromophore through AMACRpromoted E1cB elimination.
We propose the synthesis of two different thioesters as potential substrates for our
chromogenic assay (fig 1.27). The first being the conventional CoA thioester and the second
being an N-acetylcysteamine thioester. The reason for the differences in the thioester moiety
is because upon formation of the aliphatic chromophore (74), a UV maxima of 263nm is
produced.'!” '*° Adenine (which is an intrinsic part of the CoA molecule) has an extinction
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'2! This could interfere with any possiblecoefficient of 15800 at a wavelength of 260nm.
measurements of the formation of the aliphatic chromophore (74). The p-nitro chromophore
(71) has a UV maxiumum at 307nm'” which should not overlap with the CoA UV maxima.
The secondrationale for using N-acetylcysteamineis that it has recently been reported that a
number of fatty acyl-CoA ligases (FACL’s) display remarkable tolerance when the CoA
123group is replaced by N-acetylcysteamide (NAC). It is known that FACL’s contain
overlapping substrate specificities,'** which has also been proposed for AMACRandrelated
B-oxidation enzymes. Furthermore, it was found that varying the chain length did not affect
the formation of fatty acyl-CoA thioesters. These properties draw parallels with AMACR,
indicating that NAC thioesters may indeed be tolerated as an alternative to CoA-thioesters.
cl 9 OH °
cr crrA
ON2" O2N 68
69
ElcB sata, aelimination
O°
O2N
71
° °
° °
2 i.
Fig 1.27. A range of potential chromogenic substrates and their respective chromophores.
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CHAPTER 2
SYNTHESIS OF INHIBITORS
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2.1 Project Aims
Competitive inhibition studies carried out by Carnelleg a/.,''° in addition to the structural and
13 '? indicate that the a-mechanistic studies carried out by Wierengaetal.,°' and Lloyd et a
methyl and CoA thioester moieties in the substrate are crucial for binding with theactivesite.
These findings also suggest the presence of a large hydrophobic region within the catalytic
site, which allows for structural diversity in potential inhibitors and substrates. We have
designed a series of inhibitors with a high degree of structural similarity to the natural
substrates and to previously recognised inhibitors of AMACR. This chapter discusses
strategies employedandthe rationale behind the synthesis of these potential inhibitors.
2.2 Modified synthesis of a-trifluoromethyltetradecanoyl-CoA (49)
First we shall discuss the re-synthesis of the most potent inhibitor to date, a-
trifluoromethyltetradecanoyl-CoA (49). This was previously synthesised by Ian Haleetal.,'”°
by performing a Wittig reaction between the dodecyl triphenylphosphonium bromide salt
(75) and the commercially available trifluoromethyl pyruvate to yield a 1:1 mixture of EF and
Z stereoisomersof the enolate (76) (Fig 2.01). Conventionally, we would expect the Z-isomer
to predominate dueto the unstabilised nature of the ylide. However, this ratio has previously
been observed by Palecek and co-workers in their preparation of trifluoromethyl a,p-
76 using the same Wittig reaction conditions. This was followed byunsaturated esters!
hydrogenation (using 10% Pd-C in methanol) and basic hydrolysis to give the free acid (79).
Attempts at using ethyl chloroformate and triethylamine to form a mixed anhydride proved
unsuccessful in coupling to coenzyme A. However, the coupling of the free acid to coenzyme
A using CDIproved a successful alternative (Fig 2.01).
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Fig 2.01 - Reagents and conditions: i, PPh3, toluene, A, 48h, 98%; ii, nBuLi,
F3CC(O)CO,Me, THF, -78°C, 3h, 54%;iii, H»/Pd/C, MeOH,rt, 24h, 94%; iv, SN NaOH,
THF, MeOH,rt, 24h, 97%; v, CDI, THF, rt, 2h; vi, CoA-SH,(Li’)3, H.O/THF,rt, 24h.
Attempts at repeating this work were troublesome. The synthesis of 2-
trifluoromethyltetradecanoic methyl ester (78) was achieved using the previously established
route. Use of SV NaOHin a mixture of THF and methanol to hydrolyse the methyl ester did
not give the desired free acid. Instead, it was noted that HF was removedby a probable B-
elimination pathway (80) (Fig 2.01 — dashed). There is only one literature precedent which
describes a similar phenonomen with an aliphatic a-trihalomethyl ester. The B-elimination
12TA rangeprocess occurred with the use of the surprisingly mild potassium carbonate base.
of hydrolytic conditions were subsequently tested in order to obtain the desired acid. Using a
lower concentration of base yielded the same undesired product, as did using less equivalents
and changing the base from sodium hydroxide to potassium hydroxide or lithium hydroxide.
Similarly, attempts at hydrolysing the methyl ester in its unsaturated form (76) did not yield
the desired acid, but instead also resulted in elimination of fluorine. Refluxing the methyl
ester with barium hydroxide surprisingly resulted in no reaction at all and the starting
material was fully recovered. Attempts at using acidic methodsalso provedfruitless. Boiling
the methyl ester in concentrated sulphuric acid did not yield the acid, nor did the use of
concentrated hydrochloric acid. In both cases no hydrolysis was achieved. It has been
reported that a-trifluoromethyl aliphatic esters can be enzymatically hydrolysed by Lipase
PS.'*8 However, this is not the case for this substrate. A range of other lipases were also
screened, giving no product and full recovery of the starting material.
A longer alternative route was thus devised involving reduction of the methyl ester to the
corresponding alcohol and then oxidation to the free acid. Reduction of the ester using
lithium aluminium hydride to give the alcohol worked well in good yield. However,
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oxidation was problematic. Oxidation using a single step procedure such as Jones oxidation
gave a range of products by TLC. Milder stepwise oxidation procedures such as the use of
PCC or Swern conditionsto yield the desired aldehyde wereprohibitively low yielding.
Another method ofde-esterification for alkyl esters is to reflux the ester with lithium iodide
in wet DMF.Traditionally, these reagents and conditions are used to convert B-ketoesters
(81) to ketones (84) through decarboxylation (82-83). This is known as Krapcho
decarboxylation (Fig 2.02).
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Fig 2.02. Krapcho decarboxylation.
Using the Krapcho decarboxylation conditions for de-esterification purposes has been known
for the last half a century'”” but is employed infrequently. It is particularly useful for methyl
esters since the de-esterification reaction is an Sy2 process. We found that refluxing
compound (78) with lithium iodide in wet DMFbetween 8 hours and overnight furnished the
desired free acid (79) in an excellent yield. The CoA ester was madeby activating the free
acid with CDI(Fig 2.03). This was then purified by reverse phase HPLC. A description of the
development of purification of CoA thioesters by HPLC can be read in Section 3.2,
exemplified by Ibuprofenoyl-CoA (22).
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Fig 2.03. Krapcho de-esterification followed by activation of the free acid with 1,1-
carbonyldiimidazole and the subsequentthioesterification.
2.3 Incorporation of an a-dimethyl group
It is well established that AMACR accepts both enantiomers of its substrates, with little
preference for one over the other.'” By synthesising dimethylpentadecanoyl-CoA (59) we
wish to probe twoaspects of the inhibitory binding. Firstly, having both ‘orientations’ of the
methyl group present in a single molecule might increase the binding affinity of the substrate
to the enzyme and secondly, without the a-hydrogen, the compoundis unable to enolise. We
can thus study whetherit is the enolate or the ester that is the real inhibitor. Treatment of
isobutyric acid (87) with sodium hydride and diisopropylamine gave an enolate dianion
which then reacted with 1-bromododecaneto yield 2,2-dimethylpentadecanoic acid (88) (Fig
2.04). This can then be thioesterified with CoASHas described in Section 2.2.
4]
Oo OH
rr
OH 88
87
; iv, Vv
v
O
NNN
59
Fig 2.04 Reagents and conditions: i, NaH, DIPA, THF, rt, 20mins; ii, CH3(CH2),,Br, 0°C,
60mins, then rt ON;iii, aq HCl, 0°C, Smins, 58%. iv, CDI, THF,rt, 2h; v, CoA-SH,(Li’)3
THF/H,O,rt, 24h.
2.4 Incorporation of an a—chloro moiety (58).
The natural substrates of AMACR previously discussed contain an a-methyl moiety.
Chlorine is knownas an isosteric replacement of a methyl group.'*’ It can also isosterically
replace a CF; group or CN group. Replacing the a-methyl group with chlorine is a
compelling choice for a potential inhibitor as it not only has a similar size to that of the a-
methyl group, but chlorine is electronegative, which lowers the pXa of the a-proton, thus
possibly inhibiting in a similar mannerto that of a-trifluoromethyltetradecanoyl-CoA (49).
The synthesis of the free acid was achieved by following a protocol found in the textbook by
Vogel."*!
Treatment of myristic acid (89) with thionyl chloride gave tetradecanoyl chloride (90) which
was converted to its a-chloro analogue (2-chlorotetradecanoyl chloride (91)) by subsequent
treatment with 2 mole equivalents of N-chlorosuccinamide and concentrated hydrochloric
acid. The fractionally distilled 2-chlorotetradecanoyl chloride (91) was then subject to
hydrolysis using mildly acidic conditions to yield 2-chlorotetradecanoic acid'** (92). This
could then be subjected to the previously stated CoA thioesterifcation procedure (Fig 2.05).
This was not done since it was thought that the a—chloro acid would be more stable in
storage.
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Fig 2.05 Reagents and conditions: i, SOCl2, A, 30 mins; ii, SOCl2, NCS, HCl, 80°C, 1.25h;
iii, aq HCI, rt, 5 mins, 54%. iv, CDI, THF,rt, 2h; v, CoA-SH,(Li’); THF/H2O,rt, 24h.
2.5 Synthesis of aryl ether derivatives.
2.5.1 Rationale
It is well understoodthat fluorine exerts some unique properties on biological molecules.'*?
The C-F bondis notoriously strong, with a bond strength in the region of 115 kcal mol, in
comparison to the C-H bond, which has an average bond strength of 104 kcal mol. '** This
meansthat introduction of a C-F bond can beused to prevent metabolism.
Studies on anti-malarial Acridones by Winter et al., have shown someinteresting results.
Acridones were designed to inhibit the Plasmodium cytochrome bel complex.'*? This
enzymehasa relatively large hydrophobic pocket and it was found that the potency of the
acridones were reliant on the variation of the aliphatic region. The general relationship was
that the more hydrophobic the aliphatic tail, the better the ICs) of the acridone (93-95) (Fig
2.06). Presumably, this relationship occurs by anincreasedaffinity to the activesite.
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Fig 2.06 Various acridone analogues that demonstrate the influence of fluorine atoms on
antimalarial potency.
The same general argument could be proposed for AMACR. As with Plasmodium
cytochrome bcl complex, AMACR has a large hydrophobic pocket that consists of
methionines, leucines, tyrosines and phenylalanines. Designing compoundsthat incorporate a
terminal polyfluoroaliphatic moiety, accompanied by the a-trifluoromethyl group (Fig 2.07),
which had already been established to exert beneficial effect on K; compared to the natural
substrates, may decrease the K; further. It was envisaged that incorporation of an aromatic
group between the a-methyl functionality and the aliphatic perfluoro moiety would give the
potential inhibitor structural rigidity. Other derivatives such as compound (66) (the
polyfluorinated tail replaced by a hydrocarbon) and compound (96) (the a-trifluoromethyl
group is replaced with a methyl group) (Fig 2.07) are also useful probes. If the two a-
trifluoromethyl compounds have similar Ki values, but the a-methyl derivative with the
fluorinated tail showed a relatively poor Ki in comparison, this would indicate that the
binding affinity of the inhibitor is not due to the hydrophobic tail but would indicate the
importance of the a-trifluoromethyl group - either by the lowering of pKa of the a-proton or
the general affinity of the a-trifluoro group to the methyl pocket.
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Fig 2.07 Variationsofthe aryl ether inhibitors.
The optimal length of the aliphatic region in inhibitors (65)/(66)/(96) was calculated using
Spartan. From previousreports, it was shownthat the length of the aliphatic moiety extending
from the thioester must be at least 8 carbon atoms long. Using our mostpotent inhibitor (49)
as a model(14 carbons), the length was matched with our aryl ether compound(s). It was
found that an additional 8 carbons extending from the ether linkage fitted best. 1,1,1-
Trifluoro-8-halo octanes are not commercially available. However, 1-bromooctanoic acid is.
Workby Lalet al., suggested that free aliphatic acids can be converted into trifluoro groups
by reacting the acid in neat deoxofluor'*®. Deoxofluor is known to be a mild form of DAST
(diethylaminosulfurtrifluoride) and a common commercial source of nucleophilic fluorine.
Repeating this reaction was challenging. This was due to the difficulty in isolating the
product. A range of compounds were formed (noted by TLC). Furthermoreit was difficult to
quantify the extent of the reaction and to determine whether the TLC spots were
intermediates of the final compoundorside products. To partially circumventthis problem it
was decided to work with the commercially available 1,1,1,3,3,3-trifluoro-2-fluoro-6-
bromohexane. Although this is two carbonsshorter, it adheres to the minimum of 8 carbons
rule.
2.5.2 Heck coupling with trifluoromethyl acrylic acid
Our original approach for synthesis of these compounds was to perform a Heck coupling
reaction between a_ 1-halo-4-alkoxy benzene (100) and a commercially available
trifluoromethyl acrylic acid (Fig 2.09). This would then undergo hydrogenation to reduce the
double bond followed by coupling to coenzyme A. Weinitially tested this novel Heck
reaction with bromobenzene (97) and trifluoromethyl acrylic acid (98) using palladium
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acetate, triphenylphosphine and two equivalents of caesium carbonate. Although the reaction
worked, the yield was poor (21%, fig 2.08). Attempting this on a para ether compound such
as para bromoanisole did not yield the desired compound, even if the base or ligand was
varied (Cs»CO; and NEt; as bases, PPh; and P(Otol)3 as ligands). Using these conditions
caused polymerisation of trifluoromethyl acrylic acid (noted by NMR and mass
spectrometry). We attempted to overcome this problem by the addition of hydroquinone,
which can help suppress polymerisation. However, this was unfortunately ineffective.
Sidestepping polymerisation by protecting the carboxylic acid moiety, we synthesised benzyl
2-(trifluoromethyl)acrylate (102) by refluxing trifluromethyl acrylic acid (98) in benzyl
alcohol with a catalytic amount of H2SO4. The Heck coupling was repeated but still no
desired product wasisolated (Fig 2.08). Changing the X group from bromoto iodo (which
facilitates the oxidative addition) still yielded no product. As the para methoxy(or analogue)
is electron donating, a plausible explanation may be due to an increased stability of the C-X
bond. This decelerates the oxidative insertion of Pd, rendering trifluoromethyl] acrylic acid (or
analogue) more susceptible to undergo polymerisation. Moreover, there is only one reference
of a Heck coupling reaction with an a-trifluoromethyl moiety (relative to the least hindered
side of the double bond). Even then, this was restricted to 3,3,3-trifluoro-2-methylprop-1-
ene'*’; otherwise, it is unprecedented. Although theoretically possible, it is practically very
challenging. Therefore a new route wasdevised.
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Fig 2.08 Heck coupling reactions of trifluoromethyl acrylic acid with a variety of bromo
aromatic compounds. Reagents and conditions: i, PPh3, Pd(OAc)2, CsxCO3, DMF, 150°C,
O.N 21%.
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2.5.3 Successful synthesis of aryl ether derivatives
Changingstrategies involved creating an ether linkage between para hydroxy benzyl alcohol
and the desired aliphatic chain. The benzyl hydroxy group wasreplaced by iodine, which was
subsequently converted to a phosphonium salt, suitable for a Wittig reaction with
trifluoromethyl pyruvate. The resulting double bond was then reduced, followed by de-
esterification and finally CoA thioesterification (Fig 2.09).
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Fig 2.09. Reagents and conditions for Ry = : i, KxCO3, CH3(CH2)7Br, Me2CO,60°C, 4h, 83%;
ii, PPh3, Imid, b, DCM, 25°C, 30 mins 98%; iii, PPh3, Tol, A, 3h 87%; iv, n-BuLi,
CF3;C(O)C(O)OCH3, THF, -78°C, 2h 34%; v, Pt-C, H2, MeOH, 800psi 89%; vi, Lil, DMF
180°C, 8h, 70%; vii, CDI, THF,rt, 2h; viii, CoA-SH,(Li); THF/H20,rt, 24h.
Reacting the aliphatic chain with para hydroxyl benzyl alcohol (103) in the presence of
potassium carbonate in acetone'*® yielded the desired ether (104) in good yield. It does not
create an ether linkage at the aliphatic alcohol as the pKa of the aromatic hydroxyl is lower
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(pKa of an aromatic OH ~10 as compared to the pKa ofaliphatic OH~16). Next, the hydroxy
group was displaced with a halide. This can be achieved in a numberof ways including the
use of thionyl chloride/oxalyl chloride, the use of phosphorustribromide,or the use of iodide.
The iodo derivative was chosenin this instance. The R-I bond is weakest out of the available
halogens, thus facilitating the following Wittig reaction. To perform the iodoination, it was
'° (Fig 2.10). The reaction time wasdecided to use triphenylphosphine,iodine and imidazole
less than an hour and a quantitative yield was obtained. It should be noted that mass spectra
of the iodo compoundswerenot obtained due to a-cleavage.
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Fig 2.10. Mechanism of halogen displacement.
'9(106), a Wittig reaction wasAfter formation of the corresponding phosphonium salt
performed with trifluoro pyruvate. This gave (107) in a good yield with reproducible
stereoisomeric ratios of 1:1. Initial attempts at reducing the double bond using H2/Pd-C at
atmospheric pressure in methanol yielded no product and the starting material was fully
recovered. Increasing pressure to 800 psi gave a similar outcome. Changingthe catalyst to Pt-
C at 800 psi reduced the double bond successfully to yield (108). The low reactivity can be
attributed to the fact that the neighbouringtrifluoro group deactivates the double bond. Using
Pt rather the Pd overcame this problem. The aryl ether (108) was then de-esterified under
Krapcho conditions to yield the desired acid (109).
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2.5.4 Alternative synthetic strategy
Asan alternative more versatile synthetic route to this series of compounds, another strategy
was also employed. A benzyl ether linkage between the 4-hydroxy benzyl alcohol (117) and
benzyl bromide was created'*’ (118). Routine procedures to form the unsaturated methyl
ester were then executed. It was envisaged that the double bond and benzyl group would be
reduced and removed respectively by using Pt-C in methanol in order to then introduce a
phenolic alkyl group of our choosing. However, use of Pt-C at 800 psi overnight resulted in
only reduction of the double bond (122) (Fig 2.11). The fact the Pt-C did not remove the
benzyl group could be considered serendipitous. Although another reagent (Pd-C) is needed
to gain access to a range ofaliphatic aryl ethers, we now have access to compound (56),
which will add to our arsenal of hydrophobic pocketprobes.
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Fig 2.11 Reagents and conditions: i, KyCO3, 4-OHC.H,Br, acetone, 60°C, 4h, 91%; ii, PPhs,
Imid, I, DCM, 25°C, 30 mins 90%; iii, PPh3, Tol, A, 3h 90%; iv, n-BuLi,
CF3C(O)C(O)OCH3, THF, -78°C, 2h 45%; v, Pt-C, Ho, MeOH,800 psi 95%; vi, Lil, DMF,
160°C, 8h, 63%; vii, CDI, THF,rt, 2h; viii, CoA-SH, (Li’); THF/H,0,rt, 24h; ix, Pd-C, Ho,
5h, rt; x, KxCO3, Alkyl-X, acetone, 60°C.
49
2.6 Synthesis of B-trifluoroibuprofenoyl-CoA (60)
 
Work by Carnell et al., has already ascertained that Ibuprofen (22) (despite being a known
substrate of AMACR) has a comparible Ki value to that of the mono-fluorinated analogues of
branched chain fatty acids when assayed against THC-CoA(9). This fact, alongside the fact
that fluorinated analogues of the aliphatic substrates exhibit a 150 fold decrease in K;
comparedto their non fluorinated analogues (based on twoassays) lead us to envisage that
fluorinated versions of Ibuprofen may exert excellent inhibition characteristics. This is further
supported by the fact that (R)-ibuprofenoyl-CoA (22b) has a better affinity to AMACR than
all knownnatural substrates (Table 2.1).
 
 
     
Kd (MCR) Kd (AMACR)
Substrate (uM) (uM)
(S)-Ibuprofenoyl-CoA 35.7
(R, S)-THCA-CoA 26 60
(R, S)-Pristanoyl-CoA 41 76
Acetoacetyl-CoA 715
Acetyl-CoA 585
Table 2.1 Relative binding affinities of a range of natural substrates of MCR and rat
AMACR.°!
8-Trifluoroibuprofen (134) had been previously synthesised some 17 years ago by a rather
convoluted method using chloropentafluoroacetone (128) as the starting material (Fig
2.12).'” This CFC is now prohibitively expensive. A Friedel Crafts reaction was performed
with the chloropentafluoroacetone (128) and isobutylbenzene (127). This was followed by
chlorination and reduction to yield an alkene 1-isobutyl-4-(perfluoroprop-1-en-2-yl)benzene
(132) which was then attacked by sodium ethoxide in ethanol to yield the penultimate
intermediate (133) (in a 1:1 mixture of stereoisomers) and a side product. The product/side
product ratio was not discussed. The saturated intermediate (133) was then converted to the
desired product, B-trifluoroibuprofen (134). A more recent method employed the use of
electrochemical carboxylation of a chlorinated species.'*? Both these methods are impractical
in terms of large scale synthesis.
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Fig 2.12. Previous synthesis of B-trifluorolbuprofen by Middletonet al.
Ourinitial approach for the formation of B-trifluoroibuprofenoyl-CoA (60) was to use an
analogous route employed by Shiehet a/., for the formation of '3C-Ibuprofen, for metabolism
studies with rat liver mitochondria’(Fig 2.13). 9 OH
LIE Lo i Lor——___—_—_—_— od
136127 135
X=Cl, 137i I, 138OMs, 139
CF; CN x
OH 4.Cone HzSO,4 CF; iv CF;~<-------- <_<O
134 140 137-139
Fig 2.13. Reagents and conditions: i, AIC, TFAA, DCM,0°C, lh, 74%; 11, NaBH4, MeOH,
0°C, Lh; 90% iiia, SOCl, 80°C, 4h, 80%; iiib PPh3, Imid, lh, DCM, 40°C, 74%; iiic MsCl,
NEt;, DCM, 0°C, 88%.
First a Friedel Craft acylation reaction was performed with isobutylbenzene (127) and
trifluoroacetic anhydride.'** Although this is not particularly atom efficient, with the release
of one equivalent of trifluoroacetic acid, the alternative, trifluoroacetyl chloride, is
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impracticalas its boiling point is -27°C. Iron chloride wasinitially used as it is a mild Lewis
acid, but it was found that the reaction time was longer, yields were inferior and some ortho
acylation product formed in comparisonto the use of aluminium chloride. Upon formation of
the acetophenonederivative (135), reduction wascarried out by using sodium borohydride at
0°C. This reaction occurred almost instantaneously. The trifluoromethyl group leaves the
ketone much moreelectronically exposed to nucleophilic attack. The next step in this
sequence wasto convert the hydroxy (136) into a better leaving group. The first group tested
in this replacement was a chlorine (137) (as reported by Shieh ef al.). In our hands,
chlorination took longer and occurred at elevated temperatures. A chloro-cyano exchange
was then attempted with use of sodium cyanide in DMSOat 80°C butfailed. Repeating this
reaction at higher temperatures still yielded no product although no decomposition had
occurred and the starting material could be recovered. We then decided to try a range of
better leaving groups. Mitsunobu chemistry was used to incorporate an iodine (138) which
proceeded reasonably well, but again it was noted that the temperatures required to achieve
conversion were elevated from that of normal hydroxyl-iodo displacement. Repetition of the
cyanide incorporation again did notyield the desired product.
We then made the mesylate derivative (139) from the alcohol but cyanide displacement
proved fruitless. Changing the cyanide counter ion from sodium to potassium did not yield
the product, nor did changing the solvent to DCM orintroducing 18-crown-6 to complex the
potassium ion. Use of acetone cyanohydrin wasalso ineffective.
Wecan hypothesise why this cyanide insertion failed. The hydroxyl group can be displaced
146through an internal nucleophilic substitution mechanism. Whenusing thionyl chloride,” this
first reacts with the alcohol to form an alkyl chloro sulphite (141), which forms an intimate
ion pair. The second step is the concerted loss of a sulfur dioxide molecule and partial
internal replacement by the chloride (137), which was attached to the sulfite group in an Sni
mechanism (Fig 2.14). The difference between Syl and Swni is that the ion pair is not
completely dissociated, and therefore no real carbocation is formed,'*° which would
otherwise be unstable because of the adjacent trifluoromethyl group. This rationale is also
true in the formation of the iodo compound.
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Fig 2.14 Mechanism of Sni chlorination. !“°
The direct Sy2 displacement of a mesylate group with cyanide group wasnot observed. This
could be attributed to the steric effects or that the benzylic centre is deactivated by the CF;
group suchthat only intramolecular delivery of a nucleophile is possible.
We then moved onto cyanohydrin chemistry. From the fluorinated acetophenone derivative
(135) it is possible to produce a cyanohydrin (142) in two ways, either by acidifying an
aqueoussolution of sodium cyanide and the acetophenone to generate HCN in situ, or by the
use of sodium bisulfite to activate the ketone,'*’ followed by addition of sodium cyanide. The
latter is more reproducible and safer. Upon purifying the cyanohydrins one should take much
care as it can rapidly decomposebackto the starting material (135) (Fig 2.15).
rapid decompostion
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Fig 2.15 Reagents and conditions: i, A\Cl,, TFAA, DCM,0°C, 1h, 74%; ii, NaCN, NaHSOs,
H,0,rt, Lh, 30-50%; iti, P4Sj0, Tol, A, 4h, 58%; iv conc H2SO4, H2O, 2h, 79%.
After formation and fractional distillation of the cyanohydrin, we then endeavoured to
removethe hydroxyl group to give us our B-trifluoroibuprofen precursor (140). Stahly e¢ al.
a3
reported that refluxing phosphorus pentasulfide (143) in toluene with aromatic cyanohydrins
yields the desired product'** and indeed this was the case for our derivative. There is no
literature mechanistic discussion on how this reagent brings about this transformation; in a
recent review of phosphorus sulfide in organic chemistry this transformation is omitted
altogether.'*? However, one can hypothesise that the mechanism may go through a thiol
formation (144) from the phosphorus pentasulfide (143), followed by a disulfide formation
(145), driven by the formation of the very stable P=O bond (Fig 2.16). To formally ascertain
this, introduction of a deuterium atom on the hydroxyl group would indicate whether the
sameproton is reintroduced onto the product. Secondly, addition of an agent that suppresses
the sulfur-sulfur bond formation such as DTT might stop the reaction at an intermediate
stage. If there is evidence of a deuterium in a phosphorus ('H decoupled) NMR,then we can
be quite confident of this mechanism.
.
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Fig 2.16. Proposed mechanism of phosphoruspentasulfide reduction.
After formation of the deoxygenated cyanide compound (140), we hydrolysed the nitrile with
the use of a strong acid (sulphuric acid) to yield our desired compound (134). However, due
to the capricious nature of the cyanohydrin formation, this was an impractical route and so
another (more successful) route was devised (Fig 2.17). It should also be noted at this
juncture that we were unable to obtain a high res mass spectrum of the free acid. However,
we can suspect this to be the true product by performing 'H NMR, °C NMR,IR and °F
NMR.All of which are indicative of the desired structure.
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Fig 2.17. Reagents and conditions: i, n-BuLi, PPh3Mel, -78°C, 39%; ii, BH3.SMe2, DME,
90°C, ON then H,02, NaOH, 0°C 30 mins, 69%;iii, CrO3, Me2CO, rt, 2h; iv, MeOH,cat
HSO4, A, 99%; v, Mucor Jarvinicus, pH 7 buffer; vi CDI, THF,rt, 2h; vii, CoA-SH,(Li’)3
THF/H,O,rt, 24h.
From the acetophenonederivative (135) (which was prepared as previously mentioned), we
performed a Wittig reaction with commercially available triphenylphosphine methyl iodide.
The product was then hydroborated/oxidised by refluxing with borane dimethyl sulphide
followed by oxidation with 30% hydrogen peroxide solution.'"° Subsequently, the primary
alcohol (147) was oxidised with Jones’ reagent to give our desired acid'*' (60) which can
then be CoA thioestified. An interesting point about the hydroboration/oxidation process
should be madeat this juncture. A significant byproduct was observed in 30% yield. This
byproduct was characterised as being 2-(4-isobutylphenyl)propan-l-ol (153). This is
unexpected and there have been no previousreports as to this type of product forming with
these reagents. A proposed mechanism is as follows (Fig 2.18):
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Fig 2.18 Proposed mechanism for the formation of 2-(4-isobutylphenyl)propan-1-ol.
It is possible that a competing reaction is occurring between the conventional hydroboration
reaction and a hydrogen-fluoro exchange (146/149). It is anticipated that the hydroboration of
the double bondis faster than the fluoro/hydrogen exchange of the trifluoro group. This
explains why the dominant product is our desired compound. The driving force behind the
side reactionis potentially due to the formation of the stronger B-F in comparison to the B-H
(bond dissociation energies are 690 kJ/mol!” and 440 kJ/mol'®respectively), probably due
to the orbital symmetry between the boron atom andthethree similarly oriented p orbitals on
fluorine atoms. Further experiments should be conducted to ascertain the merits of this
proposed mechanism andto probeits synthetic value.
As mentioned at the beginning of the Section, the (R)-enantiomer of ibuprofenoyl-CoA (22b)
has a lower K;and better binding affinity then its (S) counterpart (22a). This inspired us to
attempt the synthesis of diasteriomerically pure analogues of [-trifluoroibuprofenoyl-CoA
(60). This was achieved byfirst esterifying the racemic free acid with the use of catalytic
H2SO,4 in MeOH andrefluxing for 4 hours. A range of enzymes were then screened for
enantioselective hydrolysis (Table 2.2).
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 Europa Lipase 15 No --
EuropaLipase 1 Yes No
Lipase FAp15 No --
Europa Lipase 20 No --
Lipase AK No oo
Lipase PS Amano No --
Novazyme KBS No --
Chirozyme L2 Yes No
Chirozyme L3 No --
Lipase 9 Amano 50 No --
 
Table 2.2 Enzyme screening for enantioselective hydrolysis of 8-trifluoroibuprofenoyl-CoA.
Only three enzymes showedactivity, Europa Lipase 1, Chirozyme L2 and Mucor jarvinicus
with only the latter showing enantioselectivity. Unfortunately the data for this
eantioselectivity is missing. HoweverKatoet al., achieved stereoselective de-esterification of
a.-(Trifluoromethyl)-1H-indole-3-acetic acid ethyl ester,'°* which was achieved with 35%
yield after 20 hours and 98% e.e of the free acid (E > 100). Although these two substrates are
quite unrelated, there are similarities in the ester region.
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Fig. 2.19 HPLC traces of B-trifluoroibuprofen (blue) and 8-trifluoroibuprofen methyl ester
(red). Peaks at 5.6 and 7.7 mins correspond to the methyl ester, peaks at 17.2 and 31.6 mins
correspondto the free acid. By comparingtherelative retention times of the Candida rugosa
promoted enantioselective hydrolysis of ibuprofen methyl ester (green), the (R)-enantiomerin
each case hasthe later retention time. For column conditions — see experimental.
2.7 Chlorinated Ibuprofenoyl-CoA derivative (64)
The rationale behind the synthesis of a-chloroibufenacoyl-CoA (64) is similar to that as the
a-chlorinated aliphatic chain (Section 2.4), being that the chlorine atom acts as an isosteric
replacementof the natural a-methyl group, andthat its electronegativity lowers the a-protons
pXa. The further advantage of using the Ibuprofen derivative, as opposed to the aliphatic
derivate, is that the side chain appears to have a higher binding affinity for the enzyme (vide
supra), thus possibly increasing its inhibition potential. The synthesis began with a Friedel
Crafts reaction of isobutylbenzene with ethyl 2-chloro-2-oxoacetate to give ethyl 2-(4-
isobutylphenyl)-2-oxoacetate (154) which was subsequently reduced to the a-hydroxyester
155. Ten equivalents of thionyl chloride in DCM wereused to chlorinate the species which
was hydrolysed using a combination of hydrochloric acid and sulphuric acid'’’ (base
mediated hydrolysis could result in the Sy2 removal of the chloro group, yielding 2-hydroxy-
2-(4-isobutylphenyl)acetic acid via chloride displacement. This free acid (157) was then
activated with CDI, followed by coupling with coenzymeA lithium salt (Fig 2.20).
58
SCoA A _oet OH= ATTYSone O 0157a
SCoA v, vi OH iv OEt
Oo Oo
156
Fig 2.20. Reagents and conditions: i, A\Cl3, CIC(O)C(O)OEt, DCM,0°C, 1h, 71%; ii, NaBHa,
MeOH,0°C, 1h, 89%; iii, SOCl, 80°C, 2h, 90%; iv, HCl, HySO4, H2O, A, 2h, 73%; v, CDI,
THF,rt, 2h; vi, CoA-SH,(Li’); THF/H20rt, 24h;vii, pH 7 buffer, Candida Rugosa, 48h,rt,
90% ee for the (R) acid.
Enantioselective hydrolysis of the racemic ethyl ester (156) was also achieved with use of
Candida rugosa (see appendix 6) This is equivalent to Candida cylindracea used by
Haughton ef al., for enantioselective hydrolysis of 1-chloro-2-aryl acetic acid esters (35%
conversion, 85% e.e).'*° This yielded (S)-a-chloro-ibufenac ethyl ester (156a) with 99% e.e
which can be hydrolysed andthioesterified in the usual fashion (Fig 2.20).
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Fig. 2.21 HPLC traces of a—-chloroibufenac (red) and a—chloroibufenac ethyl ester (green).
Peaks at 10.9 and 15.4 mins correspond to the methyl ester, peaks at 25.2 and 47.7 mins
correspond to the free acid. By comparingtherelative retention times with ibuprofen and
ibuprofen methyl ester, the (R)-enantiomer in each case has the later retention time. For
column conditions — see experimental.
2.8 Further analogues of Ibuprofenoyl-CoA
From the route stated in Section 2.7, we have made a numberof alternative analogous
precursors to modified Ibuprofenoyl-CoA derivatives. Two are depicted below (Fig 2.22).
The most obvious analogue is the conversion of the a-hydroxy ethyl ester (compound 155,
Fig 2.21) to the corresponding coenzymeA thioester (158). From the ethyl ester, we directly
hydrolysed with SNNaOH in MeOH/THFandthioesterfied in the usual fashion.
OH O
SCoA SCoA
158 159
Fig 2.22 Other variations of Ibuprofenoyl-CoA.
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The NMRchemical shifts of the a-protons of these various Ibuprofen derivativesall differ.
This is likely to be relative to the acidity of the a-proton, arising from the de-shielding affect
of the a-functional group. (Fig 2.23).
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Fig 2.23 Relative positions of the a-proton in the NMR spectra of various Ibuprofen
analogues.
Despite fluorine being the most electronegative element, it is obvious from Fig 2.23 that the
CF; group does not exert the largest effect on the a-proton. It is clear that the greatest
downfield shift is seen for the a-chloro compound.If the apparent inhibitory effect of the a-
trifluorotetradecanoyl-CoA is due to the increased acidity of the a-proton, then it is
reasonable to assumethat the a-chloro derivative should give rise to improved inhibition.
We also synthesised 2-(4-isobutylphenyl)-2-oxoacetic acid (159) (Fig 2.22). Since the
quaternary structures of formyl-CoA transferase and AMACRare very similar, and both
involve the use of Asp as a catalytic residue, then the Asp function of AMACR could mimic
the function of Asp in FRC. In the catalytic mechanism of FRC, Asp169 acts as a
nucleophile, forming a mixed anhydride with formyl-CoA. It is therefore possible that
Asp152 in AMACR,could act as a nucleophile on the a-ketone (Fig 2.24). If it exhibits good
inhibition characteristics, then we could postulate such a mechanism.
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Fig 2.24 A pictorial representation of the possible mode of binding of 2-(4-isobutylphenyl)-2-
oxoacetoyl-CoA.
2.9 Using extended conjugation as an approach for inhibition
The next potential inhibitor to be synthesised was (£)-2-methyl-4-(4-nitrophenyl)but-3-enoyl-
CoA (63) (Fig 2.25). We anticipated that an enolate intermediate formed at the active site
would bestabilised by extended conjugation, thus promoting inhibition.
on AMACR oo AMACR Nw : SCoA1 1 cry
ON O2N ON2 2
63a 160 63b
 
Fig 2.25 Enzyme catalysed formation of a stable, conjugated enolate from the potential
inhibitor 63a/b.
The originally devised route to this compound was via a Wittig reaction (Fig 2.26). 3-
Bromopropionic acid ethyl ester (161) was converted to a phosphonium salt (162) by
refluxing with triphenylphosphine in toluene. The Wittig reaction was then attempted using
n-BuLias a base and 4-nitrobenzaldehyde.
Br OEt PPh3 - rd 1. n-BuLi Ne OEtNr —> PhP OEt
O Toluene Nr 2: snitrobenzaldehyde O
4 ON 163161 82% 162 O 2
: , 1,LDAmeu ' 2. Mel
E1cBelimination y
XY OEt
OEtAN O
ON
° 164165
Fig 2.26 Initial route for (£)-2-methyl-4-(4-nitrophenyl)but-3-enoyl-CoA synthesis.
62
The required product was not formed. It was noted however that triphenylphosphine was
released. This can be rationalised by the irreversible elimination of the PPh3. The pKa
difference between the a-and B hydrogens (relative to the phosphorus) is relatively small,
with a difference of around 5. Although the proton adjacent to the phosphorus atom is more
acidic, the irreversible nature of the elimination of the PPh3 renders this ElcB elimination
morelikely.
An alternative was to perform an Aldol reaction with acetone and 4-nitrobenzaldehyde in the
presence of sodium hydroxide (Fig 2.27). The product was then dehydrated by refluxing in
acidic aqueous medium. This a,f-unsaturated ketone (167) was then reduced to the
corresponding alcohol (168) using Luche conditions and converted to the chlorinated
analogue (169) (with use of neat thionyl chloride). Chloride displacement was then attempted
with use ofNaCN in DMSOat 90°C but unfortunately provedfruitless.
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Fig 2.27. Reagents and conditions: i, NaOH, Me2CO,rt, 1h then H2SO4, H2O, 100°C, 2h;
93%; ii, CeCl, NaBHy, 0°C, MeOH, | h, 86%; iii, SOCI, 80°C, 2h 90%; iv, NaCN, DMSO,
90°C, ON,no reaction.
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From analysing the reaction performed, it was noted that little of the starting material had
reacted. Although allylic halides are generally considered more reactive then their nonallylic
counterparts, the para nitro aromatic group possibly destabilises build up of positive charge
required for displacement of the chlorine atom. Furthermore, from the NMR of the crude
reaction mixture, the aromatic region had changed from a doublet of doublets to a complex
mixture. This is possibly due to the von Richter reaction which converts aromatic nitro
compounds to aromatic carboxylic acids with the use of a cyanide ion. According to the
literature, the von Richter reaction works best when there are electronegative substituents on
the ortho and/orpara positions. Yields are always poor (<50%) and a notable amountof‘tar’
is formed.!>’
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We then decided to perform a Willgerodt Kindler reaction on compound 167 with lead
acetate and boranetrifluoride dietherate to give us the unsaturated ester (172).'8 We
envisaged that the a-methyl group could be incorporated by the use of LDA and methyl
iodide. We could then hydrolyse the methyl ester to the corresponding acid and then
thioesterify as before (Fig 2.28). At present, the synthesis of this compoundis at the point of
a-methylation. However, we do not envisage a problem with the subsequent steps. Of course
there is the possibility of y-methylation, but this can be controlled. Typically a-electrophilic
addition is kinetically favoured,’ and is the preferred carbon of attack for soft
160electrophiles'” (with methyl iodide being a moderately soft electrophile).
adil
Fig 2.28. Reagents and conditions: i, Po(OAc)4, BF3.OEt,, MeOH,Tol, rt, 24h, 55%; 11 LDA,
DMPU,-78°C, then Mel; iii, SN NaOH, MeOH/THF,iv CDI, THF; v, CoA-SH, (Li)s,
THF/H20,rt, 24h.
2.10 a-fluorinated substrate as a mechanistic probe (62).
The synthesis of a-fluoroibuprofenoyl-CoA (62) will enable us to conclusively ascertain
whetherthe reason for the inhibition by a—trifluoromethyltetradecanoyl-CoA (49) is because
of the lowering of the pKa of the a—proton or becauseof an increasedaffinity of the substrate
for the active site. The a-fluoro atom (62) is unlikely to be removed when(if) bound to
AMACR.Therefore we can directly compare the K; value for a-fluoroibuprofen with
Ibuprofen for inhibiting the racemisation of 2-methyl myristoyl-CoA (an analogue of the
natural substrate) by AMACR.If Ibuprofenoyl-CoA (22) has a lower Kj value than a-
fluoroibuprofenoyl-CoA (62), then this would suggest that the mechanism ofinhibition by
our knowninhibitors is in fact due to the lowering of the pKa of the a-proton and the
facilitation of the formation of the enolate. If however the K; values are similar, then this
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would indicate another mode of inhibition, probably due to the increased affinity of the
substrate (inhibitor) for the active site of the enzyme. The synthesis of a-fluorinated
ibuprofen (62) began with the esterification of racemic Ibuprofen to form Ibuprofen methyl
ester (176). This then underwent a-fluorination with the use of LDA and NFSI.'*' The methyl
ester was then hydrolysed'™ and thioesterified with coenzyme lithium salt (Fig 2.29).
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Fig 2.29 Reagents and conditions: i, MeOH, cat H2SO4, A, 4h, 99%; ii, n-BuLi, DIPEA,-
78°C then NFSI, warmed to rt, lhr 66%;iii, 5V NaOH, MeOH/THF,rt, ON 96%; iv CDI,
THF, v, CoA-SH,(Li’)3, THF/H20,rt, 24h.
NFSIis generally considered a good source of F+, however, surprisingly it has never been
used as a source of F+ for fluorinating 2-aryl propionic acid esters. Perhaps it was assumed
too bulky to effectively fluorinate. Nonetheless, due to its stability and ease of use (dueto it
being in a crystalline state), it was tested, and pleasingly proved successful. The initial
attempt at fluorination gave a yield of 75% (by NMRspectroscopy) with 15% unreacted
starting material. Due to the similar nature of the product and starting material on the TLC
plate, it was impossible to separate the mixture. We overcame this problem however byre-
introducing the mixture to the same reaction conditions. This time there was no starting
material seen by NMR.
65
2.11 Probing the necessity of an a—methyl group (182).
The rationale behind the synthesis of our final inhibitor/probe, 2-(4-isobutylphenyl)acetyl-
CoA (182) wasto probe the binding of Ibuprofen with and without the methyl group and thus
demonstrate how muchinfluence the a-methyl/aromatic region has on the inhibition of the
enzyme. There is conflicting evidence on the extent of enzymatic turnover ofstraight chain
8°. 8 It would therefore be interesting to investigate whether the Ibuprofenaliphatic substrates.
derivative is boundto the active site. This can easily be ascertained using isothermaltitration
calorimetry. It could also give a better insight to the significance and influence of the
interactions between the binding pocket and the ‘R’ group of the CoA thioester. The
synthesis of the title compoundwasas follows:
LO wer Iz, AJNO3,>_>s: MeOH, CH(OMe)3
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Fig 2.30 Reagents and conditions: i, AlCl; (CH3CO),0, DCM, 0°C, lh, 74%; ti, H2SOs,
PhI(OAc)2, MeOH,70°C, 2h, 63%; iii, 5V NaOH, MeOH,rt, 3h, 94%; iv, CDI, THF,rt, 2h;
v, CoA-SH,(Li’)3, THF/H;O,rt, 24h.
OMeLIS
180
OHLIT
181
Initially, a Friedel-Crafts reaction was performed with isobutyl benzene (127) and acetic
anhydride to form the para isobutyl acetophenone (179). The initial Wilgerodt Kindler
reaction with silver nitrate and trimethoxymethane in methanol did not yield the desired
intermediate (180). However, performing a carbonyl migration and esterification with the use
of diacetoxyiodobenzeneproved successful.
Conclusion
To summarise, a range of aliphatic/aromatic inhibitors/precursors (Fig 2.31/2.32) have been
synthesised using a range of different chemical techniques. Although we have a range of
thioesters for testing, we have kept a larger number of potential inhibitors as their free
acid/methyl ester precursors. Coenzyme A thioesters are notoriously difficult to store. We
have found that after a short time in storage (at -20°C), they readily undergo hydrolytic
cleavage. The hydrolysis of a thioester is thermodynamically more favourable than that of an
oxygen ester. The C-S thioester bondis not stabilised in the same manneras a C-O ester bond
due to the less efficient C-S pi interaction, rendering the thioester bond morereactive. This
reactivity is increased by the fact that the neighbouring groups are often electronegative,
further exposing the carbonyl carbon to nucleophilic attack. Moreover, the CoA moiety
contains several other positions where cleavage can occur.
Figure 2.31 shows the available CoA esters synthesised as potential inhibitors. Figure 2.32
showsthe available CoAester precursors:
ClF
SCoA SCoA
Oo oO
62 64
CF3
SCoA SCoA
Ci2H25
O O
48
182
Fig 2.31 A range of coenzymea thioesters stored in the freezer.
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Fig 2.32 A range ofpotential inhibitor precursors.
In the next chapter we will discuss the synthesis of substrates for assaying purposesin order
to test these inhibitors.
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SYNTHESIS OF SUBSTRATES
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3.1 Project aims
As we now had a rangeof potential inhibitors to test against AMACR,it was important to
obtain a reliable, convenient assayin ordertotest their efficacy. A range of different assaying
systems and model substrates were explored and their synthesis is discussed herein.
3.2 Synthesis of HPLC assay substrates
As Ibuprofenoyl-CoA (22) is a known substrate of AMACR, we envisaged that an assay
could be achieved by monitoring the conversion of enantiomerically pure (S)-Ibuprofenoyl-
CoA (22a) to its racemate. The synthesis of the substrate began with the activation of (S)-
Ibuprofen as its acyl imidazoyl derivative (analogous to Fig 2.02) which can be isolated and
characterised. This was then thioesterified by the addition of coenzyme A lithium salt in a
mixture of THF and water. The thioester was then purified by reverse phase HPLC (Zorbax
C18 column, 250mm by 4.5mm) with an eluent system of 50mM potassium phosphate buffer
(pH 6) and acetonitrile. However, upon lyophilization, a notable amountofsalt precipitated.
Therefore further purification through a desalting column was needed. Using ammonium
acetate as a volatile buffer, a range of pH’s were evaluated (see Appendix 1) and the
optimum pH of the ammonium acetate buffer was pH 6. AbovepH 7,significant hydrolysis
wasobserved while at lower pHs, the amount of product was reduced. After purification, the
ester was re-suspended in the ammonium acetate buffer in order to determine the quantity of
material. This was achieved by measuring the UV absorption in Iml of a buffered solution.
The quantity of material was then calculated based upon the extinction coefficient of the
adenosine moiety of the CoA substituent (Amax = 260nm, e=15800 M”™cm’). Thus it was
possible to accurately calculate the quantity of product generated. '”'
To initially ascertain the enantiomeric purity, a small quantity of (S)-Ibuprofenoyl-CoA (22a)
wassubjected to base hydrolysis with sodium hydroxide. The resulting free acid was injected
onto a chiral OJ column (250mm by 4.6mm) and the e.e. was obtained by measuring the
relative areas of each peak of (R) and (S)-Ibuprofen (Fig 3.01). Following thioesterification
and hydrolysis, no racemisation was observed. As this substrate became a focal point of the
research, a 'H NMRofthe sample was obtained (see Appendix2).
70
0.08 -
0.06 -
0.04 -AU
0.02 +
 
 
0 10 20 30 40 50
-0.02 - time (mins)  
Fig. 3.01 HPLC trace of racemic Ibuprofen (red) and (S)-Ibuprofen (blue). Peaks at 22.76
(blue) and 24.6 (red) correspond to the (S)-enantiomer and the peak at 32.9 mins corresponds
to the (R)-enantiomer respectively. Column: Chiral OJ (250mm by 4.6mm). For column
conditions — see experimental.
3.3 Synthesis of LCMSassay substrates
An alternative LCMSbased assay was also devised. This would enable us to monitor the
conversion of a-deuterated Ibuprofenoyl-CoA (67) to its protonated form (Fig 3.02). It was
envisaged that this could be correlated with rate of racemisation. The substrate synthesis
began by esterifying racemic Ibuprofen (177) in methanol with a catalytic amount of H2SO4
for 4 hours. This was then a-deuterated by adding sodium methoxide to a solution of
Ibuprofen methyl ester (178) in CD3;0D. This allowed us to monitor the conversion by
directly subjecting the crude reaction mixture to NMR analysis. Once complete, this was
hydrolysed with sodium hydroxideandthioesterified in the usual fashion.
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Fig 3.02 Reagents and Conditions; i, HySO4, MeOH, 80°C, 4 h, 99%; ii, NaH, THF/D,0O,rt,
12h, 99%; iii, NaOH, MeOH,rt, 2h 99%; iv, CDI, THF,rt, 2h; v, CoA-SH,(Li’)3, THF/H20,
rt, 24h.
Initially we used the same conditions for the LCMSassay as for the HPLC purification of
Ibuprofenoyl-CoA (RP C-18 with an eluent system of 66:34 10mM ammonium acetate:
MeCNrespectively), which under the HPLC conditions gave a sharp peak at 5.3 mins. With
the LCMSsystem however, the peak shape was broad and shouldered. Poor peak shape can
be caused by the compound’s reactivity towards the acidic silanols on the column - although
this was suprising as the HPLC peak shape was sharp. Adding formic acid to the eluent
(whichis traditionally used to sharpen peak shape) suppressed MSionisation altogether and
no peak wasobserved.
Sideniuset al. tested the in vitro reactivity of Ibuprofenoyl-CoA with glutathione’using
LCMSwith an eluent system of 79:21 ammonium acetate: MeCN using a phenyl hexyl
column.Initial testing of these conditions with our C-18 column gave the same peak shape. A
phenyl-hexyl column hasa stationary phase of terminal phenyls with hexyl (C6) linkers and
is known to provide separations not achievable on C18 or C8 columns. Once a phenyl hexyl
column had been obtained, Sidenius’s conditions were used and the HPLCtraces of (H)-
Ibuprofenoyl-CoA (22) and a-deutero-Ibuprofenoyl-CoA (67) were sharp and unshouldered
as can be seen from Fig 3.03.
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Fig 3.03 LCMStraces of (H)-Ibuprofenoyl-CoA (top) and a-deutero-Ibuprofenoyl-CoA
(bottom). RT = 3.2 mins Column: Phenyl-hexyl (100mm by 4.6mm). Eluent system: 79%
(v/v) 1OmM ammonium acetate-acetic acid (pH 6): 21% (v/v) MeCN. I ml/min.
3.4 Development of chromogenic assays
 
3.4.1 Synthesis of aromatic chromogen.
As discussed in Chapter one, we have endeavoured to develop a fast, reliable chromogenic
assay which would enable us to screen thousands of potential inhibitors quickly and
accurately. Our strategy was to design potential chromogens that incorporated the usual a—
methyl group in addition to a group at the B—position that could leave under mild conditions
catalysed by an active site base. The first group of chromogenic substrates included CoA
thioesters which contain a para-nitro aromatic side chain. Upon formation of the
chromophore(71), a UV max of 307nm would be observable (Fig 3.04).
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Fig 3.04. Proposed mechanism of enzymatically catalysed chromophore formation from
chromogen.
Two different leaving groups were envisaged, chloro (68) and hydroxy (67). It was
anticipated that the chloro derivative would be more prone to ElcB elimination than the
corresponding hydroxy derivative. However, by using the X-ray crystal structure of
ibuprofenoyl-CoA in MCR, it is reasonable to suggest that the B-hydroxy group can
hydrogen bond with several enzymatic residues, which could aid in the ElcB elimination (Fig
3.05). Synthesis of the chromogenic substrates were designed to have no diasteriomeric
preference. This will allow for quick analysis as to whether any diasterioisomerhasactivity.
 
Fig 3.05. Pymol image of bound ibuprofenoyl-CoA to MCR. Adapted from J. Mol .Biol.
2007, 367, 1145-1161. Hydrogen bonding between the proposed B-hydroxy thioester (67) as
represented by the ortho aromatic carbon and residues Asp156 (left) and Asn152 (right) with
bond lengths of 3.4 and 3.8A respectively. Courtesy of Dr Rob Gibson, Biological Sciences,
UoL.
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The synthesis of the chromogenic substrates began with an aldol reaction between 4-
nitrobenzaldehyde (184) and propanoic acid methyl ester (185) to give the a-methyl B-
hydroxy ester (186). The hydroxy derivative was obtained by hydrolysing the ester with
sodium hydroxide to give the free acid (188) which wasthen thioesterified. Alternatively, the
preparation of B-chloro derivative was attempted by chlorination of the B-hydroxy ester with
thionyl chloride and then de-esterification with hydrochloric acid (189) (as opposed to base
hydrolysis that could possibly lead to elimination of the chloro group) (Fig 3.06).
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Fig 3.06 Reagents and conditions; i, LDA -78°C, THF, then 4-nitrobenzaldehyde, 70%; ii,
SOCI,, 80°C, DCM, 76%; iii, SM HCl, H20, 100°C, 3h, 99%; iv, CDI, THF,rt, 2h; v, CoA-
SH, (Li’)3 THF/H,0,rt, 24h; vi, 1M NaOH, MeOH/H20,0°C, 2h, 99%.
Thioesterification of the chloro derivative (189) was problematic. Although it was possible to
obtain and isolate the acyl imidazolium intermediate (190); upon addition of coenzyme A,the
chlorine eliminated to yield a highly conjugated thioester (71). A possible reason for the
chlorine elimination may be due to the release of imidazole upon thioesterification. This may
encourage removal of the a-proton resulting in ElcB elimination of the chlorine (Fig 3.07).
This is unexpected astraditionally imidazole is a mild base, with a pKa of approximately 8
which conventionally would be too weak to removethis proton. Howeverthis proton may be
sufficiently active in this case because of the electronegative nature of the chloro and
thioester groups. The 3-hydroxy analogue (67) however does not suffer from the same
elimination and wasconvertedefficiently.
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Fig 3.07 Mechanism of chloro elimination.
3.4.2 Synthesis of aromatic chromophore
The corresponding acyl-CoA was generated in order to have a standard sample for the UV
chromophore we hopedto generate enzymatically. The synthesis began by Heck coupling 4-
nitrobromobenzene (191) and methyl acrylate (194) (Fig 3.08) to produce (£)-methyl-2-
methyl-3-(4-nitrophenyl)acrylate (193). The stereochemistry was ascertained by comparing
the 'H NMR of the aforementioned compound with (£)-ethyl-2-methyl-3-(4-
nitrophenyl)acrylate (An ethyl ester derivative that has been previously characterised by 'H
NMR"). The yield ofthis reaction was very poor with an average yield of 22%.
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Fig 3.08 Reagents and conditions; i, Pd(OAc)2, PPh3, NaxCO3, 130°C, NMP 2h, 22%;ii, 5N
NaOH, MeOH,rt, 72h, 83%; iii, CICOCOOEt, NEt;, THF, lh then CoA-SH, (Li’)3,
predissolved in H20.
This is perhapsattributed to the fact that Heck coupling reactions often need a specific set of
reaction conditions in order to proceed efficiently. This has been suggested several times'®
and often a range of Heck coupling ‘recipes’ are screened for optimisation. However, since
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we were not concerned with yield and only with the acquisition of the product, no further
studies in optimisation was performed.
The next step in the synthesis was the hydrolysis prior to CoA coupling. The same protocol
was used as with previous hydrolysis procedures. The rate of conversion wassignificantly
reduced (a reaction time of 72 hours), possibly as a consequence of the high conjugation.
In this instance a mixed anhydride method was employed, using ethyl chloroformate and
triethylamine rather than the less reactive CDI, which was ineffective. An acyl chloride on
the other hand(e.g ethyl chloroformate) is less stabilised by resonance, since the nonbonded
pair of electrons on the larger chlorine molecule is unable to delocalise as readily which
increases the electrophilicity of the carbanoyl moiety. An alternative reason for the failure of
1,1-carbonyldiimidazole mediated coupling could be due to the stability of the highly
conjugated ionic species formed from the delocalisation of a lone pair of the nitrogen in the
acyl imidazole (Fig 3.09).
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Fig 3.09. Resonance structures of (£)-1-(1H-imidazol-1-yl)-3-(4-nitrophenyl)prop-2-en-1-
one.
3.4.3 Synthesis of aliphatic chromogen
An additional chromogenic assay substrate was designed. In this substrate N-
acetylcysteamine (NAC) was used asa truncated analogue of coenzyme A. The proposed
enzymatically formed chromophore has a UV max of 263nm. The UV max of coenzyme A is
260nm, which could obscure the product observation. However, N-acetylcysteamine does not
contain the adenine ring which gives rise to UV absorbance.
Previous studies have shown that NAC thioesters are accepted by other CoA transferases
(both type 1 and II). Examples of which are 3-oxoacid CoA-transferase’® and malonyl-CoA
transferase.'®” This gives an additional rationale for the use of N-acetylcysteamine.It has also
been reported that a numberoffatty acyl-CoA ligases (FACL’s) display remarkable tolerance
v7
when the CoA group is replaced by N-acetylcysteamine.'™ It is known that FACL’s contain
overlapping substrate specificities,” which has also been proposed for AMACRandrelated
B-oxidation enzymes. Furthermore, it was found that varying the chain length did notaffect
the formation of fatty-acyl-CoA thioesters. These properties draw parallels with AMACR,
indicating that NAC thioesters may indeed betolerated as an alternative to CoA-thioesters.
The additional benefits of using N-acetylcysteamine rather than coenzyme A are thatit is
cheaper, much easier to handle and its purification is simpler as the N-acetylcysteamine
thioesters can be purified by column chromatography. One could also consider using less
truncated analogues of CoA suchaspantetheine. In this instance, a B,y-unsaturated thioester
would be converted to an a,f-unsaturated thioester giving rise to the chromophore(Fig 3.10).
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Fig 3.10 Enzymatic formation of the a-B unsaturated aliphatic chromophore.
The synthesis of the chromogenic substrate, (Z)-S-(2-acetamidoethyl)-2-methyldec-3-
enethioate (72) began by using (£)-ethyl dec-2-enoate (199) and methylating in the a-position
with the use of DMPU, LDAand methyliodide. In this instance DMPUis usedasa less toxic
analogue of HMPU,whichis used to coordinate to the lithium atom of the enolate. This helps
de-aggregate the enolates, which results in a more reactive species and promotes nucleophilic
addition. In doing so, it also helps suppress the formation of (Z)-ethyl 4-methyldec-2-enoate
(202). In this event the reaction yielded (Z)-ethyl 2-methyldec-3-enoate (200).
It is interesting to note the change of stereo geometry of this transformation. This can be
explained by the resulting carbanion that is formed. Experimental evidence for the crotyl
anion system (which is analoguous to this aliphatic substrate) demonstrates that the cis
carbanion is more stable then the trans counterpart (Fig 3.11). This can be explained by the
possibly greater strain of the CCC bond angle (133°) in the trans geometry'” (199) and also
by a possible ‘aromaticity’ that may be present in the cis conformation (198) by the
alignmentofthe pi orbitals.'”!
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Fig 3.11 Schematic representations of the relative geometries of the favoured/disfavoured
ensuing carbanions formed from the (£) isomer when exposed to LDA.
The Z isomer was confirmed by measuring the coupling constants of the double bond (Fig
3.12).
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Fig 3.12. An NMR snapshot of (Z)-(S)-(2-acetamidoethyl)-2-methyldec-3-enethioate (72) -
highlighting the alkene protons.
Generally vicinal coupling constants are larger for trans (range: 12—18 Hz, typical: 15 Hz)
than for cis (range: 0-12 Hz, typical: 8 Hz) alkenes. Taking H, as an example, (Fig 3.11) the
proton is split into an overlapping doublet of triplets. It is split by the adjacent Hy into a
doublet (J = 10.69 Hz therefore indicative of Z geometry) which is then further split into a
triplet by the adjacent CH) protons. Hy is slightly more complicated. What seems to be a
triplet of triplets is not the case. It is expected that the proton signal will split into a doublet of
2
doublets by the adjacent H, and methine couplings. Splitting by the methine (J = 11.51 Hz)
and the vicinal alkene proton (J =10.69 and 10.72 Hz) is observable. This is followed by
distant (4 bond) coupling to the alkyl protons adjacent to H, (J = 1.28 Hz). This was
confirmed bycorrelation spectroscopy (COSY).
The ethyl ester was hydrolysed by refluxing the ester in an aqueous solution of barium
hydroxide. The mild base was used to avoid re-conjugation of the double bond. This was then
thioesterified with carbonyldiimidazole and N-acetylcysteamine (Fig 3.13).
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Fig 3.13 Reagents and conditions; i, LDA, DMPU, -78°C, 30 mins then (£)-ethyl dec-2-
enoate for lh followed by Mel, 2h, -78°C-rt, 45%; ii, Ba(OH)2.8(H2O), H2O, 100°C, ON,
80%;iii, CDI, THF,rt; iv, NAC, THF,rt, 2h 64%.
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3.4.4 Synthesis of aliphatic chromophore (74)
Synthesis of the conjugated chromophore was attempted using a method analogous to that
used for a—trifluoromethyltetradecanoyl-CoA (49). Octyl bromide (203) was converted into
the phosphoniumsalt (209) by refluxing with triphenylphosphine. A Wittig reaction was then
performed with methyl pyruvate to yield the a,f-unsaturated ester (205) (1:1 mixture ofE and
Z) which was then subsequently hydrolysed with sodium hydroxide. It is noteworthy to add
that although the stereochemistry of the chromogen and chromophoreis different (Z and E/Z
respectively), it is anticipated that the enzyme should tolerate both stereoisomers. We have
some confidence of this as the hydrophobic pocket accepts long chains (cf same interacting
residues as the EF isomer) and also accepts very bulky steroidal derivatives (cf same
interacting residues as the Z isomer).
Thioesterification was then attempted using CDI and ethyl chloroformate (Fig 3.14). In both
cases no thioesterification occurred. Possible due the same reason as described in Section
3.4.2. + -NNRPPB
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Fig 3.14 Reagents and conditions; i, PPh3, Toluene, reflux 48h, 99%; ii, BuLi, THF, -78°C,
CH3C(O)CO2CHs3, 2h 45%; iti, SN NaOH MeOH,rt, on, 70%; iv CIC(O)CO2Et, NEt;, THF,
2h, rt; v, CDI, THF,4h, rt; vi, NAC, THF,2h,rt.
81
In fact, the activated carbonyl intermediates were so stable; a full set of spectra was obtained
without hydrolysis. Although the aliphatic chromophore could not be synthesised, wecanstill
identify whether the chromogen is an accepted substrate by monitoring the change in UV
absorbance. If it is accepted, then the chromogen should be formed, which will absorb UV
light at 307nm.
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4.1 Initial studies of the racemisation ofAMACR.
 
To initially ascertain the activity of AMACR towards Ibuprofenoyl-CoA (22), we took a
crude extraction of AMACRfrom rat liver (extracted by Dr Rob Gibson). This was then
incubated with enantiomerically pure (S)-Ibuprofenyl-CoA (22a) for two hours. Aliquot
portions were removed from the reaction mixture at regular intervals, subjected to base
hydrolysis (which cleaves the thioester and quenches the enzyme) and extracted into Et,O.
The extent of racemisation was noted by injecting the hydrolysed sample onto a chiral OJ
columnas described in Section 5.10. (Fig 4.1).
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Fig 4.01 First method of analysing the activity of AMACRand relevant HPLCtraces. Peaks
at 20.0 and 24.6 mins correspond to the (R)-enantiomer and (S)-enantiomerrespectively. For
column conditions — see experimental.
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4.2 Reverse phase HPLC assay
Although the initial method of assessing the activity of the enzyme via injecting the
hydrolysed sample onto a chiral OJ column is functional, it is not a practical route for an
assay as it requires post incubation chemical modification and lengthy eluting times on the
chiral OJ column. In total, each aliquot portion takes approximately lhour 40 minutes to
ascertain the extent of conversion. The use of chiral reverse phase HPLC was then
investigated. We found that the use of a chiral AGP column could separate the two
enantiomersof Ibuprofenoyl-CoA.'” This column is made upof an al-acid glycoprotein as a
chiral selector, immobilized on spherical 5p silica particles. The retention and
enantioselectivity is regulated by changes of pH, buffer concentration and organic modifier.It
was found that the use of 50mM KH,PO,-NaOHbuffer (pH 6) containing 4% (v/v) IPA gave
adequate separation of the two enantiomers (Fig 4.2). With the crude rat liver extract it was
necessary to purify the incubated Ibuprofenoyl-CoA through a C-18 column before loadingit
onto the chiral AGP column to protect it from degradation. This is an inefficient approach as
the length of time to analyse each sample is comparable with the aforementioned use of a
chiral OJ column. Ultimately we decided to use MCR (expressed in E. coli by Dr Rob
Gibson) which enabledusto directly inject the incubated sample onto the column withoutthe
risk of decomposing the protein based stationary phase.
A 10% (v/v) solution of TFA was used as a quenching reagent. The use of acetone to
precipitate the enzyme wasnot ideal as the observed peaks of the substrates were dominated
by the solvent peak of acetone. An additional obstacle with this methodis that the retention
time of (S)-Ibuprofen (177a) is similar with that of (R)-Ibuprofenoyl-CoA (22b). If
hydrolysis occurs, this could result in misinterpretation of the results. Although a possible
hindrance, this is rarely observed and can be easily distinguished using a photodiode array
detector. Below is an example of the HPLC assaying method andresults whereby TFA was
used as the quenching reagent(Fig 4.2).
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Fig 4.02a. HPLCtraces of incubated (S)-Ibuprofenoyl-CoA with MCR. Peak A corresponds
to residual Ibuprofen. Peak B correspondsto (S)-ibuprofenoyl-CoA and peak C corresponds
to (R)-ibuprofenoyl-CoA.
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Fig 4.02b. UV absorbances of peak A (green), peak B, (red) and peak C (blue). Amax = 222,
258 and 258nm respectively.
From this data, we began to generate some preliminary enzyme kinetics. Below are two
identical runs of 100uM (S)-Ibuprofenoyl-CoA with 100ng of MCR in Iml 10mM MOPS-
CH3CO;Nabuffer, pH 7, run at 37°C (Fig 4.3).
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Fig 4.03 Conversion of 100uM (S)-Ibuprofenoyl-CoAto its (R)-enantiomer with 100ng/ml
MCRin MOPS-acetic acid pH 7 buffer performed on twoseparate occasions.
The enzyme generated reproducible results within a practical time frame (60mins). Next was
the examination of enzyme kinetics. This was achieved by maintaining a constant substrate
concentration (100uM) and changing the enzyme concentration (Fig 4.4). Due to an increase
in active sites available for the substrate to bind, we would expect an increase in enzyme
concentration to provide us with a proportionate increase in initial rate of conversion of (S)-
Ibuprofenoyl-CoAto its racemate.
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Fig 4.04 Protein concentration of MCRvsinitial velocity of racemisation. For raw data see
Appendix 3.
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It should be noted that the line of best fit intersects the graph at nearly 0.00. This is to be
expected for normal enzymekinetics. We then began to collect data for Km and Vmax. This
was achieved by varying the concentration of (S)-Ibuprofenoyl-CoA and maintaining a
constant concentration of enzyme (Fig 4.5). In this case 5Ong/ml MCRwasused.
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Fig 4.05 The monitoring of racemisation of various (S)-Ibuprofenoyl-CoA concentrations
with 50ng/ml MCRin pH7buffer at 37°C. =200uM, @100uM, =450uM
Vmax or Vo represents the maximum rate of enzymereaction. A plot ofinitial velocity versus
substrate concentration increases in a hyperbolic fashion to approach the characteristic
maximum rate, Vmax, at which essentially all enzyme is saturated with substrate (Fig 4.6).
Km is knownasthe Michaelis constant, this represents the substrate concentration that results
in a reaction rate equal to one-half of Vmax. This is characteristic for each enzyme acting on
a given substrate and is a measure of bindingaffinity.
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Fig 4.06 Concentration of (S)-Ibuprofenoyl-CoA (uM)vs. Initial velocity (umoles/min).
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Using the data from Fig 4.5, the Michaelis-Menten equation (Equation 1, Fig 4.7) and
rearranging this to the Lineweaver-Burk equation (Equation 2, Fig 4.7), we can use the raw
data from Fig 4.6 to calculate the Km and Vmax by plotting the double reciprocal plot, 1/V vs
1/[S] (Fig 4.8).
  
Vmax[S]= Equation |Km +[S]
1 Km , 1 1 Poucon?
—_; = — t
V Vmax [S|] Vmax ——_
Y= m *x + €
Fig 4.07 Rearrangementof the Michaelis-Menten equation to producea linear representation
of enzymekinetics.
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Fig 4.08 1/[S] of (S)-Ibuprofenoyl-CoA (1/M) vs 1/Velocity (1/umoles/min)
The values of Km and Vmax are 144.97uM and 0.0463umoles/min respectively. This is in
reasonably close accordancewith the recent literature values published by Ouaziaet al.,'” in
which they measure the racemisation of Ibuprofenoyl-CoA by MCR using a circular
dichroism (CD)-based assay. This recorded a Km for (S)-Ibuprofenoyl-CoA of 86+/-6uM.It
is interesting to note that this article also confirmed the (slight) preference for MCR to
racemise (R)-Ibuprofenoyl-CoA with a Km of48+/-5uM.
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Unfortunately, we were unable to obtain any more data as the enzyme’s activity became
unreliable and by the time constraints of this project. Ideally all of these results would be
repeated in triplicate and at least one more variation in substrate concentration would be
included to obtain a more accurate picture of the enzyme kinetics. Nonetheless, the data
obtained thus far is in good agreementwith the recently publishedliterature.
4.3 LCMSassay
Wealso introduced development of an LCMS-basedassay as described in the introduction.
The retention time of the substrate was two minutes, which meanta very short eluting time
per sample. Additionally the peak shape was sharper and the substrate could be detected at
lower concentrations. Below is a table outlining the comparisons between the two LC assay
approaches.
 
Run time per 30 minutes 5 minutes
sample
Lowest Approx 0.5 nmoles 0.1-0.25 nmoles
detection levels
Substrate Easily synthesised Longer synthesis
Peak shape Broad and possible merging Sharper and nopossibility of
with hydrolysed free acid. peak merging with free acid.
Table 4.1 Comparisons of the HPLC/LCMSassaysystems.
To re-iterate the LCMSapproach, enzymekinetics were to be measured by monitoring the
rate in which AMACRde-deuterates a-deutero-ibuprofenoyl-CoA (67) and protonates the
supposed enzyme bound enolate to form Ibuprofenoyl-CoA (22). It was not possible to
monitor the rate of de-deuteration/protonation by taking a ratio of the two peaks. This was
due to ‘cross channelling’ between the protonated and the deuterated form - The decrease in
peak area of deuterated Ibuprofenoyl-CoA (67) did not represent a true reflection of the rate
of de-deuteration as the protonated form interfered with the signal. However, this is not the
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case vice versa which allowed us to monitor the reaction by measuring the peak area increase
of protonated Ibuprofenoyl-CoA. The results of incubations with 100uM a-deutero-
Ibuprofenoyl-CoA (67) and 100uM (S)-Ibuprofenoyl-CoA (22a) with 50ng MCRat 37°C at
pH 7 can be seen below (Fig 4.09):
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Fig 4.09 Incubation samples of a-deutero-Ibuprofenoyl-CoA (blue) and (S)-Ibuprofenoyl-
CoA (red) with 100ng MCR.
The initial burst of de-deuteration/protonation is almost double that of the rate of
racemisation (with gradients of 0.0047 pmoles/min and 0.0028 pmoles/min respectively —
See Appendix 4 for raw data). This can be explained as every time the enantiomerically pure
(S)-Ibuprofenoyl-CoA (22a) entersthe active site and is deprotonated, there is a 50/50 chance
that is it reprotonated from the same side. Whereas each time a-deutero-Ibuprofenoyl-CoA
(67) is de-deuterated, the probability that it will re-deuterate is negligible. Each time the
deuterium atom is removed from the substrate, it is likely to be lost in the bulk solvent (as
explained in Section 1.5.4). Anotherinteresting point about this apparent ‘doubling’ in rate is
that there is no kinetic isotope effect (KIE). If there was a KIE, then the rate of protonation
will be significantly slower, owing to the fact the C-D bond requires more energyto breakit.
This implies that the rate determining step of this reaction is reprotonation. This is in
agreementto the proposed mechanism ofinhibition of our currently tested inhibitors to date.
a-Trifluorotetadecanoyl-CoA (49) is postulated to discourage reprotonation by reducing
basicity of the enzyme boundenolate (possibly leading to increased bindingaffinity)
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4.4 Results of Chromogenic Assay.
Upon incubating the enzyme with our aliphatic chromogenic substrate (72), there was no
formation of the chromophore (74). We supposed this was due to inability of the enzyme to
accept the truncated from of the coenzymeA. There isalso the possibility that the chromogen
componentis not accepted. This was investigated by synthesising racemic and enantiopure
NACthioesters of Ibuprofen (55/55a) (Fig 4.10) as the p-isobutylbenzene group is a well
established accepted side chain for AMACR.
3 OO
sAJR Lorene
HO O
55
Fig 4.10. Racemic Ibuprofenoyl-SNAC(left) (S)-Ibuprofenoyl-SNAC (right).
These enantiomers ofNACthioesters can be separated by chiral chromatography(Fig 4.11).
(R) and (S)-Ibuprofenoyl-SNAC
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Fig 4.11 HPLCstraces of racemic (blue) and (S)-ibuprofenoyl-SNAC (green). The peak at
21.7 corresponds to the (R) enantiomer and 29.2 mins correspondsto the (S)-enantiomer.
Column: Chiral OJ (250mm by 4.6mm). Eluent system: 93.9: 6: 0.1 Hexane: IPA: TFA
respectively. 1ml/min.
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Incubating (S)-Ibuprofenoyl-NAC (55a) resulted in no racemisation. Synthesis of the longer
pantatheine (207) and pantatheine-11-pivolate (208) (Fig 4.12) derivatives of Ibuprofen (by
Matt Smith) also showed no racemisation.
O oO O O
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Fig 4.12. Pantatheine (left) and pantatheine-1 1-pivolate (right).
This indicates that there is an inherent need for the binding of the pyrophosphate and/or
adenosine moiety to the enzymefor catalytic activity. From the 3D structure of the enzyme
(Fig 4.13), it can be visualised that the adenine ring ‘anchors’ near the surface of the enzyme,
whichhelps guide the rest of the substrate towards the active site/hydrophobic pocket, where
it is further stabilised.
 
Fig 4.13. Pictorial representation of Ibuprofenoyl-CoA bound to MCR.Pdb file taken from
Wierenga et al.,°' 1. Adenine. 2. 1-deoxyribofuranose-3-phosphate 3. Pyrophosphate 4.
Ibuprofen.
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Additionally, incubation of the aromatic chromogen (68) with MCR also yielded no
chromophore (71). Measuring the UV absorbance of the incubated sample under standard
conditions of 37°C and pH 7 for 3 hours did not yield any discernable difference in the UV
light absorbed. Refocusing on the B-chloro derivative or perhaps a B-acetate derivative may
be a worthwhile endeavour.
Below is an HPLC trace and UV spectrum of the resulting chemically synthesised
chromophore(71) anticipated (Fig 4.14).
Aromatic conjugated chromophore
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Fig 4.14 HPLC trace and UV absorption of the conjugated chromophore (71) expected to
form enzymatically.
4.5 Free acid compoundsas prodrugs and therapeutic effects
Preliminary preclinical studies have been carried out on two of our potential prodrug
inhibitors, a-trifluorotetradecanoic acid (79) and £-trifluoroibuprofen (134). Professor Chien-
Feng and co-orkers from the Department of Pathology, Chi-Mei Medical Center, Taiwan
initially screened a range of cancerouscell lines (KEL-FIB, a hepatocellular cancercell line,
OH931, NMHF-1, both of which are myxofibrosarcomacell lines; and GIST48 and GIST882
which are gastrointestinal stromal cell lines) for expression of AMACRIA, AMACRIIA and
174PGK (phosphoglycerate kinase — a housekeeping gene '’) Of these, the most prevalent
expression of AMACRwasfound in GIST48 and GIST882 (Fig 4.15).
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Fig 4.15 AMACRexpression in a range of cancers.
The cytotoxic effect of a-trifluorotetradecanoic acid (79) was then tested on GIST882 and
was found to prove effective despite needing a high concentration (Fig 4.16).
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Fig 4.16 Cell viability vs. Time at various concentrations of a-trifluorotetradecanoic acid
(79).
Next, the two potential prodrugs were tested for toxicity in M. musculus. It was revealed that
a-trifluorotetradecanoic acid (79) had marked toxicity at a concentration of 200 uM.
However, £-trifluoroibuprofen (134) did not cause any significant acute toxicity even at 800-
1600mg/kg (administrated by I.P, three times a week, a total course of two weeks). This was
then followed bytesting 8-trifluoroibuprofen (134) on three different gall bladder carcinoma
cell types, MMNKI1(an immortalized normal cholangiocyte), RCB1130 and RCB1129,
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(biliary tract adenocarcinomacell lines). MMNK-1 has no expression of AMACR, RCB1130
has some expression of AMACR and RCB1129 has an overexpression of the enzyme (Fig
4.17).
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RCB1129 & RCB1130: gallbladder carcinomacells
Fig 4.17 AMACR and GAPDH (a housekeeping gene used in comparisons of gene
expression data'”°) expression in a range ofgall bladder cancers.
Incubating 8B-trifluoroibuprofen (134) in these cancerous cell lines demonstrated cancer
specific cytotoxicity as follows:
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Fig 4.18 Cell viability vs. time for various concentrations of B-trifluoroibuprofen (134)
againstthe gall bladdercell line RCB1129.
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Fig 4.19 Cell viability vs. time of various concentrations of B-trifluoroibuprofen (134) against
the gall bladdercell line RCB1130.
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Fig 4.20 Cell viability vs. time of various concentrations of B-trifluoroibuprofen (134) against
the gall bladdercell line MMNK-1.
It is very encouraging to note that cells which have no expression of AMACR (MMNK-1)
are impervious to the potential therapeutic activity of B-trifluoroibuprofen (134), whereas
RCB1130 and RCB1129cell lines (which expresses AMACR)havea significant loss of cell
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viability. It is however noteworthy to add that the concentration required for significant
reduction of cell viability is high. This may be attributed to the fact that in vivo
thioesterification is slow, due to the substrate being unnatural for the acyl-CoA synthetase. It
is also worthwhile to note that B-trifluoroibuprofen may act as a COX-1/2 inhibitor,'** which
may alter prostaglandin biosynthesis which can affect hormone regulation and cell growth,
producingirregularities in the results.
4.6 Future work
4.6.1 Assay Developmentand Inhibition
In this work, a range of potential inhibitors and prodrugs have been synthesised. Of these
inhibitors two have beentested in preclinical studies as anticancer agents (a-trifluoromethyl
tetradecanoic acid (79) and £-trifluroibuprofen (134)), the latter of which has given some
promising results. Nonetheless, there is no categorical proof that the latter works by
inhibiting AMACR.It is important that the efficacies of these potential inhibitors are tested
against AMACR. From the assay development discussed earlier in this Chapter, the next
logical step in this project would be to use the LCMSbased assay to test the range of
inhibitors that have been synthesised. We can then progress in determining which of these
inhibitors offers the best chanceas a potential lead for a therapeutic agent.
4.6.2 Pro drug strategy and in vitro testing.
The distinct advantage of using Ibuprofen derivatives as opposed to the previously studied
aliphatic derivatesis their increased bioavailability. Nonetheless, the use of CoA thioesters as
drug molecules is not a good idea as they are not bioavailable, susceptible to thiolytic
cleavage and can possibly interact with other CoA utilizing enzymes.It is unfortunate that the
truncated forms of known CoA ester substrates of AMACR have no enzymatic turnover.
Therefore with any designed inhibitor, we must consider the fact that only CoA thioesters are
accepted. A pro-drug strategy, whereby the proposed inhibitors are in their carboxylic acid
form is an attractive approach. This would take advantage of the CoA esterification in vivo.
To ascertain the likelihood of in vivo thioesterification, it would be worthwhile to obtain a
relevant CoA synthatase (e.g long chain fatty acyl-CoA synthetase) and test whether or not
the chosen drug molecule can be CoA esterfied in vitro. This data has already been
ascertained for some acid precursors, namely compounds (52), (54) and (79) in which all
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three were successfully thioesterified.''* This is encouragingly indicative that other
fluorinated derivatives of known substrates ofAMACR would also be activated in vivo.
4.6.3 Enolate mimics
Asa further addition to our arsenal of potential enzyme inhibitors, fluoroalkenes (209) and
thiocarbamates (210), designed as isoelectronic mimics of the assumed substrate enolate
anion, may showinhibition of AMACR(Fig 4.21). It is believed that since the enzyme may
stabilise the enolate intermediate derivation from natural substrates, enolate mimics may bind
strongly to the active site. These compounds are being prepared by a co-worker within the
group.
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Fig 4.21 Proposed enolate mimicsas potential inhibitors of AMACR.
4.6.4 Ketone analogues
To overcomethe tendency for in vivo thiolytic cleavage of thioesters, introducing a CH2
linker maybe a useful strategy. This effectively turns the thioester into a ketone, which will
presumably be morebiologically stable (Fig 4.22). The a-protons of ketonesare slightly less
acidic then their thioester analogues, which mayalter the binding affinity. However, this
strategy has been successfully employed with other CoA utilising enzymes such ascitrate
synthase, acyl-CoA dehydrogenase and palmitoyl transferase''° whereby the CoA-thioethers
are competitive inhibitors vs their CoA-thioester counterparts. As the structural change is
small (with the addition of one carbon atom), their structures are ideally suited as stable
mechanistic probes for AMACR,involving X-ray structural and kinetic studies. Work is
underwayin the group to prepare these compounds.
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Fig 4.22 Metabolism comparisonofthioesters and thioethers.
4.7 X-ray crystal structure of mitochondrial synthetic thiolase.
In an additional study carried out on the crystal structure of cytosolic thiolase by Rik
Wierenga ef al., the reaction mechanism was endeavoured to be realised. Thiolase is an
important enzymefor the synthesis of cholesterol and inhibitors of which are expected to be
of medical relevance. Slowing down the synthesis of cholesterol but not completely
preventing cholesterol synthesis is particulary important for the medication of children. The
synthesis of cholesterol in the brain is important for the maturation of the brain tissue. There
are currently no structures available of bound enolised substrates and the reaction mechanism
of thiolases are poorly understood. The best studied enzymein this respectis citrate synthase,
but there are no structures available of transition state complexes. A natural substrate of
cytosolic thiolase is 2-methylacetoacetyl-CoA. The proposed reaction cycle degrades this to
form propanoyl-CoA (Fig 4.23).
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Fig 4.23 Proposed mechanism of mitochondrial synthetic thiolase.
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Within the active site of the thiolase there are two oxyanion holes, the first of which stabilises
the enolate oxyanion and the second oxyanion hole stabilises the tetrahedral oxyanion.
Incorporation of an a—trifluoromethyl group (a-trifluoropropionyl-CoA, 211) mayfacilitate a
transition state analogue in which the enolate form is stabilised upon binding. A ligand bound
X-ray crystal structure could thus be obtained to help verify the reaction mechanism. This
could then also give insights into possible potential inhibitors.
Synthesis of this thioester was challenging. Trifluoropropionic acid has propensity to
polymerise once activated with ethyl chloroformate or CDI. However, this was
circumventented by carefully removing any excess CDI after formation of the activated acyl
imidozolium intermediate by washing the reaction medium with water. This was then subject
to thioestification with coenzyme A to yield the desired product (211) (see appendix 2).
Compound (211) has been soaked in crystals of cytosolic thiolase and is continuing to be
used by the Weirenga group in an ongoing investigation as to how it binds to the enzyme.
NH,
 
Fig 4.24 Trifluoropropionyl-CoA (211).
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CHAPTER 5
EXPERIMENTAL
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5: REAGENTS AND TECHNIQUES
5.1 Analytical thin layer chromatography(tlc)
Analytical thin layer chromatography was performed on 2 x 5cm aluminium sheets, pre-
coated with Merck Kieselgel 60 and detection by UV 254nm light. The developed
chromatograms were visualised with a UV lamp. Plates were then treated with potassium
permanganate dip and developed with a heat gun.
5.2 Flash column chromatography
The required quantity of Silica (Merck 9385 Kieselgel 60) was made into slurry with the
desired eluent and then applied to the column overa thin bed of sand or a sintered glassfrit.
The crude material was the applied to the column either dissolved in a small amount of the
eluent or absorbed onto silica and then the column was eluted with further solvent of
increasing polarity. Fractions of 5-100ml were collected and analysedbytlc.
5.3 Mass Spectrometry
Mass spectrometry analyses (ES+, ES-, EI+) were performed on a Trio1000 spectrometer and
run by the mass spectrometry service within the University of Liverpool. Where chemical
ionisations (CI) were used, ammonia was used as the carrier gas. For all non-trivial
compounds high resolution mass spectrometry was performed. For trivial/previously
published compounds nominal mass spectrometry sufficed.
5.4 NMR & IR
'H, °c, °F, COSY and HMQC NMRspectra were recorded on a Bruker AMX-400 machine.
Coupling constants (J-values) are reported in Hz. Chemical shifts are given in ppm,
downfield from an internal standard of tetramethylsilane (TMS).
IR spectra were recorded as neat samples or diluted with DCM (having ran a background
DCMspectra) using a Jasco 4200 FT-IR spectrometer in the range 4000-600cm'', previously
washed with ethanol.
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5.5 pH measurements
pH measurements were taken using a Metrohm 691 pH meter. This was calibrated prior to
use with buffers purchased from Thermo Russell (pH 4.00, 7.00 and 10.00 +0.01 at 25°C)
5.6 High pressure liquid chromatography
5.6.1 Analysis of racemisation
Analytical reverse phase HPLC was performed on a Waters 2695 separations module
equipped with a Waters 996 photo diode array detector. Separations were carried out using a
Chiral AGP, 150mm x 4.0mm columnpacked with a)-acid glycoprotein (AGP) as the chiral
selector immobilized on spherical 5 um silica particles. An isocratic gradient using 96% (v/v)
50mM KH2PO,4-NaOH(pH 6) and 4% (v/v) MeCN with a flow rate of 0.7ml/min was used
5.6.2 Enantiomeric resolution of acid/ester precursors
Analytical normal phase HPLC was performed the same system as 5.5.1. Separations were
carried out using a Chiral OJ column. 250mm x 4.6mm column packed with Cellulosetris (4-
methylbenzoate) coated on 10um silica-gel. An isocratic gradient using 98.9% (v/v) Hexane,
1% (v/v) IPA and 0.1% (v/v) TFA with a flow rate of 1ml/min was used unless otherwise
stated.
5.6.3 Analysis and purification of substrates/inhibitors
Analytical reverse phase HPLC was performed on a Gilson separations equipped with 306
pumpsand a Gilson 118 UV detector. Separations were carried out using a Knauer C-18, 5p,
250mm x 4.6mm column packed with 5um eurosphere 100-5 silica. An isocratic gradient
using 66% (v/v) 10mM NHsOAc-CH3CO2Na,(pH 6) and 34% (v/v) MeCN with a flow rate
of 1ml/min wasused unlessotherwisestated.
Preparative RP-HPLC was performed on the same Gilson system using a Knauer C-18 5p,
250mm x 20mm column packed with 5um eurosphere 100-5 silica. An isocratic gradient
using 66% (v/v) 10mM NH4,OAc-CH3CO2Na, (pH 6) and 34% (v/v) MeCN with a flow rate
of 10ml/min was used unless otherwise stated.
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5.7 Liquid chromatography mass spectrometry
Aliquots of the quenched incubated sample (3uL) were chromatographed at room
temperature on a Phenomenex Phenyl-hexyl column (150 x 4mm)fitted with a phenyl-hexyl
guard column by isocratic gradient elution with 70% (v/v) 10mM NHsOAc-CH3CO,Na
buffer, pH 6/ 30% (v/v) MeCN for 10 mins with a flow rate of 0.8ml/min. The flow rate of
eluate to the LC-MSinterface was ca. 160uL/min. An Applied Biosystems/MDS Sciex API
2000 mass spectrometer was operated with a TurbolonSpray electrospray source. The
interface temperature was 400°C; electrospray capillary voltage, 5.0kV; heater gas (Gas2)
setting 75. The instrumentwasset up for scanning between the ranges of 956.5 (161.1)-957.5
(162.1) with a scan time of 5s. Instrument management and data processing were
accomplished through analyst 1.4 software.
5.8 UV Spectroscopy
The UV absorbances of stock solutions of CoA thioesters were measured using a
PerkinElmer Lambda Bio + diode array detector in quartz curvettes of lcm pathlength. UV
absorbance measurements were madebyserial dilutions of the stock thioester solution until a
reading of 0.3-3 was obtained.
The UV absorbance of the incubated sample of compound (73) with MCR was measured
using a PerkinElmer Lambda 25 UV/VIS spectrometer with a Peltier water system and
temperature programmer.
5.9 Solvents
Analytical grade solvents were used for reactions involving aqueous media. All solvents
were distilled and kept over 3A molecular sieves prior to use. Purified / dried solvents were
obtained as follows:
Dichloromethane (DCM)- Distilled from calcium hydride before use.
N,N-Dimethylformamide (DMF)- Sureseal™ anhydrous solvent purchased from Aldrich or
distilled from calcium hydride before use.
Methanol (MeOH)- Distilled from a magnesium andiodinestill for 2-3 hours under argon
atmospherebefore use.
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Tetrahydrofuran (THF)- Dried from sodium and benzophenone until purple colouration
persisted and then distilled under atmospheric pressure.
5.10 Reagents
CoA-SH,(Li’)3 was purchased from Larodan.All other reagents were purchased from
Sigma-Aldrich unless otherwisestated.
5.11 Incubation technique
Example 1: 100uM (S)-ibuprofenoyl-CoA (22a) with 50ng MCR in Iml 10mM MOPS-
CH3CONa buffer (pH 7).
A stock solution of MCR in a mixture of 10mM MOPS-CH;CO.Na buffer (pH 7) and
glycerol (1:1) was supplied by Dr Rob Gibson, and stored in a freezer at -20°C. From the
concentration given (4.15mg/ml), the mixture was warmed to room temperature and 12uL of
which was mixed with 965uL 10mM MOPS-CH3CO2Nabuffer, pH 7 (made up of 97pL
100mM MOPS-CH3CONa buffer solution and 869uL H2O). A separate buffered solution of
ibuprofenoyl-CoA was made using the same buffer as stated and the concentration was
accurately calculated with use of the extinction coefficient of CoA (Amax of 260nm -
| '21) to be 4.35mM.Both samples were placed in anextinction coefficient of 15800M'cm
incubator at 37°C, whilst being stirred at 180 rpm for 10 minutes, after which time 23uL of
the substrate sample was injected into the enzyme solution. At regular intervals aliquot
portions of the incubated sample were removed (5OuL) and injected into a vial containing an
aqueous 10% (v/v) TFA solution (SuL). The samples were well mixed (by removing the
entire contents of the vial (10uL) and re-introducing the solution into the same vial several
times with use of a micropipette). The aliquot portions were then subject to analysis by chiral
HPLCorif a—-deutero-ibuprofenoyl-CoA was used, the samples werestored in the freezer (-
20°C) where the samples were analysed at a later date with use of LCMS.
Example 2: 100uM 3-hydroxy-2-methyl-3-(4-nitrophenyl)propanoyl-CoA (68) with 100ng
MCRin Iml 10mM MOPS-CH3CO.Nabuffer, pH 7.
From the aforementioned stock solution of MCR, 24uL was mixed with 913uL 10mM
MOPS-CH3CO2Nabuffer (made up of 91uL 100mM MOPS-CH3CO2Nabuffer solution and
822uL HO). Again a separate solution of 68 was made using the same buffer as stated and
calculated to have a concentration of 1.59mM from the extinction coefficient of the adenine
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ring. The enzyme solution was placed in a 1ml quartz cuvette equipped with a magnetic
stirrer and placed into a PerkinElmer Lambda 25 UV/VISspectrometer. The temperature was
set to 37°C and after 10 minutes the homogenised sample was subject to spectrophotometric
analysis to allow for a 0 reading to be made. 63uL of the stock solution of the aromatic
chromogen was then injected into the solution and a further measurement was made.
Measurments were repeated over the course of 3 hours. The results of which can be seen in
Fig 4.13
Example 3: 100uM (S)-ibuprofenoyl-CoA (22a) with 50 ng MCR in Iml 10mM MOPS-
CH;CONabuffer, pH 7.
As with example 1, the incubation was carried out at 37°C. At regular intervals 100nL was
removed and added dropwise to IM NaOH (500uL) This was allowed to stir at room
temperature for | hour. After which time the mixture wasacidifed with the dropwise addition
of 1M HCI (550pL). The hydrolysed free acid was extracted into EtyO (2 x 200uL) and
subject to HPLCanalysis.
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5.12 Synthesis of Inhibitors
5.12.1 Dodecyltriphenylphosphonium bromide (75)'!° 
2 4 6 8 10 12
ffPg1 3 5 7 9 4 13
To 1-bromododecane (5.0ml, 20.66mmol) in anhydrous toluene (50ml) was added
triphenylphosphine (4.41g, 20.66mmol). The solution was then heated under reflux for 48
hours after which time the solvent was removed under reduced pressure to yield the title
compoundasan off-white solid. Yield 8.74g, 98%.
'H NMR (400 MHz, CDCl3) 8: 0.88 (3H,t, J = 6.94 Hz, H-1), 1.19-1.38 (22H, m, H-2-12),
7.69-7.87 (15H, m, H-13).
'5C NMR (100 MHz, CDCI) 8: 14.46 (C-1), 23.10 (C-2), 23.528 (C-3), 30.88-29.56 (C-4-
11), 32.26 (C-12), 135.38-119.3161 (18C, C-13);
HRMScalcd for C39H4oP (M+) 431.2868; found 431.2881
5.12.2 Methyl 2-(trifluoromethyl)tetradec-2-enoate (76)!'°
 
1.6 M n-BuLi (2.2ml, 3.52mmol) was added dropwise to a cooled solution of compound 75
(1.38g, 3.2mmol) in THF (50 ml) at -78°C. The mixture was allowed to warm to room
temperature over 2 hoursandstirred for an additional 1 hour. The dark red mixture was again
cooled to ca -78°C and trifluoromethyl pyruvate (0.5g, 3.2mmol) was added dropwise. The
resulting yellow solution was monitored by TLC until conversion was complete. The mixture
was then allowed to warm to room temperature,filtered through a short columnofsilica gel
(30g) to removethe triphenylphosphine oxide and salts. The crude material was concentrated
in vacuo and purified bysilica gel flash chromatography using 1:4 Et,O:hexaneto yield both
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geometric isomers (1:1) of the title compoundas a pale yellow oil. Yield 0.23g, 23%. Rf =
069, 1:4 Et)O:hexane;
(E)-isomer: 'H NMR (400 MHz, CDCI;)6: 0.88 (3H,t, J = 7.0 Hz, H-14). 1.22-1.38 (16H,
m, H-8-13), 1.41-1.52 (2H, m, H-5), 2.56-2.62 (2H, m, H-4), 3.82 (3H, s, H-16), 6.84 (1H,tq,
J34= 7A Hz, H-3),
'3C NMR(100 MHz, CDCls) 8: 14.5 (C-14). 23.0-32.3 (C-4-13), 52.3 (C-16), 128.9 (C-15),
151.1 (C-3), 169.1 (C-1),
(Z)-isomer: 'H NMR (400 MHz, CDCl) 5: 0.88 (3H, t, J = 7.0 Hz, H-14). 1.22-1.38 (16H,
m, H-8-13), 1.41-1.52 (2H, m, H-5), 2.42-2.48 (2H, m, H-4), 3.82 (3H,s, H-16), 7.21 (1H,tq,
J34 =7.4 Hz, H-3),
'3C NMR (100 MHz, CDCl) 8: 14.5 (C-14). 23.0-32.3 (C-4-13), 52.3 (C-16), 128.9 (C-15),
151.1 (C-3), 169.1 (C-1);
HRMScalcd for CjsH3;F302N (M+NH4q’) 326.2307; found 326.2301
1165.12.3 Methyl 2-(trifluoromethyl)tetradecanoate (78)
 
To a solution of compound 76 (0.4g, 1.5mmol) in distilled MeOH wasadded 1 micro spatula
of palladium over activated carbon. The vessel was evacuated under reduced pressure and
flushed 3 times with H2 andstirred over night. It was then flushed with N»2 and openedto the
atmosphere. The mixture wasfiltered through a pad of celite and washed with MeOH. The
solvent was the concentrated in vacuo to yield the title compound. This gave to give the
desired productas a yellow oily residue Yield 0.123g, 60%. Rf = 0.69, 1:4 EtpO:hexane;
'H NMR (400 MHz, CDCI;) 5: 0.88 (3H,t, J = 7.0Hz, H-14), 1.22-1.38 (20H, m, H-4-13),
1.72-1.79 (1H, m, H-3), 1.83-1.91 (1H, m, H-3), 3.05-3.14 (1H, m, H-2), 3.77 (3H,s, H-16).
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'3C NMR (100 MHz, CDCIs) 8: 14.41 (C-14). 23.03 (C-3), 26.50-32.28 (C-4-13), 50.57 (C-
2), 52.83 (C-16), 126.50 (C-15), 168.54 (C-1),
HRMScalcdfor C16H33F30.N (M+NH,') 328.2463; found 328.2460
5.12.4 2-Trifluoromethyl)tetradecan-1-ol (212)
 
To compound 78 (0.1g, 0.322mmol) in MeOH (5 ml) at 0°C was added LiAHy,(0.12g,
3.22mmol) in one portion. The mixture was allowed to warm to room temperature andstirred
for 1 hr. HO (2ml) was added dropwise and MeOH was removed under reduced pressure.
Et)O (5ml) was then added, the aqueous layer was removed andthe organic layer was washed
with brine (10ml), followed by HO (10ml). The Et,O layer was then dried over Na2SO4 and
concentrated in vacuo. The crude oil was purified by silica gel flash chromatography, using
3:7 ethyl acetate/hexane to give the title compoundas a colourless liquid. Yield 0.04g, 44%.
Rf = 0.31, 1:4 EtpO:hexane;
'H NMR (400 MHz, CDCl) 5: 0.88 (3H, t, J = 6.84, H-14). 1.21-1.36 (16H, m H-5-13),
1.44-1.54 (2H, m, H-4), 1.59-1.72 (2H, m, H-3), 2.16-2.27 (1H, m, H-2), 3.81 (2H, d, J= 4.4
Hz H-1),
'3C NMR (100 MHz, CDCl) 8: 14.46 (C-14), 23.06-32.30 (C-3-13), 46.01 (C-2), 60.37 (C-
1), 129.78 (C-14).
(Cl) m/z for C1sH2F30 (M+): 282 (100.00)
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5.12.5 .10 2-(Trifluoromethyl)tetradecanoic acid (79)
 
To a solution of compound 78 (0.1g, 0.32mmol) in wet DMF (1ml) was added lithium iodide
(0.047g, 0.35mmol). This was heated to reflux for 12 hours. After which time the solution
was diluted with water, acidified to pH 2 with the dropwise addition of 2M HCl and extracted
with Et)O (Sml). This was then dried over Na2SOuq, concentrated in vacuo and purified using
column chromatography using 2:5 Et,O:hexaneto yield the title compound asa pale yellow
solid. Yield 0.058g, 61%. Rf= 0.18, 1:4 EtpO:hexane;
'H (400MHz, CDCI;) 8: 0.88 (3H, t, J = 7.0 Hz, H-14), 1.22-1.36 (20H, m, H-4-13), 1.72-
1.78 (1H, m, H-3), 1.83-1.92 (1H, m, H-3), 3.06-3.14 (1H, m, H-2);
5 3C (100MHz, CDCI) 8: 14.4 (C-14), 23.0-32.3 (C-3-13), 50.8 (C-2), 168.5 (C-1) ; Umax
/em'! 1756 (C=O), 3300-2950 (O-H acid).
HRMScalcd for C1sH3;F302N (M+NH,') 314.2307; found 314.2315
5.12.6.10 2-(Trifluoromethy])tetradecanoyl-CoA (48)'"°
To a stirred solution of carbonyldiimidazole (28mg, 0.169mmol) desiccated over silica
crystals overnight) in tetrahydrofuran (0.5ml) was added compound 79 (50mg, 16.87pmol).
After 2 hours stirring at room temperature, a solution of CoA-SH, (Li‘)3 (13.2mg,
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0.169mmol) in water (0.5ml) was added. The resulting solution was allowed to stir at room
temperature overnight. The product was then purified by preparative reverse phase HPLC.
The crude material was dried by the removal of the organic solvent under reduced pressure,
followed by removalof the aqueoussolvent through lyophilisation to give thetitle compound
as a white amorphouswhite solid (3.1mg, 21% yield- calculated from relative abundance of
CoA-SH,(Li’)3;
HRMScalcd for C36Ho0F3N7O17P3S (M-H)1044.2982; found 1044.2898
5.12.7,2-Dimethylpentadecanoic acid (88)
 
To a suspension of NaH (3.99g of 60% in oil, 100mmol) in anhydrous THF (83.3ml) and
diisopropylamine (14.1ml, 100mmol) was added dropwise isobutyric acid (9.28ml,
100mmol). When gas evolution was complete, the mixture was heated and refluxed for 20
minutes. This was then cooled to 0°C and n-bromododecane (24ml, 100mmol) was added
dropwise. The resulting solution wasstirred for 60 minutes at 0°C and was allowed to warm
to room temperature overnight. This was then re-cooled to 0°C and a minimum amount of
HO was added. The solution was acidified pH 2 with the dropwise addition of conc HCl.
Diethyl ether (SOml) was added and separated. The aqueous layer was further washed with
ether (5Oml1) and the combined organic layers were washed with brine and dried over MgSOx.
Filtration and concentration afforded a white solid which was purified by silica gel flash
chromatography using 1:9 EtOAc/hexane. Yield 14.8 g, 57.8%. Rf = 0.32, 1:9 EtOAc:hexane
'H NMR (400 MHz, CDCl;) 8: 0.88 (3H,t, J =6.85, H-14), 1.18-1.21 (6H, m, H-15-16),
1.21-1.30 (22H, m, H-4-13), 1.51-1.55 (2H, m, H-3).
'3C NMR (100 MHz, CDCI) 5: 14.46 (C-14), 23.06 (C-13), 25.31 (C-15/16), 29.35-32.31
(C-4-12), 40.954 (C-3), 42.519 (C-2), 185.11 (C-1). Umax /em! 2915.84 (C-H), 1700.91
(C=O). (Cl) m/z for C}6H3502N (M + NH’): 274 (100.00)
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5.12.8 2-Chlorotetradecanoic acid (92)
 
Myristic acid (5.0 g, 20.0 mmol) and thionyl chloride (6.39ml, 80.0mmol) were added to a
reaction vessel and heated to reflux for 30 minutes. The reaction was monitored by TLC until
the reaction had completed (95:5 dichloromethane/methanol). This was cooled to room
temperature and to this was added N-chlorosuccinimide (5.34g, 40.0mmol), followed by conc
HC] (2 drops) and an additional 4ml1 of thionyl chloride. This was then heated to 80°C for
1.25 hr. The solvent was then removed under reduced pressure and the remaining solid was
washed with hexane (50ml) to remove the N-chlorosuccinimide. This was then re-washed
with HO (2 x 50ml), dried over MgSO, and the remaining organic solvent was removed
under reduced pressure.
The resulting a-chlorinated acid was added to a 1:1 mixture of THF and 2M HCI(4ml) and
extracted with CHCl;. The organic layer was dried over MgSO, and the solvent was removed
under reduced pressure. The resulting white solid was purified by flash column
chromatography using 3:7 EtOAc/hexane. Yield 54%. Rf = 0.5, 3:7 EtOAc:hexane.
'H NMR (400 MHz, CDCI;) 5: 0.88 (3H, t, J = 13.16, H-14), 1.36-1.32 (18H, m, H-5-13),
1.51-1.39 (2H, m, H-4), 1.99-1.90 (1H, m, H-3), 2.08-2.00 (1H, m, H-3), 4.31 (1H, dd, J =
5.9 Hz, J = 6.94 Hz, H-2).
'5C NMR (100 MHz, CDCI3) 8: 14.46 (C-14), 23.06 (C-13), 26.28 (C-5), 30.005-29.205 (C-
6-12), 32.29 (C-4), 35.18 (C-3), 57.52 (C-2), 175.31 (C-1).
(Cl) m/z for C14H3)°’ClIO2N (M+NH,’): 282 (100.00)
Elemental Analysis: Theoretal C: 63.98%, H: 10.35% Found C: 62.90%, H: 10.15%
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5.12.9 (E/Z)-3-Phenyl-2-(trifluoromethyl)acrylic acid (99)
 
Triphenylphosphine (0.084g, 0.32mmol), palladium acetate (0.024g, 0.l1mmol), caesium
chloride (2.28g, 7.14mmol) and bromobenzene (1. 68ml, 10.71mmol ) in 10ml dry DMF was
added 2-(trifluoromethyl)-acrylic acid (0.5g, 3.57mmol) dropwise under a strict No
atmosphere. This was heated to 130°C over night. After which time the solution was acidified
to pH 3-4 with the dropwise addition of 1M HCl and extracted with EtOAc (2 x 20ml). The
crude product waspurified by flash column chromatography using 4:6 EtOAc:hexaneto yield
the title compound as a brownsolid. Yield 0.77 g, 67%. Rf = 0.21, 4:6 EtOAc:hexane;
(Z)-isomer 'H NMR(400 MHz, CDCI,) 5: 7.23-7.38 (5H, m, H-5,6,7,8,9), 7.79 (1H,s, 3H),
°C NMR (100 MHz, CDCIs) 5: 120.74, 124.31, 128.73-130.85, 132.67, 142.45, 167.69.
(E)-isomer 'H NMR (400 MHz, CDCI3) 8: 7.23--7.23 (5H, m, H-5,6,7,8,9), 7.71 (1H,s, H-3),
'5C NMR(100 MHz, CDCl) 5: 120.74, 124.31, 128.73-130.85, 132.67, 142.45, 167.69.
m/z for C19Hi0F302N (M tr NH’): 234 (100.00)
5.12.10 (4-(Octyloxy)phenyl)methanol'’”’ (104)
 
To 4-hydroxybenzyl alcohol (5g, 40.28 mmol) in DMF (40ml) was added potassium
carbonate (5.57g, 40.30mmol) at room temperature. This was followed by the dropwise
addition of 1-bromo-octane (7.65ml, 35.43 mmol). The solution was allowed to stir at that
temperature for 20 minutes. This was then gradually brought to 60°C for 4 hours. The
reaction was quenched with water (40ml), extracted with Et,O (2 x 50mL), washed with brine
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(SOml) and finally washed with water (SOml). The organic layer was then dried over Na,SOq4
and the solvent removed under reduced pressure. The crude solid was purified using column
chromatography using 3:7 EtyO: Hexaneto yield a white solid. Yield 8.6g, 83%. Rf = 0.19,
3:7 EtpO:hexane;
'H_ (400MHz, CDCI;) 5: 0.91 (3H, t, J = 7.45 Hz, H-8”), 1.27-1.58 (10H, m, H-2”-7”) 3.20
(2H, m, H-1”), 3.79 (2H, s, H-1), 6.54 (2H, d, J = 8.83 Hz, H -3’,5’), 6.76 (2H, d, J = 9.02
Hz, H-2’,6’);
°C (100MHz, CDCls) 8: 14.53 (C-8”), 23.08-32.23 (C-2”-7”), 65.54 (C-1), 68.48 (C-1”)
114.97 (C-3’,5’), 129.06 (C-2’,6’), 133.28 (C-1’) 159.22 (C-4’);
HRMScalcd for C};H2s02 (M+H’) 237.0891; found 237.0891.
5.12.11 1-(odomethyl)-4-(octyloxy)benzene (105)
 
 
To a solution of triphenylphosphine (4.33g, 16.5mmol) in dry DCM (15ml) was added
imidazole (1.12g, 16.5mmol) followed by iodine (4.19, 16.5mmol) under Nz. This was
allowed to stir for 5 minutes. During which time the solution changed from a colourless
solution, to a yellow, and finally to a bright orange solution with a white precipitate. To this
was then added compound 104a(3 g, 12.7 mmol) in one portion whilst still maintaining an
inert atmosphere. This was allowedto stir at room temperature for 30 minutes. After which
time the solid wasfiltered off and the organic layer was subsequently washed with saturated
sodium thiosulfate (20ml), H.O (20ml), and finally with brine (20ml). The organic layer was
then dried over Na2SO, and concentrated under reduced pressure. The crude extract was
mounted onto silica and purified using flash chromatography with an eluent system of 3:7
Et,O:hexaneto yield a white solid. Yield 4.35g, 98%. Rf = 0.67, 3:7 EtxO:hexane
'H (400MHz, CDCI;) 5: 0.91 (3H,t, J = 7.45 Hz, H-8”), 1.27-1.58 (10H, m, H-2”-7”) 3.20
(2H, m, H-1”), 3.79 (2H, s, H-1), 6.54 (2H, d, J = 8.83 Hz, H -3’,5’), 6.76 (2H, d, J = 9.02
Hz, H-2’,6’);
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'3C (100MHz, CDCI;) 8: 7.26 (C-1), 14.53 (C-8”) 23.08-32.23 (C-2”-7”), 68.48 (C-1”),
115.21 (C-3’,5°), 129.81 (C-2’,’6’), 131.47 (C-1’) 159.22 (C-2’);
5.12.12 Iodo(4-(octyloxy)benzyl)triphenylphosphorane (106)
 
To compound 105a (2.17 g, 6.26 mmol) and triphenylphosphine (2.46, 9.39 mmol) was
added dry MeCN (10ml) under N>. A white precipitate began to form almost immediately.
This was then heated to reflux for 24 hours. After which time the reaction vessel was cooled
to room temperature and the solvent was removed under reduced pressure. The gummy white
solid was washed with hexane to remove and unreacted starting material. This was dried
under vacuum overnightto yield a white solid. Yield 3.3g, 87%.
'H_ (400MHz, CDCI) 8: 0.88 (3H, t, J = 6.88 Hz, H-8”), 1.22-1.50 (10H, m, H-3”-7”), 1.75
(2H, m, H-2”) 3.20 (2H, m, H-1”), 3.79 (2H, s, H-1), 6.54 (2H, d, J = 8.83 Hz, H-3’,5’), 6.76
(2H, d, J = 9.02 Hz, H-2’,6’);
"°C (100MHz, CDCI3) 5: 14.53 (C-8”) 21.87-32.19 (C-2”-7”,1), 68.47 (C-1”), 115.30 (C-
3’,5’), 117.57-138.25 (C-1’,2’,6’), 159.22 (C-4’);
HRMScalcd for C33H3,0P (M+) 481.2660; found 481.2645
5.12.13 (E/Z)-Methyl 3-(4-(octyloxy)phenyl)-2-(trifluoromethyl)acrylate (107)
Iodo(4-(octyloxy)benzyl)triphenylphosphorane (106) (1.3g, 2.1mmol) was reacted according
to the procedure described in Section 5.11.2 to yield thetitle compound 107asa thick orange
oil. The crude material was purified by silica gel flash chromatography using 1:9
Et)O:hexanetoyield the title compoundasa pale yellow oil. Yield 0.26g, 34% Rf= 0.59, 2:8
Et)O:hexane.
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'H (400MHz, CDCI;) 8: 0.92 (3H, t, J = 6.79 Hz, H-8”), 1.27-1.55 (10H, m, H-3”-7”) 1.83
(2H, m, H-2”) 3.86 (3H, s, H-5), 4.01 (2H, t, J = 6.54 Hz, H-1”), 6.92 (2H, d, J = 8.82 Hz,
H-3’,5’), 7.36, (1H, s, H-4) 7.41 (2H, d, J = 8.83 Hz, H-2’,6’);
°C (100MHz, CDCI3) 5: 14.51 (C-8”), 23.08-32.23 (C-2”-7”), 52.89 (C-5), 68.40 (C-1”)
114.94 (C-3’,5’), 120.27 (C-3, q, J cr = 0.31 Hz), 132.04 (C-2’,6’) 134.24 (C-4), 140.82 (C-
1’), 161.67 (C-4’), 164.721 (C-1); Umax om’! 2979.48 (C-H), 1749.09 (C=O), 1604 (C=C),
HRMScalcd for C}9H29F303N (M+NH,') 376.20995; found 376.21095.
5.12.14. Methyl 3,3,3-trifluoro-2-(4-(octyloxy)benzyl)propanoate (108)
 
In a high pressure lab autoclave, a solution of methyl 3-(4-(octyloxy)phenyl)-2-
(trifluoromethyl)acrylate (107) (0.150g, 0.42mmol) in distilled MeOH (S5ml) was added 1
micro spatula of 5% platinum over activated carbon. The vessel was flushed 3 times with Ho,
pressurised with H, to 800 psi andstirred overnight. After careful release of H2, the mixture
was filtered through a pad of celite and washed with MeOH. The solvent was the
concentrated in vacuo and the crude material was purified by flash column chromatography
with an eluent system of 2:8 Et,O:hexaneto yield the title compound as a white solid. Yield
0.135g, 89%. Rf = 0.59, 2:8 Et,O:hexane.
'H_ (400MHz, CDCI) 5: 0.88 (3H, t, J = 6.92 Hz, H-8”), 1.23-139 (10H, m, H-3”-7”) 1.77
(2H, m, H-2”) 3.08 (2H, dd J= 13.92, 4.58 Hz, H-4a,4b) 3.37 (1H, m, H-2) 3.65 (3H,s, H-5),
3.92 (2H,t, J = 6.60 Hz, H-1”), 6.82 (2H, d, J = 8.73Hz, H -3’,5’), 7.08 (2H, d, J = 8.64 Hz,
H-2’,6’);
'3C (100MHz, CDCI;) 8: 14.51 (C-8”), 23.06-32.22 (C-2”-7”), 52.99 (C-5), 53.00 (C-2),
68.40 (C-1””) 115.09 (C-3’,5’), 128.26 (C-1’), 130.15 (C-2’,6’), 158.69 (C-4’), 167.89 (C-1);
HRMScalcd for C}9H2703F3Na (M+Na) 383.1810; found 383.1792.
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5.12.15 3,3,3-Trifluoro-2-(4-(octyloxy)benzyl)propanoic acid (109)
OH
 
Methyl 3,3,3-trifluoro-2-(4-(octyloxy)benzyl)propanoate (108) (0.05g, 0.014mmol) was
reacted according to the procedure described in Section 5.11.5 to yield the title compound as
a white solid. Yield 0.033g, 70%. Rf = 0.32, 2:8 EtpO:hexane
'H (400MHz, CDCI;) 6: 0.88 (3H,t, J = 6.91 Hz, H-8”), 1.23-139 (10H, m, H-3”-7”) 1.77
(2H, m, H-2”) 3.08 (2H, dd J= 13.85, 10.72, 4.65 Hz, H-4a,4b) 3.40 (1H, m, H-2), 3.92 (2H,
t, J = 6.60 Hz, H-1”), 6.82 (2H, d, J = 8.73Hz, H -3’,5’), 7.08 (2H, d, J = 8.64 hz, H-2’,6’);
'3C (100MHz, CDCI3) 5: 14.51 (C-8”), 23.00-32.19 (C-2”-7”), 55.25 (C-2), 68.40 (C-1”)
115.09 (C-3’,5’), 128.26 (C-1’), 130.15 (C-26’), 158.70 (C-4’), 173.52 (C-1);
HRMScalcd for CjgH2s03F3Na (M+Na) 369.1653; found 369.1639.
5.12.16 (4-(6,7,7,7-Tetrafluoro-6-(trifluoromethyl)heptyl)phenyl)methanol (104a)
 
gn FC
To 4-hydroxy benzyl alcohol (0.69g, 6.l1mmol) was reacted according to the procedure
described in Section 5.11.10, using DMF (10ml), potassium carbonate (1.53g, 11.07mmol)
and 1,1,1,2-tetrafluoro-2-trifluoromethyliodohexane (2g, 5.68mmol). Again the crude
material was purified using flash column chromatography using 3:7 Et,O:hexaneto yield a
white solid. Yield 1.83g, 86%
'H (400MHz, CDCI3) 5: 1.81 (4H, m, H3”-4”), 2.15 (2H, m, H-2”), 3.99 (2H,t, J = 5.80 Hz,
H-1”), 4.59 (2H, s, H-1) 6.87 (2H, d, J = 8.58 Hz, H-2’,6’) 7.28 (2H, d, J = 8.52 Hz, H-
3,5’)
'3C (100MHz, CDCl;) 5: 18.94 (C-4”), 29.10-29.59 (C-2”,3”), 65.37 (C-1), 67.54 (C-1”)
92.50 (C-6”-7”), 114.91 (C-3’,5’), 121.20 (C-5”), 129.08 (C-2’,6’), 133.71 (C-1’) 158.82 (C-
4’).
HRMScaled for Cj4H;502F7Na (M+Na) 371.0858; found 371.0858
118
5.12.17 1-(lodomethyl)-4-(5,6,6,6-tetrafluoro-5-(trifluoromethyl)heptyl)benzene (105a)
 
gn F3C
Compound 104a wasreacted according to the procedure described in Section 5.11.11. The
crude extract was mountedonto silica and purified using flash chromatography with an eluent
system of 3:7 EtpO:hexaneto yield a white solid. Yield 1.18g, 90%.
'H (400MHz, CDCI) 5: 1.81 (4H, m, H3”-4”), 2.15 (2H, m, H-2”), 3.99 (2H,t, J = 5.80 Hz,
H-1”), 4.47 (2H, s, H-1) 6.87 (2H, d, J = 8.71 Hz, H-2’,6’) 7.28 (2H, d, J = 8.52 Hz, H-
3’,5’)
3 (100MHz, CDCl) 8: 14.52 (C-4”), 23.07 (C-1), 26.46-32.23 (C-2”-3”) 68.39 (C-1”),
115.08 (C-3°,5’), 128.25 (C-1’), 128.90 (C-5”), 130.16 (C-2’,6’), 132.41 (C-6"-7”), 160.71
(C-1’) 158.68 (C-4’).
 
5.12.18 Iodotriphenyl(4-(6,7,7.7-tetrafluoro-6-trifluoromethyl)heptyl)benzyl)phosphorane
(106a)
-"CF;
F
5 3" 1
gr FC
Compound 105a (1g, 2.18mmol) was reacted according to the procedure described in Section
5.11.12. The gummy white solid was washed with hexane to remove and unreactedstarting
material. This was dried under vacuum overnightto yield a white solid. Yield 1.41g, 90%
'H (400MHz, CDCls) 5: 1.74 (6H, m, H3”-4”), 2.15 (2H, m, H-2”), 3.90 (2H,t, J = 5.60 Hz,
H-1”), 5.18 (2H, d, J = 13.57 Hz, H-1), 6.64-7.79 (19H, m, H-2’,3’,5’,6’.2).
'3C (100MHz, CDCl) 8: 18.92 (C-3”), 29.04-31.07 (C-2”-4”,1), 67.53 (C-1”) 115,19-118.72
(C-3°5’,5”),), 128.97 (C1’)133.16 (C-2’,6”), 134.79 (C-2), 135.50 (C-2), 159.36 (C-4’)
Umax em’! 1232.29 (C-O), 2983.34 (C-H)
HRMScalcd for C33H29OF7P (M+) 593.1844; found 593.1855.
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5.12.19 4-(Benzyloxy)phenylmethanol!”* (118)
 
To a mixture of 4-hydroxy benzyl alcohol (4g, 32.22mmol) and potassium carbonate (4.45g,
32.22mmol) in dry acetone (100ml) was added benzyl bromide (5.51g, 3.83ml, 32.22mmol)
in portions. This was allowed to reflux for 4 hours. After completion (by TLC) the solution
was cooled to room temperature and filtered. The collected solid was washed with ether. The
combined ether and acetone solutions were evaporated to dryness and the re-dissolved in
ether (100ml). This was then washed with 1M HCl (50ml), followed by H2O (2 x 100ml).
The ether layer was the dried over MgSO,,filtered and the solvent was then removed under
reduced pressure. The crude product wasthen purified using flash column chromatography
using an eluent system of 1:9 Et,O:hexane to yield the titled compound as a white solid.
Yield 6.28g, 91%. Rf = 0.30, 1:9 EtpO:hexane.
'H (400MHz, CDCI;) 5: 4.62 (2H, s, H-1), 5.07 (2H, s, H-1”), 6.98 (2H, d, J = 8.66 Hz, H-
3’,5’), 7.26-7.44 (7H, H-3”,4”,5”,6”,7”,2’,6’).
'3C (100MHz, CDCI) 5: 65.48 (C-1), 70.44 (C-1”), 115.35 (C-3’.5’), 127.86-129.09 (C-
3”,4",5”,6",7",2’,6°). 133.78 (C-1’), 137.34 (C-2”), 158.82 (C-4’).
Umax /em’! 3365.17 (OH), 3027.69 (C-H), 1504.2 (C=C), 1236 (C-O).
HRMScaled for C}4H)402Na (M+Na) 237.0891 found 237.0891
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5.12.20 1-(Benzyloxy)-4-(iodomethyl)benzene (119)
 
Compound 119 was prepared in a similar manner to the other aryl ether derivatives
(105/105a) using triphenylphosphine (3.18g, 12.13mmol), imidazole (0.83g, 12.13mmol),
iodine (1.54g, 12.13mmol) and 4-(benzyloxy)phenyl)methanol (118) (2g, 9.33mmol). The
crude extract was mountedontosilica and purified using flash chromatography with an eluent
system of 3:7 Et,O:hexane to yield a white solid. Yield 2.72g, 90%. Rf = 0.72, 1:9
Et)O:hexane.
'H (400MHz, CDCI) 5: 4.47 (2H, s, H-1), 5.04 (2H, s, H-1”), 6.90 (2H, d, J = 8.73 Hz, H-
3,5’), 7.299-7.43 (7H, H-3”,4”,5”,6”,7”,2’,6’).
'3C (100MHz, CDCI;) 5: 6.98 (C-1), 70.46 (C-1”), 115.57 (C-3°-5’), 127.89-130.49 (C-
3”,4",5",6",7",2’,6”), 132.02 (C-1’), 137.13 (C-2”), 158.81 (C-4’).
Umax ‘cm’! 3027.69 (C-H), 1240.00 (C-O), 1506.13 (C=C).
5.12.21 (4-(Benzyloxy)benzyl)iodotriphenylphosphorane (120)
1-(Benzyloxy)-4-(iodomethyl)benzene (119) (2g, 6.17mmol) was reacted in accordance to
the procedurecarried out in Section 5.11.12 using 1.62g, 6.17mmol, triphenylphosphine. The
gummy white solid was washed with hexane to remove and unreactedstarting material. This
was dried under vacuum overnight to yield a white solid. Yield 3.25g, 90%.
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'H (400MHz, CDCI;) 8: 4.98 (2H, s, H-1”), 5.19 (2H, d, J = 13.57, H-1), 6.75 (2H, d, J =
8.41 Hz, H-3’,5’), 6.99-7.02 (2H, dd, J = 8.8 Hz, 2.49, H-2’-6’) 7.26-7.80 (20H, H-
3”,4",5”,6”,7”,2).
3 (100MHz, CDCl;) 8: 6.98 (C-1), 70.46 (C-1”), 115.57 (C-3’-5’), 127.89-130.49 (C-
3”,4",5",6",7",2’,6’), 132.02 (C-1’), 137.13 (C-2”), 158.81 (C-4’).
HRMScalcd for C32H»g,0P (M+) 459.1878; found 459.1897
5.12.22 (E/Z)-Methyl 3-(4-(benzyloxy)phenyl)-2-(trifluoromethyl)acrylate (121)
 
Compound 120 (1g, 1.7mmol) was reacted in accordance to the procedure described in
Section 5.11.2, using 2.5M n-BuLi (0.75ml,1.88mmol) andtrifluoromethyl pyruvate (0.174g,
0.17ml, 1.7mmol). The crude material was concentrated in vacuo and purified by flash
column chromatography using an eluent system of 2:8 Et,O:hexane to yield the title
compoundasa pale yellow oil. Yield 0.26g, 45%. Rf = 0.3, 1:9 EtpO: Hexane
'H (400MHz, CDCI;) 5: 3.71 (2H, s, H-5), 4.99 (2H, s, H-1”), 6.87 (2H, d, J = 8.93 Hz, H-
3’,5°), 7.23-7.33 (8H, H-3”,4”,5”,6”,7”,2’,6’,4).
'3C (100MHz, CDCI;) 5: 52.97 (C-5), 70.50 (C-1”), 115.36 (C-3’-5”), 120.62-121.55 (C-3),
127.35-132.78 (C-3”.4”,5”,6",7,1’,2’.6°), 13.69 (C-1”), 140.73 (C-4), 161.23 (C-4’), 164.67
(C-1).
Umax /om’! 2915.84 (C-H), 1702.84 (C=O), 1606.41 (C=C), 1245.79 (C-O)
HRMScalc for C18H15O03F3Na (M+Na) 359.1009; found: 359.0877
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5.12.23 Methyl 2-(4-(benzyloxy)benzyl)-3,3,3-trifluoropropanoate (122)
 
Compound 122 was synthesised in an analogous method to compounds 108/108a to yield a
pale yellow oil. Yield = 0.19g, 95%. Rf = 0.35, 1:9 Et.O: hexane.
'H (400MHz, CDCI;) 8: 3.09 (2H, m, H-4), 3.36 (1H, m, H-2), 3.63 (3H, s, H-5), 5.02 (2H,s,
H-1”), 6.90 (2H, d, J = 8.64 Hz, H-3’,5’), 7.12 (2H, d, J = 8.60 Hz H-2’,6’) 7.30-7.43 (5H,
H-2”,3”,4,5”,6”,7”).
'3C (100MHz, CDCl) 8: 31.78 (C-4) 52.95 (C-2) 53.05 (C-5), 70.40 (C-1”), 115.48 (C-
37,5’), 127.94-130.28 (C-3”,4”,5”,6",7",1’,2’,6,3), 137.30 (C-2”), 158.34 (C-4’), 167.86 (C-
1).
HRMScaled for C;gH|7F303Na (M+Na) 361.1027; found 361.0998
5.12.24 2-(4-(Benzyloxy)benzyl)-3,3,3-trifluoropropanoic acid (123)
OH
Methyl 2-(4-(benzyloxy)benzyl)-3,3,3-trifluoropropanoate (122) (0.1g, 0.29mmol) was
reacted according to the procedure described in Section 5.11.5. Purification by flash column
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chromatography using 2:8 Et)O:hexaneafforded the title compound as a white solid. Yield
0.06g, 63% Rf = 0.37, 8:2 EtpO: Hexane;
'H (400MHz, CDCI) 8: 3.09 (2H, m, H-4), 3.37 (1H, m, H-2), 5.01 (2H, s, H-1”), 6.90 (2H,
d, J = 8.64 Hz, H-3’,5’), 7.12, (2H, d, J = 8.60 Hz H-2’,6’) 7.30-7.43 (5H, H-
2”,3”,4",5”,6",77).
'3C (100MHz, CDCl) 8: 18.62 (C-4) 52.81 (C-2) 70.41 (C-1”), 115.48 (C-3,5’), 127.90-
129.00 (C-3”,4”,5”,6”,7",1’,2’,6’), 137.27 (C-2”), 158.37 (C-4’), 171.10 (C-1).
HRMScalcd for C)7H)s5F303Na (M+Na) 347.0870; found 347.0885
5.12.25 2,2,2-Trifluoro-1-(4-isobutylphenyl)ethanone (135)
 
To a stirred solution of AICI; (10.9g, 81.7mmol) in DCM (30ml) under Nz was added a
mixture oftrifluoroacetic anhydride (7.8g, 5.17ml, 37.2mmol) and isobutyl benzene (6.87g,
5.86ml, 37.2mmol) dropwise over the course of an hourat 0°C. The reaction was allowed to
stir at that temperature for an additional 60 minutes. The reaction mixture was quenched by
carefully pouring onto ice and acidified to pH 1 with conc HCl. The organic compounds were
extracted with DCM (2 x 100ml) and washed with 2N NaOH (2 x 50ml) followed by brine
(100ml). The combined organic layers were then dried over Na2SO4, concentrated in vacuo
and chromatographed onsilica gel using an eluent system of 1:9 Et,O:hexaneto afford the
title compoundas pale yellow oil. Yield = 6.3g, 74%. Rf = 0.52, 1:9 Et)O:hexane.
'H (400MHz, CDCI) 5: 0.93 (6H, d, J = 6.62 Hz, H-3”), 1.89-1.96 (1H, m, H-2”), 2.58 (2H,
d, J = 7.18 Hz, H-1”), 7.32 (2H, d, J = 10.28 Hz, H-2’,6’), 7.99 (2H, d, J = 7.64 Hz, H-
3’,5°);
'5C (100MHz, CDCI) 5: 22.70 (C-3”), 30.48 (C-2”), 45.95 (C-1”), 117.18 (q, J = 2.90, C-2),
128.08 (C-1’), 130.24 (C-3’,5’), 130.55 (C-2’,6’), 151.11 (C-4’), 180.38 (q, J = 0.35 Hz, C-1)
>
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Umax om1712.48 (C=O), 2958.27 (C-H);
HRMScaled for C;2H17F;0N (M+NH,') 248.12622; found 248.12606
5.12.26 2,2,2-Trifluoro-1-(4-isobutylphenyl)ethanol (136)
 
To compound 135 (2.69g, 11.7mmol) in ethanol (20ml) was added sodium borohydride
(0.44g, 23.4mmol) at 0°C portionwise. This was allowedto react for 30 minutes. After which
time the solvent was removed. Et2O (50ml) was then added andacidified to pH 3 with the
addition of 1M HCl (S5ml). The organic layer was separated and washed with brine (50ml)
followed by H2O (50ml). It was then dried over Na:SO4 and concentrated in vacuo.
Purification by flash column chromatography yielded the title compound as a yellow oil.
Yield 2.44g, 90%. Rf = 0.26, 1:9 EtpO:hexane.
'H (400MHz, CDCI) 5: 0.90 (6H, d, J = 6.61 Hz, H-3”), 1.73-1.83 (1H,sept, J = 6.79 H-
2”), 2.40 (2H, d, J = 7.21 Hz, H-1”), 4.86 (1H, q, J = 6.90 Hz, H-1), 7.09 (2H, d, J = 8.11
Hz, H-2’,6”), 7.27 (2H, d, J = 8.01 Hz, H-3’,5’)
'3C (100MHz, CDCI) 5: 22.73 (C-3”), 30.58 (C-2”) 45.54 (C-1”), 73.20 (q, J = 31.92 Hz, C-
1), 124.90 (q, J = 281.93 Hz, C-2) 127.63 (C-3°,5’), 129.79 (C-2’,6’), 131.72 (C-1’), 143.75
(C-4’)
Umax /cm'! 2965.98 (C-H), 3397.96 (OH).
HRMScalcd for C12Hj95F30N (M+NH4") 250.14187; found 250.14238
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5.12.27. 1-(1-Chloro-2,2,2-trifluoroethyl)-4-isobutylbenzene (137)
 
To compound 136 (0.4g, 1.72mmol) in 10ml DCM was added thionyl chloride (5ml,
0.0258moles). This was allowed to reflux for 4 hours. After which time the solvent and
excess thionyl chloride was removed under reduced pressure. The remaining oil was
extracted into diethyl ether (20ml) and washed with H2O (2 x 20ml). The combined organic
extracts dried over NaySO,4 and removed under reduced pressure. The compound was then
purified by flash column chromatographyto yield the title compound as a yellow oil. Yield
0.34g, 80% Rf = 0.73, 1:9 EtpO:hexane.
'H (400MHz, CDCI;) 0.90 (6H, d, J = 6.53 Hz, H-1), 1.76-1.89 (1H,sept, J = 6.72 H-2),
2.49 (2H, d, J = 7.28 Hz, H-1”), 5.08 (1H, q, J = 6.90 Hz, H-1), 7.17 (2H, d, J = 8.21 Hz,
H-6,8), 7.39 (2H, d, J = 8.21 Hz, H-5,9).
"SC (100MHz, CDCI;) 5: 22.71 (C-3”), 30.54 (C-2”) 45.52 (C-1”), 59.10 (q, J = 34.13 Hz, C-
1), 124.00 (q, J = 279.11 Hz, C-2) 128.86 (C-3’,5’), 129.0 (C-1’,2’,6’), 144.41 (C-4’) Omax
/em'' 2965.98 (C-H).
HRMScaled for Cy2H,4°°CIF3(M+) 250.07361; found 250.07389
5.12.28 1-Isobutyl-4-(2,2,2-trifluoro-1-iodoethyl)benzene (138)
To a solution of triphenylphosphine (0.47g, 2.32mmol), in dry DCM (15ml) was added
imidazole (0.12g, 2.32mmol) followed by iodine (0.45g, 2.32mmol) under N>. This was
allowed to stir for 5 minutes. During which time the solution changed from a colourless
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solution, to a yellow, and finally to a bright orange solution with a white precipitate. To this
was then added 2,2,2-trifluoro-1-(4-isobutylphenyl)ethanol (136) (0.415g, 1.79mmol) in one
portion whilst still maintaining an inert atmosphere. This was allowed to stir at room
temperature for 30 minutes. The temperature was then increased to 60°C for 2 hours. After
which time the temperature was reduced to 25°C andthe solid wasfiltered off. The organic
layer was subsequently washed with saturated sodium thiosulfate (3 x 20ml), H2O (2 x 20ml),
and finally with brine (20ml). The organic layer was then dried over NazSO4 and
concentrated under reduced pressure. The crude extract was mountedonto silica and purified
by column chromatography (100% hexane) to yield the title compoundas a yellow oil. Yield
0.59g, 74%, Rf = 0.78, 100% hexane.
'H (400MHz, CDCIs)5: 0.83 (6H, d, J = 6.61 Hz, H-3”), 1.76-1.89 (1H, m, H-2”), 2.42 (2H,
d, J = 7.19 Hz, H-1”), 4.91 (1H, q, J = 6.71 Hz, H-2), 7.16 (2H, d, J = 8.06 Hz, H-2’,6’),
7.30 (2H, d, J = 7.95 Hz, H-3’,5’)
'3¢ (100MHz, CDCl) 22.76 (C-3”), 30.59 (C-8) 45.23 (C-2”), 73.20 (q, J = 31.93, C-1),
127.62 (C-3’,5’), 129.80 (C-2’,6’), 130.27 (C-1’) 143.76 (C-4’)
5.12.29 2,2,2-Trifluoro-1-(4-isobutylphenyl)ethyl methanesulfonate (139)
 
To compound 136 (0.7g, 3.0mmol) in DCM (3ml) was added triethylamine (0.839ml, 6
mmol) under N>. After 30 minutes ofstirring at this temperature mesyl chloride (0.23ml,
3mmol) was added dropwise and the reaction was allowed to stir at that temperature for a
further hour. The reaction was quenched with HO (5ml), and separated. The organic layer
was then washed with brine (S5ml) followed by HO (2 x 10ml) and dried over NazSOq, The
solvent was then removed under reduced pressure and the crude colourless oil was then
purified by column chromatography using 1:9 Et,O:hexaneto yield the title compound as a
colourless oil. Yield 0.82g, 88%. Rf = 0.3, 1:9 EtpO:hexane.
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'H (400MHz, CDCl) 8: 0.90 (6H, d, J = 6.53 Hz, H-3”), 1.83-1.93 (1H,sept, J = 6.72 H-
2”), 2.50 (2H, d, J =7.16 Hz, H-1”), 2.93 (3H, s, OMs) 5.75 (1H, q, J = 6.38 Hz, H-1), 7.23
(2H, d, J = 8.15 Hz, H-2’,6’), 7.41 (2H, d, J = 8.00 Hz, H-3’,5’)
'3C (100MHz, CDCIs) 8: 22.72 (C-3”), 30.49 (C-2”), 39.83 (OMs) 45.54 (C-1”), 78.70 (q, J
= 34.45 Hz, C-1), 123.00 (q, J = 280.64 Hz, C-2) 126.97 (C-1’) 128.36 (C-3’,5’), 130.20 (C-
2’,6”), 145.22 (C-4’)
5.12.30 3,3,3-Trifluoro-2-hydroxy-2-(4-isobutylphenyl)propanenitrile (142)
 
To, compound 135 (1g, 4.3mmol) in distilled HzO (10ml) was added sodium bisulfite (1.48g,
8.6mmol) at room temperature. This was allowedto stir for 1 hour. After which time a white
precipitate was formed and sodium cyanide (0.42g, 8.6mmol) was then added. Theprecipitate
then disappeared over the course of an hour and to this was added Et2O (10ml). The aqueous
layer was separated and washed with ether three more times. The combined organic layers
were dried over Na2SO, and removed under reduced pressureto yield the title compoundas a
yellow oil which was used without further purification. Yield 0.55g, 50%
'H (400MHz, CDCI;) 5: 0.95 (6H, d, J = 6.64 Hz, H-3”), 1.86-1.96 (1H,sept, J = 6.77 H-
2”), 2.55 (2H, d, J = 7.74 Hz, H-1”), 4.13 (1H,s, OH), 7.29 (2H,d, J = 8.01 Hz, H-2’,6’),
7.61 (2H, d, J = 8.10 Hz, H-3’,5’)
'3C (100MHz, CDCI) 8: 22.70 (C-3”), 30.51 (C-2”), 45.42 (C-1”), 74.40 (q, J = 33.75 Hz,
C-2), 116.09 (C-1) 122.00 (q, J = 286.23 Hz, C-3) 126.76 (C-3’,5’) 128.31 (C-1’) 130.20 (C-
2”,6’), 145.57 (C-4’).
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5.12.31 3,3,3-Trifluoro-2-(4-isobutylphenyl)propanenitrile (140)
 
To compound 142 (0.1g, 3.88mmol) in toluene (1ml) was added phosphorus pentasulfide
(0.17g, 3.88mmol) and allowed to reflux for 4 hours. The solid wasfiltered off and washed
with toluene. Thefiltrate was diluted with Et.O (2ml) and washed with 1 N sodium hydrogen
carbonate solution (2ml) followed by water (2ml). The organic layer was dried over Na2SO4
and evaporated to dryness to yield the desired compound as a yellow oil. No further
purification was necessary. Yield 0.54g, 58%.
'H (400MHz, CDCI;) 5: 0.91 (6H, d, J = 6.62 Hz, H-3”), 1.83-1.93 (1H, sept, J = 6.79 H-
2”), 2.52 (2H, d, J = 7.24 Hz, H-1”), 4.44 (1H, q, J = 7.59 Hz, H-2), 7.23 (2H, d, J = 8.16
Hz, H2’,6’), 7.36 (2H, d, J = 8.16 Hz, H-3’,5’).
'3C (100MHz, CDCl) 8: 22.69 (C-3”), 30.52 (C-2”), 43.30 (C-1), 45.39 (C-1”), 116.09 (C-
2), 129.27 (C-3’,5’) 130.51 (C-2’,6’).
5.12.32 1-Isobutyl-4-(33 ,3-trifluoroprop-1-en-2-yl)benzene (146)
Triphenylphosphine methyl iodide (1.76g, 4.35mmol) in THF (35ml) at -78°C under N2 was
added 2.5M n-BuLi (1.911ml, 4.78mmol). This was allowed to stir at that temperature for |
hour and then allowed to warm to room temperature over the course of 2 hours. The
temperature was then reduced to -78°C and compound 135 was added dropwise (1g,
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4.35mmol). This was allowed to stir at that temperature for 1 hour. After which time the
mixture was then warmed to room temperature andfiltered through a short column ofsilica
gel (30g) to removetriphenylphosphine oxide andsalts. The crude product was concentrated
in vacuo and chromatographedonsilica gel using an eluent system of 1:20 Et,O:hexane to
yield the title compoundasa pale yellow. Yield = 0.39g, 39%. Rf = 0.55 100% hexane.
'H_ (400MHz, CDCl;) 5: 0.93 (6H, d, J = 10.52 Hz, H-3”), 1.89-1.96 (1H, m, H-2”), 2.58
(2H, d, J = 7.18 Hz, H-1”), 5.73 (1H, H-1), 5.89 (1H, H-1), 7.15 (2H, d, J = 8.10 Hz, H-
2’,6’) 7.37 (2H, d, J = 8.07 Hz, H-3’,5’).
'3C (100MHz, CDCI) 3: 22.75 (C-3”), 30.72 (C-2”), 45.69 (C-1”), 119.98 (C-1), 123.90 (q, J
= 2.72, C-3), 128.52 (C-2’-6’), 129.71 (C3’-5”), 131.38 (C-1’) 139.43 (q, J = 0.297 Hz, C-2),
143.17 (C-4”) ; Umax /om’! 1681.62 (C=C), 2956 (C-H).
HRMScalcd for C)3HisF3 (M+) 228.25730; found 228.25741.
5.12.33 3,3,3-Trifluoro-2-(4-isobutylphenyl)propan-1-ol (147)
 
To 1-isobutyl-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene (146) (0.457g, 2mmol) in DME (5ml)
was added a 90% solution of borane dimethylsulfide (0.23g, 0.316ml, 1.5mmol) under No.
This was allowed to reflux overnight. This solution was then cooled to 0°C to which a 50%
NaOHsolution was added followed by H2O> (30% solution in HO). This was allowedto stir
at that temperature for 30 minutes. The solution was then quenched with H2,O (10ml) and
extracted with Et)O (3 x 20ml). The combined organic layers were then dried over Na2SOu,
concentrated in vacuo and chromatographedonsilica gel using 100% Et2O to afford the title
compoundas pale yellow oil. Yield 0.34g, 69%. Rf = 0.72, 100% Et,O.
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'H_ (400MHz, CDCI) 6: 0.93 (6H, d, J = 10.52 Hz, H-3”), 1.89-1.96 (1H, m, H-2”), 2.47
(2H, d, J = 2.79 Hz, H-1”), 3.50, (1H, m, H-2) 3.97 (1H, m, H-1), 4.13, (1H, m, H-1), 7.15
(2H, d, J = 8.10 Hz, H-2’,6’) 7.37 (2H,d, J = 8.07 Hz, H-3’,5’).
°C (100MHz, CDCI) 8: 22.78 (C-3”), 30.54 (C-2”), 45.52 (C-1”), 52.49 (q, J = 0.253, C-
2), 61.72 (C-1), 125.79 (q, J = 2.79, C-3), 126.19 (C-2’,6’), 129.24 (C-3’,5’) 130.05 (C-1’),
142.70 (C-4’).
Umax /em™' 3289.96 (C-OH).
HRMScaled for C}3H)7F30 (M+) 246.27258; found 246.27271.
5.12.34 3,3,3-Trifluoro-2-(4-isobutylphenyl)propanoic acid!” (134)
 
To chromium trioxide (0.32g, 3.248mmol) in acetone (11 ml) was added 1.5M H2SO, (5.4ml,
8.12mmol) at 0°C. To this was added compound 147 (0.2g, 0.812mmol) (predissolved in Iml
acetone). This was then allowed to warm to room temperature andstirred overnight. This was
then diluted with Et,O (10ml) and washed with brine (10ml). The organic layer was then
extracted with 1M NaOH (2 x 10ml) followed by acidification of the aqueous layer with
1.5M H2SO,4 to pH 1/2. The product was then extracted into ether (3 x 20ml) and the
combined organic layers were then dried over Na2SO,, concentrated in vacuo and
chromatographed onsilica gel using 100 Et,O to afford the title compound as colourless
solid. Yield 0.207g, 99%. Rf = 0.34, 100% Et,O;
'H_ (400MHz, CDCl) 5: 0.83 (6H, d, J = 10.52 Hz, H-3”), 1.74-1.82 (1H, m, H-2”), 2.37
(2H, d, J = 4.35 Hz, H-1”), 4.23, (1H, q, J = 8.41, H-2) 7.08 (2H, d, J = 8.16 Hz, H-2’,6°)
7.26 (2H, d, J = 8.04 Hz, H-3’,5’). °C (100MHz, CDCI) 8: 22.78 (C-3”), 30.54 (C-2”),
45.52 (C-1”), 52.49 (q, J = 0.253, C-2), 61.72 (C-2), 125.79 (q, J = 2.79, C-3), 126.19 (C-
2°,6’), 129.24 (C-3’,5’) 130.05 (C-1’), 142.70 (C-4’). 19F (400MHz)-68.15 (CF3).0max /em’!
3400 (C-OH). (CI) m/z for C;3HigF302N (M+NHy’): 278 (100.00)
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5.12.35 methyl 3,3,3-trifluoro-2-(4-isobutylphenyl)propanoate (148)
 
B-trifluoroibuprofen (134) (0.1g, 0.39mmol) in MeOH (1ml) was added cone H2SO, (1 drop)
and allowedto reflux for 4 hours. After which time the solvent was removed under reduced
pressure and the dark yellow oil was purified by flash column chromatography using 100%
Et,O to afford the title compound as pale yellow oil. Yield 0.094g, 89%. Rf = 0.69, 100%
EtO.
'H_ (400MHz, CDCI) 6: 0.83 (6H, d, J = 10.52 Hz, H-3”), 1.74-1.82 (1H, m, H-2”), 2.37
(2H, d, J = 4.35 Hz, H-1”), 4.23, (1H, q, J = 8.41, H-2) 7.08 (2H, d, J = 8.16 Hz, H-2’,6’)
7.26 (2H, d, J = 8.04 Hz, H-3’,5’).
'5C (100MHz, CDCI3) 5: 22.78 (C-3”), 30.54 (C-2”), 45.52 (C-1”), 52.49 (q, J = 0.253, C-2),
61.72 (C-5), 125.79 (q, J = 2.79, C-3), 126.19 (C-2’,6’), 129.24 (C-3’,5’) 130.05 (C-1),
142.70 (C-4’).
Umax ‘em’! 3400 (C-OH).
5.12.36 Ethyl 2-(4-isobutylphenyl)-2-oxoacetate (154)
To a suspension of AICI; (5.95g, 44.62mmol) in dry DCM (30ml) at 0°C was added
chlorooxoacetate (6.1g, Sml, 44.7mmol) dropwise. After 10 minutes at this temperature
isobutylbenzene (2.98g, 3.5ml, 22.24mmol) was then added dropwise. This was allowed to
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stir at 0°C for 1 hour. This was then poured onto ice and acidified with conc HCl to pH 1,
extracted with EtyO (2 x 50ml) and washed with 1M NaOH (40ml) and brine (50ml). The
organic layers were dried over Na2SOy, andthe resulting yellow oil was purified by flash
column chromatographyto yield the titled compoundas pale yellow oil. Yield 3.70g, 71%.
Rf = 0.68, 7:3 Et.O:hexane.
'H (400MHz, CDCI;)8: 0.88 (6H, d, J = 6.64, H-3”), 1.39 (3H, t, J = 7.12, H-4), 1.90 (1H,
m, H-2”), 2.52 (2H, d, J = 7.21, H-1”), 4.45 (1H, q, J = 7.11, H-3), 7.26 (2H, d, J = 8.16, H-
3’,5°), 7.90 (2H, d, J = 8.20, H-2’,6’).
'3C (100MHz, CDCI) 5: 14.46 (C-4), 22.65 (C-3”), 30.37 (C-2”), 45.81 (C-1”), 62.62 (C-3),
126.43 (C-2’,6’), 129.62-132.70 (C-3’-5°), 150.80 (C-4’) 164.50 (C-2), 186.59 (C-1); Umax
/om'! 2962.13 (C-H), 1733.69 (C=O), 1618.18 (C=O); (CD).
m/z for C14H2}03N (M+NH,’): 252 (100.00).
5.12.37 Ethyl 2-hydroxy-2-(4-isobutylphenyl)acetate (155)
 
To compound 154 (2g, 8.54mmol) in ethanol (10ml) at 0°C was added NaBH, (0.32g,
8.54mmol) portionwise. This was allowedto stir at that temperature for an hour. After which
time the solvent was removed. Et.O (20ml) was then added along with 1M HCI (10ml). The
organic layer was separated and washed with brine, dried over NajSO4 and purified using
flash column chromatography. Yield 1.79g, 89%. Rf = 0.55, 7:3 EtpO:hexane.
'H (400MHz, CDCI) 8: 0.88 (6H, d, J = 6.62, H-3”), 1.39 (3H,t, J = 1.73, H-4), 1.90 (1H,
m, H-2”), 2.45 (2H, d, J = 7.12, H-1”), 3.70 (1H, d, J = 5.89, OH), 4.19 (1H, dq, J = 17. 27,
10.48, H-3), 5.15 (1H, s, H-2) 7.11 (2H, d, J = 8.08, H-3’,5’), 7.31 (2H, d, J = 8.08, H-
2’,6’)
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'3C (100MHz, CDCI) 6: 14.42 (C-4), 22.75 (C-1), 30.45 (C-2”), 45.53 (C-1”), 62.40 (C-3),
73.25 (C-2) 126.43 (C-3’,5’), 129.60 (C-2’,6’), 136.28 (C-1”), 142.29 (C-4’), 174.19 (C-1);
Umax ‘em’! 3421.10 (OH), 2958.27 (C-H), 1708.62 (C=O).
(CI) m/z for C14H2303N (M+NH,’): 254 (100.00).
5.12.38 Ethyl 2-chloro-2-(4-isobutylphenyl)acetate (156)
 
 
A solution of compound 155 (1g, 4.23mmol) in dry DCM (10ml) wasreacted according to
the procedure described in Section 5.11.27 using thionyl chloride (5g, 3.1ml, 42.3mmol) and
a reaction time of 2 hours. The crude compound waspurified by column chromatography
using an eluent system of 1:9 Et.O:hexane. Yield 0.97g, 90%. Rf = 0.54, 2:8 EtgO:hexane;
'H (400MHz, CDCl) 5: 0.89 (6H, d, J = 6.64, H-3”), 1.26 (3H,t, J = 7.17, H-4), 1.87 (1H,
m, H-2”), 2.47 (2H, d, J = 7.21, H-1”), 4.23 (1H, m, H-3), 5.32 (1H, s, H-2), 7.15 (2H, d, J
= 8.07, H-3’,5’), 7.40 (2H, d, J = 8.16, H-2’,6’)
°C (100MHz, CDCl) 5: 14.42 (C-4), 22.75 (C-3”), 30.45 (C-2”), 45.53 (C-1”), 60.10 (C-2),
62.39 (C-3), 128.22 (C-3’,5”), 130.10 (C-2’,6”), 136.28 (C-1’), 142.29 (C-4’), 174.19 (C-1);
HRMScalcd for C4H1902°°CINa (M+Na) 277.0971; found 277.0965. HRMScalcd for
C14H1902°’CINa (M+Na) 277.0942; found 277.0950
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5.12.39 2-Chloro-2-(4-isobutylphenyl)acetic acid (157)
 
To compound 156 (0.5g, 1.96mmol) in acetic acid (2ml) and concentrated hydrochloric acid
(3ml), was heated under reflux for 1.5 hours. The solvent was then removed under reduced
pressure. The residue was allowed to cool to room temperature and poured into saturated
sodium bicarbonate solution (10ml) at 0°C. The aqueouslayer was then washed with ether (2
x 10ml). The aqueous phase wasthenacidified with dropwise addition of 5M HCIto pH 1-2.
The orange precipitate was then extracted into ether (3 x 10ml), washed with water (2 x
10ml) and dried over NaySO4. The solvent was removed under reduced pressure and the
resulting dark solid was purified by column chromatography using an eluent system of 1:1
Et,O:hexaneto yield the title compoundas an orange solid. Yield 0.32g, 73%. Rf = 0.15, 7:3
EtpO:hexane.
'H (400MHz, CDCI) 5: 0.89 (6H, d, J = 6.58 Hz, H-3”), 1.80-1.90 (1H, sept,J = 6.71 Hz H-
2”), 2.46, (2H, d, J = 7.16 Hz H-1”), 5.54 (1H, s, H-2) 7.16 (2H, d, J = 8.10 Hz, H-2’,6’)
7.40 (2H, d, J = 8.17 Hz, H-3’,5’).
'3C (100MHz, CDCI) 8: 22.78 (C-3”), 30.56 (C-2”) 45.52 (C-1”), 59.13 (C-2), 128.21 (C-
2°,6’), 130.12 (C-3’,5’), 132.67 (C-1’) 143.91 (C-4”) 174.81 (C-1).
HRMScalcd for C1oH\50.°°CINa (M+Na) 249.0658; found 249.0647. HRMScalcd for
Cy2H50.°’CINa (M+Na) 251.0629; found 251.0623.
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5.12.40 2-Chloro-2-(4-isobutylphenyl)acetoyl-CoA (64)
 
a-Chloroibufenac (157) (20mg, 88.24umol) was reacted according to the procedure described
in Section 5.11.6 to afford the title compound as a crystalline solid (2.15mg, 25%) based on
relative HPLC traces of coenzyme A and product; HRMScalcd for C33Hag?CIN7O17P3S
974.1729 (M+H_); found 974.1732.
5.12.41 (S)-a-Chloro-ibufenac (156a)
To 0.1M potassium phosphate buffer (pH 7, Iml) was added Candida rugosa (15mg)
followed by a-chloro-ibufenac ethyl ester (156). This was stirred at room temperature for 5
hours. After which time 100uL was removed and extracted with EtyO (1001). The ether
layer was subject to HPLC analysis to ascertain extent of chiral hydrolysis
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5.12.42 2-(4-Isobutylphenyl)-2-oxoacetic acid (213)
 
 
To a solution of 2N sodium hydroxide (2ml) in MeOH (S5ml) was added compound 154 (0.5g,
2.11mmol). This was allowed to stir at room temperature for 2 hours. After which time the
solution was diluted with water (10ml) and the methanol was removed under reduced
pressure. The aqueous solution was washed with diethyl ether (2 x 10ml) and acidified with
2M HCIto which a white precipitate formed. This was extracted into ether (3 x 10ml), dried
over MgSO,and evaporated to dryness to yield the desired compoundas a white solid. Yield
= 0.44g, 73%. Rf = 0.26, 7:3 EtpO:hexane.
'H (400MHz, CDCIs)8: 0.91 (6H, d, J = 6.63, H-3”), 1.92 (1H,sept, J = 6.70, H-2”), 2.56
(2H, d, J = 7.22, H-1”) 7.29 (2H,d, J = 8.25, H-3’,5’) 8.16 (2H, d, J = 8.31, H-2’,6’)
'3C (100MHz, CDCI) 8: 22.74 (C-3”), 30.58 (C-2”), 45.51 (C-1”), 129.94 (C-3’,5’), 131.32
(C-2’,6”), 135.52 (C-1’), 151.17 (C-4’), 164.23 (C-1), 185.07 (C-2);
Umax ‘em’! 2979.48 (C-H), 1677.77 (C=O) 1604.48 (C=O).
HRMScalcd for C}2H1403Na (M+Na) 229.0840 found; 229.0836.
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5.12.43 2-Hydroxy-2-(4-isobutylphenyl)acetic acid (214)
 
Ethyl-2-hydroxy-2-(4-isobutylphenyl)acetate (155) (0.5g, 2.12mmol) was reacted in
accordance with the procedure stated in Section 5.11.42 to yield the desired compoundas a
white solid. This was then purified by flash column chromatography using an eluent system
of 7:3 EtpO:hexane. Yield 0.41g, 92%. Rf = 0.18, 7:3 EtpO:hexane.
'H (400MHz, CDCI) 8: 0.89 (6H, d, J = 6.62, H-3”), 1.84 (1H, sept J = 6.70, H-2”), 2.46
(2H, d, J = 7.18, H-1”) 4.64 (1H, s, OH), 5.17 (1H, s, H-2), 7.13 (2H, d, J = 8.03, H-3’,5’)
7.32 (2H, d, J = 8.03, H-2’,6’).
'3C (100MHz, CDCI) 8: 22.75 (C-3”), 30.58 (C-2”), 45.51 (C-1”), 72.99 (C-2) 126.83 (C-
3’,5°), 129.85 (C-2’,6), 135.52 (C-1’), 142.77 (C-4’), 177.04 (C-1).
Umax cm’! 3515.6 (O-H), 2979.48 (C-H), 1693.19 (C=O).
HRMScalcd for C12H\603Na (M+Na) 231.0997 found; 231.0989.
5.12.44 (E)-4-(4-Nitrophenyl)but-3-en-2-one (167)!”
p-Nitrobenzaldehyde (5g, 33.09mmol) was dissolved in acetone (60ml) at 0°C. An aqueous
solution of NaOH (6ml, 1% solution) was added dropwise and allowed to stir at that
temperature for 15 minutes. The solution was acidified to pH 2 with dropwise addition of
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1.5M H2SO, and the acetone was removed under reduced pressure. To the resulting crude 4-
hydroxy-4-nitrophenyl-butan-2-one was added 35ml 1.5M H2SO, and washeated to reflux
for 2 hours. The resulting orange solid wasthenfiltered off and recrystallized from ethanolto
yield the title compoundasa bright yellow solid. Yield = 5.88, 93%. Rf = 0.55, 100% Et,0.
'H (400MHz, CDCI) 8: 2.43 (3H, s, H-1), 6.83 (1H, d, J = 16.25 Hz, H-3), 7.54, (1H, d, J =
16.34 Hz H-4), 7.71 (2H, d, J = 8.70 Hz, H-2’,6’) 8.27 (2H, d, J = 8.59 Hz, H-3’,5’).
'3C (100MHz, CDCI) 8: 28.47 (C-1), 124.62 (C-3’,5’) 129.22 (C-2’,6’), 130.78 (C-3) 140.48
(C-4), 141.07 (C-1’), 148.99 (C-4’), 197.96 (C-2).
Umax cm’! = 2886.92 (C-H), 1710.55 (C=O) 1596.77 (C=C), 1513.85, 1344.14 (NOs).
(Cl) m/z for CpHsNO3(M-H): 190.1 (100.00)
5.12.45 (£)-4-(4-Nitrophenyl)but-3-en-2-o0l (168)
 
To a solution of compound 167 (3g, 15.69mmol) and CeCl;.7H20 (5.84g, 15.69mmol) in
MeOH (20ml) was added NaBH, (0.59g, 15.69mmol) in one portion, with stirring. A
vigorous gas evolved, together with a temperature rise to ~35-40°C. After 30 minutes the pH
was adjusted to 7 with 1M HCl. The mixture was then extracted with Et2O (2 x 20ml) and
dried over Na2SO4. The solvent was then removed under reduced pressure and purified with
flash column chromatographyto yield a yellow solid. Yield 2.606g, 86%. Rf = 0.48, 100%
Et,O.
'H (400MHz, CDCIs) 8: 1.41 (3H, d, J = 6.44 Hz, H-1), 4.56 (1H, m, H-2) 6.45 (1H,dd, J
H2-H3 = 5.67Hz, J 43-4 = 15.90, H-3), 6.66, (1H, d, J = 16.01 Hz H-4), 7.50 (2H, d, J = 8.84
Hz, H-2’,6’) 8.16 (2H, d, J = 8.85 Hz, H-3’,5’).
'3C (100MHz, CDCl)8: 23.76 (C-1), 68.77, (C-2), 124.39 (C-3’,5’) 127.37 (C-2’,6’), 127.38
(C-4) 138.88 (C-3), 143.79 (C-1’), 147.26 (C-4’).
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Umax /em! = 2884.99 (C-H), 1636 (C=C), 1517.7, 1346.07 (NO). HRMS calcd for
CioH1103Na (M+Na)216.0637; found 216.0641.
5.12.46 (£)-1-(3-Chlorobut-1-en-1-yl)-4-nitrobenzene (169)
 
(£)-1-(3-chlorobut-1-en-1-yl)-4-nitrobenzene (169) was synthesised in the same manner as
compound (156), using (£)-4-(4-nitrophenyl)but-3-en-2-ol (168) (1g, 5.18mmol), DCM
(20ml) and thionyl chloride (6.15g, 3.75ml, 51.75mmol) to yield the title compound as a
yellow solid. Yield 0.99g, 90%. Rf = 0.75, 100% Et,0.
'H (400MHz, CDCI;) 5: 1.73 (3H, d, J = 6.65 Hz, H-4), 4.74 (1H, m, H-3) 6.46 (1H, dd, J 47.
12 = 7.80Hz, J 12-13 = 15.69, H-2), 6.66,(1H, d, J = 15.76 Hz H-1), 7.53 (2H,d, J = 8.76 Hz,
H-2’,6’) 8.20 (2H, d, J = 8.81 Hz, H-3’,5’).
'3C (100MHz, CDCI) 8: 25.42 (C-4), 57.53, (C-3), 124.45 (C-3’,5’) 127.68 (C-2’,6”), 129.16
(C-1) 135.92 (C-2), 142.84 (C-1’), 147.69 (C-4’).
HRMScalcd for CioH1O2’CINa (M+Na) 236.0268; found 236.0274. HRMScalcd for
C1oH1002*°CINa (M+Na) 234.0298; found 234.0290.
5.12.47 (E)-Methyl 4-(4-nitrophenyl)but-3-enoate (172)!
A mixture of compound 167 (0.5g, 2.62mmol), methanol (0.25g, 0.32ml, 7.85mmol) and
borontrifluoride etherate (3.22g, 3l1mmol, 1.97 ml) was added in one portion to a stirred
suspension of lead(IV) acetate (1.34g, 3.01mmol) in dry toluene (10 ml) at room temperature.
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This was allowed to stir at room temperature for 1 hour after which time it was washed with
saturated sodium hydrogen carbonate (2 x 10ml), followed by brine (10ml). The organic layer
was then dried over Na2SO, and evaporated to dryness to yield the crude material as dark
brown oil. This was then purified by flash column chromatography to yield the title
compoundasa pale yellow oil. Yield 0.32g, 55%. Rf = 0.12, eluent: 7:3 Et,O:hexane.
'H (400MHz, CDCI;) 8: 3.33 (2H, d, J = 5.97 Hz, H-2), 3.74 (3H,s, H-5) 6.47-6.60 (2H, m,
H-3,4), 7.51 (2H,d, J = 8.87 Hz, H-2’,6°) 8.16 (2H,d, J = 8.87 Hz, H-3’,5’).
'3C (100MHz, CDCI) 8: 38.49 (C-2), 52.51, (C-5), 124.37 (C-2’,6”) 127.23 (C-3’,5’), 127.28
(C-4), 131.13 (C-3) 143.60 (C-1’), 147.31 (C-4’), 171.70 (C-1). Umax /om’! 2979.48 (C-H),
1729.83 (C=O), 1596.77 (C=C), 1517.7, 1344.14 (NO,).
HRMScalcd for C, 1HjpNO4(M-H’) 220.0603; found 220.0610.
5.12.48 Methyl 2-(4-isobutylphenyl)propanoate!®? (176)
 
Ibuprofen (175) (1g, 4.85mmol) in methanol (20ml) was reacted according to the procedure
described in Section 5.11.41. The crude material was purified with flash column
chromatography using an eluent system of 1:1 Et,O:hexaneto yield the title compoundas a
yellow oil. Yield 1.00g, 99%. Rf = 0.57, 1:1 EtpO:hexane.
'H (400MHz, CDCl) 8: 0.82 (6H, d, J = 6.64 Hz, H-3”), 1.42 (3H, d, J = 7.18 Hz, H-3)
1.72-1.82 (1H, sept,J = 6.71 Hz H-2”), 2.37, (2H, d, J = 7.27 Hz H-1”), 3.56 (3H,s, H-4),
7.03 (2H, d, J = 8.09 Hz, H-2’,6’) 7.15 (2H, d, J = 8.09 Hz, H-3’,5’).
'3C (100MHz, CDCl) 5: 13.76 (C-3) 21.96 (C-3”), 29.69, (C-2”), 30.58 (C-2) 45.44 (C-1”),
52.54 (C-4), 125.70 (C-2’,6’), 129.76 (C-3°,5°), 140.45 (C-1’), 142.31 (C-4’) 177.85 (C-1).
(Cl) m/z for Cy4H>402N (M + NHg"): 238 (100.00),
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5.12.49 Methyl 2-fluoro-2-(4-isobutylphenyl)propanoate!®! (177)
 
To compound176 (0.67g, 3.04 mmol) in THF (20ml) at -78°C under N2 was added 2M LDA
(premade with 1.58ml of 2.5M n-BuLi and 0.56m1 diisopropylamine predissolved in THF
(Sml)) dropwise. This wasallowedto stir at that temperature for 30 minutes. To this was then
added N-fluorobenezesulfonimide (previously dissolved in a minimum amount of THF)
dropwise. This was allowed to stir at that temperature for 1 hour. The reaction was then
quenched with saturated ammonium chloride (20ml) and diluted with EtyO (20ml). The
aqueous layer was separated and the organic layer was washed with brine (20ml), followed
by H,O (2 x 20ml). The organic layer was then dried over Na2SO, and evaporated under
reduced pressure. The crude product wasthen purified using flash column chromatography
using an eluent system of 1:4 EtOAc:hexaneto yield the title compound as a colourlessoil.
Yield = 0.47g, 66%. Rf = 0.57, 1:1 Et.O:hexane.
'H (400MHz, CDCI;) 5: 0.81 (6H, d, J= 6.71 Hz, H-3”), 1.73-1.80 (1H, m, H-2”), 1.87, (3H,
d, J= 22.12 Hz H-3) 2.38 (2H, d, J= 7.15 Hz, H-1”), 3.66 (3H, s, H-4), 7.07 (2H, d, J= 8.12
Hz, H-2’,6’) 7.31 (2H, d, J = 8.23 Hz, H-3’,5’).
'5C (100MHz, CDCI) 5: 21.31 (C-3”), 23.68, (d, J = 23.78, C- 3), 29.11 (C-2”) 43.97 (C-1”),
51.80 (C-4), 93.57 (d, J = 185.33 (C-2), 123.33 (d, J = 8.17, C-2’,6’), 128.18 (C-3’,5’),
135.37 (d, J =22.79, C-1°) 141.29 (C-4’) 170.52 (d, J = 27.27, C-1).
HRMScaled for C}4H}902FNa (M+Na) 261.1267; found 261.1258.
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5.12.50 2-Fluoro-2-(4-isobutylphenyl)propanoic acid'*” (178)
 
To compound 177 (0.3g, 1.26mmol) in a mixture of methanol (3ml) and THF (2ml) was
added 2 equivalents of 1M KOH (2ml) dropwise. This was allowed to stir at room
temperature for 3 hours. After which time methanol and THF were removed under reduced
pressure. The residual aqueous solution wasdiluted with H,O (Sml) and extracted with Et,O
(2 x 10ml). The aqueous layer wasthen acidified with 1M HCI to pH 2/3 whichresulted in
the precipitation of a white solid. This was then washed with Et,O. The organic layer was
dried over Na2SO4 and removed under reduced pressure to yield the desired compound as
white solid. Yield 0.27g, 96%. Rf = 0.32, 1:1 EtpO:hexane.
'H (400MHz, CDCI) 5: 0.95 (6H, d, J = 5.90 Hz, H-3”), 1.83-1.99 (1H, m, H-2”), 2.00, (3H,
d, J = 22.12 Hz H-3) 2.67 (2H, d, J = 7.15 Hz, H-1”), 7.22 (2H, d, J = 7.31 Hz, H-2’,6’)
7.49 (2H, d, J = 7.41 Hz, H-3’,5’), 11.60 (1H,s, OH).
'3C (100MHz, CDCl3) 8: 22.80 (C-3”), 24.68, (d, J = 23.44, C- 3), 30.59 (C-2”) 45.45 (C-
1”), 94.48 (d, J = 185.60 (C-2), 125.01 (C-2’,6’), 129.76 (C-3’,5’), 136.01 (d, J =22.92 Hz,
C-1°) 143.14 (C-4’) 177.72 (d, J. = 28.33, C-1) ; Umax /em’' 3509.09 (OH), 2956.34 (C-H),
1731.76 (C=O).
HRMScaled for C}3H,}7O2FNa (M+Na) 247.1110; found 247.1099.
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5.12.51 a—Fluoroibuprofenoyl-CoA (62)
 
o-Fluoroibuprofen (178) (50mg, 0.22mmol) and CoA-SH,(Li')3 (17mg, 21.68pmol) were
reacted according to the procedure described in Section 5.11.6. to afford the title compound
as a crystalline solid (4.64mg, 22%) based on relative HPLC traces of coenzyme A and
product; HRMScalcd for C34HsoFN7017P3S (M+H_) 972.2181; found 972.2163
5.12.52 p-Isobutylacetophenone!** (179)
Isobutylbenzene (4.5ml, 29mmol) wasreacted in accordance to Section 5.11.5 using AlCl;
(8.5g, 63.8mmol), DCM (20ml) and acetic anhydride (2.74m1, 29mmol) with a reaction time
of 2 hours. The crude material was chromatographed onsilica gel using 100% hexane to
afford the title compoundasa pale yellow oil. Yield 6.3g, 74%. Rf = 0.43, 100% :hexane.
'H (400MHz, CDCI;)5: 0.91 (6H, d, J = 6.59 Hz, H-3”), 1.91 (1H, sept, J = 6.77, H-2”),
2.52, (1H, s, H-2) 2.55 (2H,d, J = 7.22 Hz, H-3’,5’), 7.27 (2H, d, J = 8.43 Hz, H-2’,6’) 7.93
(2H, d, J = 8.40 Hz, H-5,9).
'3C (100MHz, CDCIs) 8: 22.71 (C-3”), 26.85, (C-2), 30.50 (C-2”) 45.95 (C-1”), 129.85 (C-
1’) 130.04 (C-2’,6’), 130.70 (C-3’,5’), 149.98 (C-4”) 201.36 (C-1”). Umax /em’! 2979.48 (C-
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H), 1681.62 (C=O). No MSdata obtained. NMR data synomouswith previously published
work.
5.12.53 Methyl 2-(4-isobutylphenyl])acetate (180)
 
Sulfuric acid (0.37ml, 6.8mmol) was added to a stirred solution of compound 179 (1g,
5.67mmol) and diacetoxyiodobenzene (2.19g, 6.8mmol) in 15ml MeOHat room temperature
under N>. The reaction wasstirred for 5 hours at 60°C, quenched with the addition of water
(10ml), and extracted with ether (2 x 10ml). This was washed with H2O (2 x 10ml) and dried
over MgSO,. The solvent was removed under reduced pressure and purified by column
chromatography using an eluent system of 1:1 Et,O:hexaneto yield the titled compoundas a
pale yellow oil. Yield 0.73g, 63%. Rf = 0.55, eluent: 7:3 EtpO:hexane.
'H_ (400MHz, CDCI;) 6: 0.89 (6H, d, J = 6.59 Hz, H-3”), 1.78-1.89 (1H, sept, J = 6.70 H-
2”), 2.44 (2H, d, J = 7.14 Hz, H-1”), 3.57 (2H, s, H-2), 3,65 (3H, s, H-3) 7.08 (2H, d, J =
8.05 Hz, H-2’,6’), 7.17 (2H, d, J = 7.99 Hz, H-3’,5’).
'3C (100MHz, CDCIs) 8: 22.80 (C-3”), 30.62 (C-2”) 40.21(C-2) 45.51 (C-1”), 52.31 (C-3),
129.38 (C-3°,5’), 129.74 (C-2,6’), 131.67 (C-1’), 140.90 (C-4’) 172.58 (C-1) Umax /em’!
2950.55 (C-H), 1737.55 (C=O).
HRMScalcd for C:3H1s02Na (M+Na)229.1205; found 229.1201
5.12.54 2-(4-Isobutylphenyl)acetic acid!®** (181)
Compound (180) (0.5g, 2.42mmol) was used to synthesise (181) in the same manner as
described in Section 5.11.42. This was purified by flash column chromatography using an
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eluent system of 1:1 Et)O:hexane to yield the titled compoundas a white solid. Yield 0.44,
94%. Rf = 0.42, eluent: 7:3 EtpO:hexane.
'H (400MHz, CDCI;) 6: 0.89 (6H, d, J = 6.57 Hz, H-3”), 1.91 (1H, sept, J = 6.69 H-2”),
2.44 (2H, d, J = 7.13 Hz, H-1”), 3.68 (2H, s, H-2), 7.25 (2H, d, J = 7.95 Hz, H-2’,6’), 7.17
(2H, d, J = 7.95 Hz, H-3’,5’).
°C (100MHz, CDCI) 8: 22.74 (C-3”), 30.54 (C-2”) 41.13 (C-2) 45.47 (C-1”), 129.49 (C-
3,5”), 129.94 (C-2’,6’), 130.88 (C1’), 141.23 (C-4’) 178.61 (C-1) max /em™! 2950.55 (C-H),
1698.98 (C=O).
HRMScalcd for Cj2H;s02Na (M+Na) 215.1048; found 215.1050.
5.12.55 2-(4-Isobutylphenyl)acetoyl-CoA (182)
 
Ibufenac (181) (Smg, 0.26mmol) was reacted with CoA-SH, (Li’); (5mg, 6.4umol)
according to the procedure described in Section 5.11.6. to afford the title compound as a
crystalline solid (1.03mg, 20%) based on relative HPLC traces of coenzyme A and product;
HRMScalcd for C33H49N7O17P3S 940.2119 (M+H); found 940.2120
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5.13 Synthesis of Substrates
5.13.1 Ibuprofenoyl-CoA (22)
 
NH2
OTTOKE OTDnN N
(S)-Ibuprofen (175a) (Smg, 24.24umol) and CoA-SH, (Li+)3 (20mg, 25umol) was reacted
according to the procedure described in Section 5.11.6. to yield the title compound as a
crystalline white solid. Yield = 10.36mg, 43%.
'H (400MHz, CDCI;) 5: 0.70, (3H, s, H-13/14), 0.80 (6H, d, J = 6.60Hz, H-1), 0.85 (3H,s,
H-13/14),1.44 (3H, d, J = 6.99Hz, H-7) 1.73 (1H, sept, J = 6.89Hz, H-2), 2.22 (2H,t, 6.38
Hz, H-10), 2.38 (2H, d, J = 7.02 Hz, H-3), 2.96 (2H, m, H-8), 3.28 (4H, m, H-9-11), 3.53
(2H, m, H-15), 3.82 (2H, m, H-16), 3.96 (1H, q, J = 7.02Hz, H-6), 3.99 (1H, s, H-12), 4.24
(2H, m, H-17-18), 4.57 (1H, m, H-19), 6.14 (1H, d, J = 6.47Hz , H-20), 7.11 (2H, d, J =
7.94Hz, H-5), 7.19 (2H, d, J = 7.94Hz, H4), 8.20 (1H, s, H-21), 8.54 (1H, s, H-22)
HRMScalcd for C34Hs1N7O17P3S (M+H) 954.2275; found 954.2465
5.13.2 a-Deutero-methyl 2-(4-isobutylphenyl)propanoate!® (183)
 
To compound 176 (0.8g, 3.88mmol) in CD30D (7ml) was added NaOMe(0.2g, 3.88mmol)
andstirred underreflux for 20 hours. The reaction was stopped with the dropwise addition of
2M HCIat 0°C until a pH of 7 was obtained. This was then filtered through a pad ofcelite,
concentrated, diluted with hexane (10ml), washed with H2O (2 x10ml), dried over NazSO4
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and concentrated under reduced pressure. This was then purified by column chromatography
using an eluent system of 1:1 Et,O:hexaneto yield the title compound as a yellow oil. Yield
0.8g, 99%. Rf = 0.57, 1:1 EtpO:hexane;
'H (400MHz, CDCI;) 8: 0.90 (6H, d, J = 6.61 Hz, H-3”), 1.44 (3H, s, H-3) 1.79-1.89 (1H,
sept, J = 6.76 Hz H-2”), 2.45, (2H, d, J = 7.21 Hz H-1”), 3.37 (3H,s, H-4), 7.09 (2H, d, J =
8.26 Hz, H-2’,6”) 7.19 (2H, d, J = 8.25 Hz, H-3’,5’);
°C (100MHz, CDCI) 8: 18.93 (C-3), 22.81 (C-3”), 30.60 (C-2”), 45.47 (C-1”), 127.66 (C-
2’,6’), 129.77 (C-3’,5’), 138.11 (C-1’), 140.97 (C-4’), 175.69 (C-1). No MSdata obtained.
NMRdata synonymouswith previously published work.
5.13.3 a-Deutero-Ibuprofen (183)'*
 
Sodium hydride, 60% dispersed in mineral oil (0.099g, 2.48mmol) was slowly added to a
stirred solution of a-D-methyl-2-(4-isobutylphenyl)propanoate (183) (0.5g, 2.26mmol) in
THF/D,O (20 ml, 3:1) at room temperature. The resulting solution wasstirred for 12hoursat
that temperature. The reaction was quenched with the addition of water (20 ml), and acidified
with 5ml 1M HCl. This was extracted with DCM (2 x 10ml) and the combined organic layers
were dried over MgSO, and evaporated under reduced pressure to give the title compound as
a white solid. Yield 0.46g, 99%. Rf = 0.32, 1:1 EtpO:hexane;
'H (400MHz, CDCI;) 8: 0.82 (6H, d, J = 6.64 Hz, H-3”), 1.42 (3H, s, H-3) 1.72-1.82 (1H,
sept,J = 6.71 Hz H-2”), 2.37, (2H, d, J = 7.27 Hz H-1”), 7.03 (2H, d, J = 8.09 Hz, H-2’,6’)
7.15 (2H, d, J = 8.09 Hz, H-3’,5’);
HRMScalcd for C}3H;702Na (M+Na) 230.1267; found 230.1276.
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5.13.4 a-Deutero-Ibuprofenoyl-CoA (67)
 
a-D-Ibuprofen (220) (Smg, 24.12umol) was reacted according to the procedure described in
Section 5.11.6 to afford the title compoundas crystalline solid. Yield = 4.61mg, 20%;
HRMScalcdfor C34Hs3N707P3SD (M-2H)” 477.1135; found 477.1128
5.13.5 Methyl 3-hydroxy-2-methyl-3-(4-nitrophenyl)propanoate (186)
To 2.198ml (22.8mmol) propionic acid methyl ester in 200ml DCM wasadded dibutyl boron
triflate (29.64ml of 1M solution in DCM, 29.64mmol) and diisopropyl ethyl amine (4.42g,
5.95ml, 34.2mmol) at 0°C. This was allowedto stir at that temperature for 30 minutes. After
which time the reaction temperature was reduced to -78°C and 4-nitrobenzaldehyde was
added (predissolved in 30ml DCM). This was allowed to stir at that temperature for 30
minutes and then at room temperature for 2 hours. The reaction mixture was then quenched
with potassium phosphate buffer (pH7, 100ml) and extracted with ether (2 x 100ml). The
extract was then washed with 2N HCl (100ml), saturated sodium carbonate (100ml) and
finally brine (100ml). The organic layers were dried over Na2SO4, evaporated to dryness
under reduced pressure and purified by column chromatography using 1:1 Et,O:hexane to
yield the title compound as a pale yellow solid. Yield 3.93g, 72%. Rf = 0.32, 7:3
Et)O:hexane.
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'H (400MHz, CDCI) 8: 1.08 (3H, d, J = 7.32 Hz, H-4), 2.82 (1H, dq J = 7.2, 3.6, H-2), 3.72
(3H, d, J = 6.16 Hz, H-5), 5.25, (1H, d, J = 3.48, H-3) 7.53 (2H, d, J = 8.72 Hz, H-2’.6’)
8.21 (2H, d, J = 8.84 Hz, H-3’,’5’).
'3C (100MHz, CDCI3) 8: 10.62 (C-4), 46.14 (C-2), 52.59 (C-5), 72.87 (C-3), 123.93 (C-
3”,5°), 127.25 (C-2’,6”), 127.86 (C-4”), 149.01 (C-1’) 176.419 (C-1).
Umax ‘om’! 3484.74 (OH), 2956.7 (C-H), 1708.82 (C=O), 1513.85 (NO), 1342.21 (NO)).
5.13.6 3-Hydroxy-2-methyl-3-(4-nitrophenyl)propanoic acid (188)
 
To compound 186 (0.5g, 2.09mmol) in MeOH (3ml) was added 2ml 5N KOHdropwise at
0°C and left to stir for 1 hour. After this time MeOH wasevaporated under reduced pressure
and the mixture was then washed with EtOAc (2 x Sml) to remove any unreacted starting
material. The aqueous layer wasacidified with the dropwise addition of conc HCl to pH 2
and extracted with EtOAc (2 x Sml). The organic layer was dried over Na2SO,4 and
evaporated to give the title compound as a pale yellow solid without need for further
purification. Yield 0.33g, 70%. Rf= 0.4, 100% EtOAc.
'H (400MHz, CDCI3)8: 1.13 (3H, d, J = 7.32 Hz, H-4), 2.87 (1H, m, H-2), 5.34, (1H, d, J =
3.32, H-3) 7.53 (2H, d, J = 7.56 Hz, H-2’,6’) 8.25 (2H, d, J = 8.76 Hz, H-3’,6’).
'5C (100MHz, CDCI;) 5: 10.30 (C-4), 46.19 (C-2), 72.68 (C-3), 124.04 (C-3’,5’), 127.27 (C-
2’,6’), 131.74 (C-4’), 148.75 (C-1”) 180.91 (C-1).
Umax /em’' 3384.46 (OH), 1695.12 (C=O), 1511.92 (NO>), 1344.14 (NO2).
HRMScaled for C29H29N2019Na (2M+Na-2H)471.1016; found 471.0990.
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5.13.7 3-Hydroxy-2-methyl-3-(4-nitrophenyl)propanoyl-CoA (68)
 
3-hydroxy-2-methyl-3-(4-nitrophenyl)propanoic acid (188) (20mg, 88.81umol) was reacted
according to the procedure described in Section 5.11.6. to afford the title compound as a
crystalline solid (1.56mg, 18%) based on relative HPLC traces of coenzyme A andproduct.
HRMScalcd for C3;H44NgO20P3S 973.1606 (M+H_); found 973.1522.
5.13.8 Methyl 3-chloro-2-methyl-3-(4-nitrophenyl)propanoate (167)
Cl O
To compound 186 (0.5g, 2.09mmol) in dry DCM (S5ml) wasaddedthionyl chloride (2.49g,
1.52ml, 21mmol). This was refluxed for 2 hours after which time the solvent was removed
under reduced pressure to give a thick orange oil. This was purified by column
chromatography using 100% Et,O to afford the title compoundas a pale yellow oil. Yield
0.41¢g,76%. Rf = 0.18, 7:3 EtpO:hexane.
'H (400MHz, CDCI;) 6: 1.41 (3H, d, J = 6.93 Hz, H-4), 3.09 (1H, m, H-2), 3.57, (3H,s, H-
5), 5.24 (1H, d, J = 8.25, 7.53, H-3) 7.59 (2H,d, J = 8.82 Hz, H-2’,6’) 8.21 (2H, d, J = 8.83
Hz, H-3’,5’).
'3C (100MHz, CDCl) 5: 14.59 (C-4), 48.60 (C-5), 52.54 (C-2), 63.31 (C-3), 124.02 (C-
3°,5°), 128.60 (C-2’,6”), 130.61 (C-1’), 147.58 (C-4’) 173.06 (C-1).
vmax /cm’! 2979.48 (C-H), 1733.69, 1521.56, 1344.14 (NO);
HRMScalcd for C};Hj2N*°ClO4Na (M+Na) 280.0353; found 280.0359.
15]
5.13.9 3-Chloro-2-methyl-3-(4-nitrophenyl)propanoic acid (189)
 
 
To compound 167 (0.3g, 1.16mmol) in H.O (2ml) was added H2SO, (1ml) and the solvents
allowedto reflux for 4 hours. This was then cooled to room temperature, extracted with Et.O
(2 x 5ml), dried over Na2SO, and evaporated to dryness under reduced pressure. This was
then purified by flash column chromatography using 7:3 Et,O:hexane. Yield 0.28g, 99%. Rf
= 0.32, eluent: 7:3 Et.O:hexane.
'H (400MHz, CDCI) 5: 1.35 (3H, d, J = 10.60 Hz, H-4), 3.04 (1H, m, H-2), 5.21 (1H, d, J =
7.60 Hz, H-3) 7.67 (2H, d, J = 8.84 Hz, H-2’,6’) 8.15 (2H, d, J = 8.72 Hz, H-3’,5’).
'5C (100MHz, CDCI) 5: 13.99 (C-4), 48.28 (C-2), 62.74 (C-3), 124.13 (C-3’,5’), 128.86 (C-
2°,6’), 130.75 (C-1"), 146.68 (C-4’) 178.32 (C-1).
Umax /em™' 2979.48 (C-H), 1733.69 (C=O), 1521.56, 1344.14 (NO).
HRMScalcd for CioHipNO4?Cl (M+Na’) 266.0196 found 266.0188, HRMScalcd for
CjoHpNOq*’CINa (M+Na) 268.0167 found 268.0176.
5.13.10 (£)-Methyl] 2-methyl-3-(4-nitrophenyl)acrylate (193)
To 4-nitrobromobenzene (lg, 4.95mmol), palladium acetate (0.033g, 0.149mmol),
triphenylphosphine (0.026, 0.099mmol) and sodium carbonate (1.05g, 9.9mmol) in 20ml
NMPwasadded methyl-methacrylate under N2. This was then heated to 130°C for 5 hours.
After which time, the reaction mixture was cooled to room temperature, filtered through a
small pad ofcelite, diluted with EtyO (20ml) and washed with 0.1M HCI (20ml) and H20 (2
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x 20ml). The organic layer was then dried over MgSO, and concentrated. The crude oil was
purified by flash column chromatography (100% hexane). The solvent was removed under
reduced pressure to yield the title compound as a yellow solid. Yield 0.22g, 22%. Rf = 0.44,
2:8, EtOAc:hexane.
'H (400MHz, CDCI) 5: 2.13 (3H, s, H-4), 3.85 (3H,s, H-5), 7.53 (2H, d, J = 8.39, H-2’,6’),
7.70 (1H, s, H-3), 8.26 (2H, d, J = 8.88, H-2’6’).
"°C (100MHz, CDCIs) 5: 14.63 (C-4), 52.82 (C-5), 124.07 (C2’,6’), 130.60 (C-3’,6’), 132.37
(C-2) 136.70 (C-1’), 142.00 (C-4’), 146.61 (C-3), 169.98 (C-1).
Umax /om ' 2979.48 (C-H), 1508.06, 1336.43 (NO2); 1627.63 (C=C), 1702.84 (C=O)
HRMScaled for C};H;;O4NNa (M+Na) 244.0586; found 244.0597.
5.13.11 (E)-2-Methyl-3-(4-nitrophenyl)acrylic acid'®° (194)
 
To compound 193 (45mg, 0.255mmol) in in MeOH (2ml) was added 2ml 5N NaOHsolution
and the mixture allowed to stir at room temperature for 3 days. This was then acidified with
the dropwise addition of 1M HCIto pH 2. The product wasextracted into ether (2 x Sml) and
washed consecutively with brine (Sml) and water (Sml). The organic layer was dried over
MgSOg,concentrated in vacuo and chromatographedonsilica gel using an eluent system of
50:50 EtOAc: Hexane. The solvent was removed under reduced pressure to yield the title
compoundasa yellow solid. Yield 0.035g, 83%. Rf= 0.23 1:1 EtOAc:hexane.
'H (400MHz, CDCI;) 8: 2.00 (3H,s, H-4), 7.55 (2H, d, J = 8.39, H-2’,6’), 7.64 (1H,s, H-3),
8.20 (2H, d, J = 8.88, H-3’,5’).
'3C (100MHz, CDCl;) 8: 14.75 (C-4), 125.00 (C-2’,6’), 130.09 (C-2) 132.01 (C-3’,5’),
133.94 (C-3) 137.83 (C-1’), 144.37 (C-4’), 171.62 (C-1).
Umax /em’' 2979.48 (C-H), 1511.92, 1344.14 (NO2); 1683.55 (C=O).
HRMScalcd for C29H;7OgN>2 (2M-H) 413.0985; found 413.0998.
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5.13.12 (£)-2-Methyl-3-(4-nitrophenyl)acryloyl-CoA (71)
 
To a solution of compound 194 (20mg, 0.096mmol) in THF (0.5ml) was added NEts (13.4 ul,
0.096mmol) followed by ethyl chloroformate (9.21, 0.096mmol) at 0°C. This was brought to
room temperature and allowedto stir for 4 hours. After which time CoA-SH,(Li’); (7.5mg,
predissolved in 0.5ml H2O) was added andthe reaction was allowedto stir over night. The
reaction medium was then subject to HPLC purification to afford the title compound as a
crystalline solid Yield = 1.38mg, 15% based on relative HPLC traces of coenzyme A and
product. HRMScalcd for C3;H42NgO0j9P3S 955.1500 (M+H_); found 955.1490.
5.13.13 (Z)-Ethyl 2-methyldec-3-enoate (200)
To diisopropylamine (0.7ml, Smmol) in THF (10ml) was added n-BuLi (2ml, 2.5M, Smmol)
at 0°C. This was allowedto stir for 30 minsat that temperature. The reaction is then cooled to
-78°C and DMPU(0.6ml, 5mmol) was added. This wasallowedto stir for a further 30 mins.
After which time (£)-ethyl dec-2-enoate (1g, 1.13ml, 5mmol), predissolved in 2m1 THF, was
added dropwise. This was allowedto stir at 30 minutes at that temperature to which methyl
iodide (0.31ml, 4.98mmol) was added dropwise and the reaction mixture wasallowedtostir
154
at that temperature for 2 hours. The reaction mixture was then poured into ice and extracted
with diethyl ether (2 x 20ml). This was then washed with Brine (40ml) followed by H20
(40ml), dried over Na2SO, and evaporated to dryness under reduced pressure. This was then
chromatographed on silica gel using 1:9 Et,O: hexane to yield the titled compound as a
colourless oil. Yield 0.48g, 45% Rf = 0.6, 1:9 EtpO:hexane.
'H (400MHz, CDCI;) 5: 0.81 (3H, t, J = 7.20 Hz, H-10), 1.15 (3H, t, J = 7.13 Hz H-2’) 1.21
(11H, m, H-6-9, 11) 2.01 (2H, q, J = 7.20 Hz, H-5) 3.34 (1H, dq, J = 7.00 Hz, 9.2 H-2), 4.05
(2H, q, 7.15 Hz, H-1’), 5.31, (1H, tt J = 10.01, 1.42 Hz, H-4), 5.39 (1H, m, H-3).
°C (100MHz, CDCl) 8: 14.54 (C-2’), 14.62 (C-10), 18.46 (C-11), 23.01-32.79 (C-5-9),
38.50 (C-2), 60.77 (C-1’), 128.99 (C-4) 132.25 (C-3), 175.53 (C-1).
Umax ‘em’! 2969.84 (C-H), 1708.62 (C=O) 1616.36 (C=C).
HRMScaled for C}3HysO2 (M+H") 213.18545; found 213.18574
5.13.14 (Z)-2-Methyldec-3-enoic acid (201)
 
 
To compound 206 (2.2g, 10.38mmol) in 85ml H2O was added Ba(OH)2.8H20 (6.5g,
20.7mmol). This was allowed to reflux for 4 hours. The precipitated barium salt wasfiltered
from the hot solution andthefiltrate was transferred immediately to a cool (25°C) solution of
1M H»2SO, (18 ml). This was extracted with EtpO (2 x 50ml) and washed with H20 (2 x
50ml). The organic layer was dried over MgSOu, concentrated in vacuo and purified by flash
column chromatography using an eluent system of 3:7 EtpO: Hexane + 3% acetic acid to
yield the desired compoundas a white solid. Yield 1.53g, 80%. Rf = 0.36, 3:7 EtpO: Hexane
+ 3% acetic acid.
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'H (400MHz, CDCI;) 6: 0.811 (3H, t, J = 6.90 Hz, H-10), 1.18 (3H, d, J = 7.02 Hz H-11)
1.19-1.34 (8H, m, H-6-9),) 2.01 (2H, dq, J = 7.30, 1.30 Hz, H-5) 3.38 (1H, dq, J = 7.02,
0.73 Hz H-2), 5.34, (1H,tt, J = 10.01, 1.52 Hz, H-4), 5.39 (1H, m, H-3);
°C (100MHz, CDCl) 8: 14.44 (C-10), 18.29 (C-11), 22.91-32.79 (C-5-9), 38.39 (C-2),
128.40 (C-4) 133.37 (C-3), 182.04 (C-1) ; max /em’' 3392 (OH), 2969.84 (C-H), 1699.81
(C=O) 1617.15 (C=C);
HRMScalcd for C};H2402N (M+NH,4') 202.1807; found 202.1814.
5.13.15 (Z)-S-(2-Acetamidoethyl) 2-methyldec-3-enethioate (72)
 
To carbonyldiimidazole (0.13g, 0.81mmol) in THF (Sml) was added compound 207 (0.150g,
0.81mmol) (predissolved in 1ml THF). This was allowed to stir at room temperature for 2
hours. To this was then added N-acetylcysteamine (0.086ml, 0.81mmol) dropwise and the
reaction mixture was then allowed to stir over night. The solvent was evaporated and the
residue was re-dissolved in EtyO (15ml). This was washed with H,O (2*20ml), dried over
MgSOu,, and concentrated in vacuo. The colourless oil was purified using column
chromatography using an eluent of 1:9 MeOH:DCM and dried under reduced pressure to
yield the title compound as a colourless oil. Yield = 0.148g, 64%. Rf = 0.43, 1:9
MeOH:DCM.
'H (400MHz, CDCI;) 5: 0.89 (3H, t, J = 6.88 Hz, H-10), 1.25 (3H, d, J = 6.92 Hz, H-11)
1.37-1.42 (6H, m, H-6-9),) 1.95 (3H, s, H-4’) 2.09 (2H, m, H-5) 3.00 (2H,t, J = 6.50 Hz, H-
1’), 3.42 (2H, q, J = 6.2, H-2’) 3.48 (1H, q, J = 7.02, H-2) 5.35 (1H,dd, 11.51, 10.69 Hz, H-
3), 5.57 (1H, dt J = 10.69, 7.35 Hz, H-4) 5.85 (1H, s, NH);
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ne (100MHz, CDCl) 6: 14.49 (C-10), 18.54 (C-11), 23.03-34.36 (C-5-9, 17,4’), 40.14 (C-
2°), 47.44 (C-2), 128.16 (C-3) 134.11 (C-4), 170.62 (C-3’), 202.83 (C-1);
HRMScalcd for C;5H2702NS (M+H’) 286.18408; found 286.18390.
5.13.16 Bromo(octyl)triphenylphosphorane (204)
Compound 210 was prepared in an identical manner as described in Section 5.11.1, using
triphenylphosphine (2.72g, 10.35mmol) and 1-bromo-octane (2g, 1.79ml, 10.35mmol) in dry
toluene (20ml)to yield the title compound as a white solid. Yield = 4.6g, 99%.
'H NMR (400 MHz, CDCI;) 5: 0.75 (3H, t, J = 6.96 Hz, H-1), 1.15-1.36 (22H, m, H-2-7),
1.40-1.45 (2H, m, H8) 7.82-7.11 (15H, m, H-9). °C NMR (100 MHz, CDCI) 5: 14.44 (C-1),
22.99 (C-2), 29.10-34.51 (C-3-8), 119.16-135.46 (18C, C-9), (Cl) m/z for C26H32P (M+): 375
(100.00).
5.13.17 (E/Z)-Methyl 2-methyldec-2-enoate!*’ (205)
 
Compound 210 (4.55g, 10mmol) was subjected to the same conditions as described in
Section 5.11.2, using THF (75ml), 2.5M n-BuLi (4.42ml, 11mmol) and methyl pyruvate
(1.02g, 0.9ml, 10mmol). The titled compound was purified by flash column chromatography
using 10:90 Et.O:hexaneto yield the title compoundas a colourless oil. Yield = 0.89g, 45%.
Rf (Z) = 0.62, (E) = 0.70, 2:8 Et2O:hexane.
(Z)-isomer 5 'H (400MHz, CDCI;) 5: 0.81 (3H, t, J = 3.37 Hz, H-1), 1.22 (10H, m, H-2-6)
1.30-1.37 (2H, m, H7) 1.76 (3H, s, H-12) 3.67 (3H, s, H-11) 5.97 (1H, dt, J = 7.4, 1.52 Hz,
H-8); °C (100MHz, CDCls) 12.74 (C-1), 14.47-32.21 (C-2-7, 12), 51.56 (C-11), 127.02 (C-
9), 143.26 (C-8) 168.97 (C-10).
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(E)-isomer 'H (400MHz, CDCl) 5: 0.81 (3H, t, J = 3.37 Hz, H-10), 1.22 (10H, m, H-5-9)
1.30-1.37 (2H, m, H-4) 1.82 (3H, s, H-1’) 3.67 (3H, s, H-11) 6.99 (1H,dt, J = 7.44, 1.42 Hz,
H-3); '3C (100MHz, CDCI3) 12.74 (C-10), 14.47-32.21 (C-4-9,1”), 52.04 (C-11), 127.75 (C-
2), 144.22 (C-3) 169.19 (C-1); max /om’! 2979.48 (C-H), 1716.34 (C=O), 1645.45 (C=C);
HRMScaled for C2H>302N (M+H") 199.16980; found 199.16980
5.13.18 (E/Z)-2-Methyldec-2-enoic acid!*® (206)
 
Compound 212 was synthesised in an analogous manner to compound (188), using (£/Z)-
methyl 2-methyldec-2-enoate (211) (0.5g, 2.52mmol), methanol (Sml), and SN NaOH (2ml).
This was then purified by flash column chromatographyusing 20:80 EtO:hexaneto yield the
title compound as a colourless oil (0.33g, 70%) . Rf (E/Z) = 0.17, 2:8 EtpO:hexane;
(E)-isomer 'H (400MHz, CDCI;) 8: 0.88 (3H,t, J = 6.93 Hz, H-10), 1.22-1.49 (10H, m, H-5-
9), 1.92 (3H, s, H-11), 2.51 (2H, dq, J = 7.4, 1.33 H-4) 6.95 (1H,dt, J = 7.55, 1.422 Hz, H-
3);
"°C (100MHz, CDCI3) 5: 12.34 (C-11), 20.87 (C-10) 28.84-32.21 (C-4-9), 126.46 (C-2),
145.97 (C-3) 174.31 (C-1).
(Z)-isomer 'H (400MHz, CDCI3) 5: 0.88 (3H,t, J = 6.93 Hz, H-10), 1.22-1.49 (10H, m, H-5-
9) 1.82 (3H, s, H-11), 2.20 (2H, dq, J = 7.4, 0.66 Hz, H-4) 6.10 (1H,dt, J = 7.44, 1.43 Hz,
H-3);
°C (100MHz, CDCl) 8: 14.48 (C-11), 23.06 (C-10) 28.84-32.21 (C-4-9), 127.33 (C-2),
147.45 (C-3) 174.31 (C-1). Umax /em’! 3400 (C-OH); 1699.84 (C=O), 1645.45 (C=C);
HRMScalcd for C;;H2402N (M+NH,) 202.18070; found 202.18140
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5.13.19 2-Methyldec-2-enoic propionic anhydride (215) :
 
O
To a solution of compound 212 (0.078g, 0.42mmol) in THF (2ml) was added NEt; (0.058ml,
0.42mmol) followed by ethyl chloroformate (0.04ml, 0.42mmol). This was allowedto stir at
room temperature for 4 hours. After which time the solvent was removed followed by
introduction of Et,O (Sml). This was subsequently washed with H2O (2*5ml) followed by
brine (Sml). The organic layer was dried over Na,SO4 and purified by flash column
chromatography to yield the title compound as a colourless oil. Yield: 0.082g, 82% Rf =
0.41, 2:8 Et)O:hexane;
(E)-isomer 'H (400MHz, CDCI3)6: 0.88 (3H,t, J = 6.94 Hz, H-10), 1.25-1.47 (10H, m, H-5-
9), 1.38 (3H, t, J= 7.15 Hz, H-3’), 1.92 (3H, s, H-11), 2.51 (2H, dq, J = 7.51, 1.33 H-4), 4.34
(2H, q, J = 7.14 Hz, H-2’), 6.95 (1H,dt, J = 7.51, 1.36 Hz, H-3);
'C (100MHz, CDCI3) 6: 12.59 (C-11), 20.66 (C-10) 28.67-32.18 (C-4-9), 65.99 (C-2’)
126.36 (C-2), 148.57 (C-3), 150.22 (C-1’) 162.84 (C-1).
(Z)-isomer 'H (400MHz, CDCI) 5: 0.88 (3H,t, J = 6.94 Hz, H-10), 1.25-1.47 (10H, m, H-5-
9), 1.38 (3H,t, J= 7.15 Hz, H-3’), 1.87 (3H, s, H-11), 2.22 (2H, dq, J = 7.42, 0.78 Hz, H-4),
4.34 (2H, q, J = 7.14 Hz, H-2’) 6.10 (1H, dt, J = 7.45, 1.45 Hz, H-3);
'3C (100MHz, CDCl3) 8: 12.59 (C-3’), 14.48 (C-11), 23.06 (C-10) 28.84-32.21 (C-4-9),
65.93 (C-2’) 124.91 (C-2), 148.57 (C-3), 150.01 (C-1") 162.07 (C-1).
HRMScalcd for C}4H2304N (M+NHg') 274.20183; found 274.20242
159
5.13.20 S-(2-acetamidoethyl) 2-(4-isobutylphenyl)propanethioate (55)
 
To Ibuprofen (173) (0.89 g, 4.3 mmol) in THF (15ml) was added dicyclohexylcarbodiimide
(0.89 g, 4.3 mmol) and 1-hydroxybenzotriazole (0.59 g, 4 mmol) followed by N-
acetylcysteamine (0.52 g, 4.3 mmol). After stirring at room temperature for 45 minutes
K,CO; (0.299 g, 2.1 mmol.) was added and the reaction stirred for 3 hours at room
temperature. The reaction wasthen filtered and concentrated in vacuo. The residue was taken
up in ethyl acetate (20ml) and washed once with 10% aqueous NaHCO; (20ml). The organic
layer was dried over Na2SO,4 and concentrated. The crude product was purified by flash
chromatography (3-5% MeOHin CH2Cl,) and concentrated. Yield 0.77g, 59%. Rf = 0.47 1:9
MeOH:DCM
'H NMR (400MHz, CDC];) 5: 0.83 (6H,d, J = 6.81 Hz H-3”), 1.50 (3H, d, J= 7.1 Hz, H-
3), 1.88-1.80 (4H, m, H-2”,4a) 2.44 (2H, d, J = 7.18 Hz, H-1”), 3.36 (2H, J = 6.1 Hz, H-1a),
3.68 (1H, gq, J = 7.09 Hz, H-2), 3.88 (2H, m, H-2a), 7.18 (2H, d, J = 6.33 Hz, H-3’,5’), 7.28
(2H,d, J = 6.33 Hz, H-2’,6’).
'5C NMR(100MHz, CDCI3) 5: 18.57 (C-3). 22.78 (C-3”), 23.27 (C-4a), 30.34 (C-2”), 30.53
(C-1a), 40.01 (C-2a), 45.45 (C-1”), 54.44 (C-2), 126.88-141.52 (C-1’,2’,3’,5’.4’,6’), 171.23
(C-3a), 204.11 (C-1), (Cl) m/z for Cj7H29NO2S 325 (M + NHg’): 137 (100.00)
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5.13.21 Trifluoropropionyl-CoA (211)
s AX, A é °ETA OLoO
 
 
To trifluoropropionic acid (0.021mg, 0.23mmol) was added carbonyldiimidazole (0.038g,
0.23mmol) in THF (1ml). This was allowed to stir at room temperature for 2 hours. After
which time the solvent is removed under reduced pressure andthe oil/solid mixture wasre-
dissolved in EtyO (2ml) and washedthree times with HO (3*2ml). The organic layer was
dried over Na2SO, and removed underreducedpressure. The colourless oil was resuspended
in THF (0.5ml) and to this was added CoA-SH,(Li’)3; (20mg, 25.51pmol, predissolved in
0.5ml H2O). This was allowed to stir at room temperature over night. The reaction mixture
was then subject to HPLCpurification to yield the title compound (216) 4.03mg, 18% yield-
based on relative HPLCtraces of coenzyme A andproduct.
'H (400MHz, CDCIs) 5: 0.69, (3H, s, H-7/8), 0.82 (3H, s, H-7/8), 2.35 (2H,t, 6.52 Hz, H-4),
2.99 (2H, m, H-2), 3.07 (2H, q, J = 11.38hz, H-1), 3.28 (4H, m, H-5), 3.37 (2H, m, H-3) 3.50
(2H, m, H-19), 3.77 (2H, m, H-10), 3.99 (1H, s, H-6), 4.18 (2H, m, H-17-18), 4.52 (1H, m,
H-19), 6.06 (1H, d, J = 6.56Hz , H-20), 8.12 (1H, s, H-21), 8.45 (1H, s, H-22)
HRMScaled for C24H36F3N7017P3S (M+H_) 876.1065; found 876.1053
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Appendix 1
HPLCtraces of Ibuprofenoyl-CoA at various pH’s cont
66% (v/v) 10mM Ammonium acetate-ammonium hydroxide,
(pH 7.5), 34% (v/v) MeCN.
Ibuprofenoyl-CoA RT = 5.21
Free thio RT = 3.59 significant hydrolysis
66% (v/v) 1OmM Ammonium acetate-acetic acid, (pH 7),
34% (v/v) MeCN. ee4 6 8 10
Time (mins)
66% (v/v) 10mM Ammonium acetate-acetic acid, (pH 6.5),
34% (v/v) MeCN.
Time (mins)
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a 66% (v/v) 10mM Ammonium acetate-acetic acid, (pH 6),
34% (v/v) MeCN.
10 -
Sharp peak0 -y - a
0 1 2 3 4 5 6 7 8
-10 4
Time (mins)
a
746 45 | 66% (v/v) 1OmM Ammoniumacetate-acetic acid, (pH 5.5),
a 34% (v/v) MeCN.|5 | Broad peak — possibly due to multiple protonation states.241
0 oe Sm J T ae
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24
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12 - 66% (v/v) 10mM Ammonium acetate-acetic acid, (pH 3.5),
9m4 34% (v/v) MeCN.
8 Compound unobservable.
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Appendix 2
NMR’s of CoA coupled substrates
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 Appendix3.
Incubations of 100uM (S)-Ibuprofenoyl-CoA at various protein concentrations at 37°C and at
pH 7.
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Appendix 3 continued
Raw data for substrate concentration variation
200uM (S)-Ibuprofenoyl-CoA
 
    
Time (%R) umoles converted
0 0 0
4 4.05 0.0081
6 6.47 0.01294
8 9.92 0.01984
12 13.56 0.02712
16 13.99 0.02798
18 16.95 0.0339
40 26.19 0.05238
120 38.16 0.07632 
100uM (S)-Ibuprofenoyl-CoA
 
    
Time (%R) uumoles converted
0 0 0
6 17.83 0.01783
10 25.2 0.0252
14 29.67 0.02967
20 31.46 0.03146
60 41.26 0.04126 
50uM (S)-Ibuprofenoyl-CoA
 
   
Time (%R) uumoles converted
0 0 0
2 8.2 0.0041
8 17.66 0.00883
12 21.07 0.010535
20 25.36 0.01268
46 35 0.0175  
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Appendix 4
Raw data for assay comparisons
MassSpecassay of 100ng MCR with 100M [D]-Ibu-CoA
 
      
Area of [H]-
Time IbuCoA Area of [D]-IbuCoA % conversion uumoles converted
0 0 0 0 0)
2 2.02 10.72 15.855573 0.015855573
4 3.12 7.87 28.38944495 0.028389445
6 2.99 4.85 38.1377551 0.038137755
8 4.4 5.077 46.42819458 0.046428195
10 4.77 4.08 53.89830508 0.053898305
12 5.17 3.68 58.4180791 0.058418079
14 5.69 3.65 60.92077088 0.060920771
16 5.99 3.29 64.54741379 0.064547414
18 6.74 3.26 67.4 0.0674
20 6.1 2.67 69.55530217 0.069555302
30 7.11 2.15 76.78185745 0.076781857
40 7.83 1.88 80.63851699 0.080638517
60 8.56 2.02 80.9073724 0.080907372
HPLCassay of 100ng MCR with 100uM(S)-Ibu-CoA
 
 
time % (R) % (S) Lumoles converted
0 0 100 0
2 9.73 90.27 0.00973
4 14 86 0.014
6 22.09 77.91 0.02209
8 22.12 77.88 0.02212
10 24.5 75.5 0.0245
12 31.49 68.51 0.03149
16 30.73 69.27 0.03073
18 35.43 64.57 0.03543
20 34.59 65.41 0.03459
60 43.06 56.94 0.04306    
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Appendix 5
HPLCtraces of various CoA thioesters
Ibuprofenoyl-CoA
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Appendix 6
Enzymehydrolysis of a—chloroibufenac ethyl ester
Racemic a—chloroibufenac ethyl ester before incubation
2.50 ;
2.00 ;
1.50 |
1.00 +
0.50
 0.00 1
14 19 24 29 34
 
-0.50
Enzyme Reaction after 3 hours
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